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Abstract 
Congenital heart disease (CHD) is the most common congenital malformation 
with a birth prevalence of 7/1000. CHD may occur as Mendelian syndromic 
disorders or as isolated conditions. The latter represent the majority (~80%) of 
CHD cases.  Recent technological advancements have allowed large-scale 
genome-wide characterization of copy number variants (CNVs), which have 
been proposed to contribute to the risk of sporadic CHD.  
This thesis presents a genome-wide CNV study involving 2256 sporadic, 
isolated CHD patients, 283 trio CHD families, and 1538 ancestry-matched 
controls that were typed on the Illumina 660W-Q SNP platform. This was 
followed by an extensive validation study using comparative genomic 
hybridization arrays, multiplex ligation-dependent probe amplification and 
quantitative-fluorescent PCR assays. A global enrichment of rare genic 
deletions was identified in CHD patients (OR = 1.8, P = 0.001), compared to 
controls. Rare deletions that are associated with CHD had higher gene content 
(P = 0.001) and higher haploinsufficiency scores (P = 0.03). Additionally, they 
were enriched with genes involved in the Wnt signalling pathway, known for its 
pivotal role in cardiac morphogenesis. Rare de novo CNVs were also identified 
in ~5% CHD trios; 91% of which occurred on the paternal, as opposed to the 
maternal chromosome (P = 0.01). They spanned previously known candidate 
loci as well as novel loci for CHD. Individual locus enrichments in cases vs. 
controls were identified for CNVs at chromosomes 1q21.1 and 15q11.2. A 
phenotype-specific effect was observed for the 1q21.1 CNVs, and GJA5 was 
identified as the causative gene for CHD in this locus.  
In conclusion, global rare genic deletions contribute ~4% of the population 
attributable risk of sporadic CHD. CNVs implicating 1q21.1, 15q11.2 and Wnt 
signalling genes are associated with CHD. Rare de novo CNVs identified in 
CHD trios exhibit a paternal origin bias possibly of relevance to the 
epidemiology of CHD. 
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1.1 Preface 
This thesis describes a genome-wide study of the contribution of copy number 
variants (CNVs) to the risk of sporadic congenital heart disease (CHD). This 
chapter aims to provide a concise overview of the spectrum of human genetic 
variation and its contribution to complex traits, followed by a more in-depth 
review on the topics of CNVs that include segmental duplications, CNV 
generating mechanisms, the currently available CNV detection methods, as well 
as the associated challenges. Next, I will introduce the phenotype under study 
i.e. CHD, specifically in light of the previously established genetic and 
environmental contributors in both the Mendelian and sporadic forms of CHD.  
1.2 Contribution of human genetic variation to complex traits 
Human genetic variation that shapes the human genome ranges from single 
base pair variation (e.g. SNPs) to structural variation that includes small indels, 
submicroscopic copy number variants to microscopically visible chromosomal 
events (see Table 1.1). Large-scale studies of human genetic variation in the 
beginning focused mainly on identifying and cataloguing single nucleotide 
differences, notably in the International HapMap project (2003, 2005). It was 
estimated that the human genome contains at least 11 million SNPs, with ~7 
million of those occurring with minor allele frequency (MAF) >5% while the 
remaining have MAF between 1 and 5% (Kruglyak and Nickerson, 2001). 
However, the more recent estimation from the 1000 Genomes Project predicted 
that the human genome contains nearly 37 million SNPs (2010). The genome-
wide association study (GWAS) is currently the most widely used method to 
assess the contribution of SNPs to the phenotypic diversity. GWAS is a 
powerful tool that can test a few hundred thousand to a million tag-SNPs with 
minor allele frequency >5% simultaneously for associations with a given trait 
(Manolio, 2010). A tag-SNP represents all the SNPs in a region of the genome 
that are in high linkage disequilibrium (LD; non-random associations of alleles at 
multiple loci) - in other words, all SNPs in high LD are inherited together in 
“blocks”, which make it possible to test for the association of all ~37 millions of 
SNPs without genotyping all of the SNPs. As of July 2011, ~1500 GWAS have 
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identified thousands of associations of common tag-SNPs with >200 complex 
traits (NHGRI Catalogue of Genome-wide Association Studies, 
http://www.genome.gov/GWAStudies) (Hindorff et al., 2009). 
However, it is now clear that GWAS can only identify a small portion of 
heritability (Manolio et al., 2009, McCarthy et al., 2008, Lander, 1996). Recently, 
large-scale studies of structural variation began to emerge and it became 
evident that structural variants represent another major source of genetic 
variation, much more than previously realized (Iafrate et al., 2004, Sebat et al., 
2004, Pennisi, 2007). Therefore, some of the efforts of finding the “missing 
heritability” of complex traits in recent years have been directed towards 
identifying both common and rare variants that make up this structural diversity 
in the human genome, particularly the class of variants known as copy number 
variants (CNVs) (Eichler et al., 2010, Manolio et al., 2009).   
Table 1.1 - Spectrum of genetic variation in the human genome 
Variation Description Size range 
Single nucleotide variant Single nucleotide polymorphisms (SNPs, ~10million 
in the human population), point mutations 
1 bp 
Insertion/deletion variant (InDel) Binary insertion/deletion events of short sequences 
(majority <10bp in size) 
1bp - 1kb 
Microsatellite (e.g. CAn repeats) Variable 1-6bp repeats totalling <200bp in length, 
account for >1million (~3%) of the human genome 
<200bp 
Minisatellite, variable numbers 
of tandem repeats (VNTR) 
20-50 copies of variable 6-100bp repeats, ~20% are 
polymorphic 
100bp-20kb 
Retroelement insertions (SINE, 
LINE, LTR, ERV) 
Discrete sequences with capability to transport and 
duplicate, account for ~45% of the human genome 
300bp -10kb 
Copy number variant (CNV) Deletions, duplications, tandem repeats. If frequency 
>1% in human population, it is called copy number 
polymorphism (CNP) 
>1kb 
Inversion Rearrangement causing a segment of DNA to be 
present in reverse orientation 
>1kb 
Chromosomal abnormalities Large cytogenetically visible deletions, duplications, 
translocations, inversions and aneuploidy 
~5Mb to entire 
chromosome 
SINE = short interspersed element, LINE = long interspersed element, LTR = long terminal repeat, ERV = 
endogenous repeat virus. Adapted from various publications (Sharp et al., 2006, Feuk et al., 2006b, Xing 
et al., 2009) 
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1.3 Copy number variants  
Copy number variants (CNVs) are structural variants that alter DNA dosage, i.e. 
those involving gains (e.g. duplications) or losses (deletions) of DNA segments 
that are >1kb (Feuk et al., 2006a, Redon et al., 2006). It was estimated that 
~20% of the human genome is copy number variable (Iafrate et al., 2004, Sebat 
et al., 2004, Redon et al., 2006, Conrad et al., 2010). CNVs have been shown to 
alter transcription levels, and thus likely to contribute significantly to the 
phenotypic diversity (Stranger et al., 2007, Schuster-Bockler et al., 2010). CNV 
loci can either be biallelic or multiallelic. The majority of CNVs are biallelic (copy 
number 0, 1 or 2 for deletion loci and copy number 2, 3 or 4 for duplication loci), 
while the minority, accounting for 1-2% of all CNVs, is multiallelic (Redon et al., 
2006, Conrad and Hurles, 2007).  
CNVs were first described in the 1970s from the work on α-globin genes. In the 
early 1990s, relatively large CNVs of submicroscopic size (>1Mb) were reported 
to cause some Mendelian traits (Lupski et al., 1991, Chance et al., 1993). But it 
wasn’t until 2004, with the advent of genome-wide approaches, that two 
collaborative groups conducted large-scale CNV detection studies in healthy 
individuals and showed that CNVs are widespread across the human genomes 
and represent a significant source of genetic variation (Iafrate et al., 2004, 
Sebat et al., 2004) – see Figure 1.1. 
CNVs are known to have important roles in adaptive forces, e.g. CNVs in the 
amylase gene were found to be highly correlated with the level of starch diet in 
the respective population (Perry et al., 2007, Xue et al., 2008, Iskow et al., 
2012). Their roles in the emergence of some advantageous traits have also 
been reported, e.g. in cognition, endurance running as well as in resistance to 
sepsis and malaria (Dumas et al., 2007, Lupski, 2007, Xue et al., 2006, Flint et 
al., 1986).  Most importantly, CNVs have been shown to cause various human 
genomic disorders (Lupski, 1998, Stankiewicz and Lupski, 2002, Carvalho et al., 
2010, Girirajan and Eichler, 2010) as well as to contribute to the risk of various 
complex disease phenotypes (Gonzalez et al., 2005, 2008, Stefansson et al., 
2008, Schaschl et al., 2009). 
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Many different mechanisms have been implicated in the formation of CNVs. 
Most of the well-characterized CNVs are generated by homologous 
recombination mechanism that is mediated by segmental duplications (SD).   
 
Figure 1.1 – Large-scale detection of CNVs in the human genome 
This figure shows the result of one of the first studies that showed the extent of 
the abundance of CNVs in the human genome. Circles to the right of each 
chromosome ideogram show the number of individuals with copy gains (blue) 
and losses (red) for each clone among 39 unrelated healthy individuals. Green 
circles to the left indicate known genome sequence gaps within 100kb of the 
clone, or segmental duplications known to overlap the clone. Cytogenetic band 
positions are shown to the left.  (From Iafrate et al., 2004) 
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1.3.1 Segmental duplications 
A significant part (~14%) of the human genome is made of blocks of highly 
homologous (>90% identical) duplicated sequences termed segmental 
duplications (SD), also known as “low-copy repeats” (LCR). These duplication 
blocks may be organized in tandem or in interspersed locations and they may 
contain any constituent of “standard” genomic DNA, e.g. coding sequence and 
common repeats (Bailey and Eichler, 2006). These elements are particularly 
challenging to characterize, thus they caused major difficulties in the assembly 
and annotation of the human genome (Bailey et al., 2001). To this day, the 
majority of CNV detection methods still can’t properly assess such regions, 
partly also due to the fact that these regions are poorly covered in most 
detection platforms. Yet this highly-ordered architectural feature has critical 
roles in human disease and evolution. SD has been recognized as one of the 
primary mechanisms for gene evolution, e.g. via subfunctionalization or dosage 
selection of duplicated genes (Bailey and Eichler, 2006, Conant and Wolfe, 
2008). But more importantly, SD provides the substrate for recombination and 
recurrent chromosomal rearrangements that may result in pathogenic CNVs 
(see Figure 1.2). The following section of this chapter will thus review this 
particular role of SD in more depth. 
1.3.2 Segmental duplication-mediated mechanisms for CNV formation 
The high sequence identity between SDs can result in misalignment and 
subsequent unequal crossing over, leading to a CNV formation. Nonallelic 
homologous recombination (NAHR) is the mechanism by which non-allelic 
copies of a pair of SD are involved in such process. NAHR predominantly occur 
during meiosis (Turner et al., 2008), although at a lower frequency, it may also 
occur in mitotically dividing cells (Lam and Jeffreys, 2006, Lam and Jeffreys, 
2007). NAHR is the primary generating mechanisms for large CNVs in the 
human genome. It may occur between the paralogue of homologous 
chromosomes (interchromosomal), sister chromatids (interchromatid) or within a 
chromatid (intrachromatid) – see Figure 1.3. The relative positions, size and 
degree of identity of the SD pair are known to influence the rate of the NAHR 
events (Liu et al., 2011a). Thus, certain regions of the genome, known as 
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“hotspots” are more prone to rearrangements than the rest of the genome and 
they generate recurrent CNVs with repeated breakpoints, many of which are 
pathogenic (see Figure 1.4 and 1.2).  
  
Figure 1.2 – Genome-wide pattern of segmental duplications 
The figure shows the patterns of intrachromosomal and interchromosomal segmental 
duplications (SD) that are ≥10kb with ≥95% homology. Intrachromosomal SD pairs are 
connected with blue lines and interchromosomal SD are indicated with red bars. Purple bars 
represent areas that are not targeted by the Human Genome Project. Predicted rearrangement 
hotspots regions (≥50kb and <10Mb) that are flanked with SD pairs (≥10kb and ≥95% 
homology) are shown as gold bars. A total of 169 regions (~298Mb of sequence) were identified 
as potential hotspots and many of such regions have been associated with various genomic 
disorders, including Gaucher disease (A), familial juvenile nephronophthisis (B), 
fascioscapulohumeral muscular dystrophy (C), spinal muscular atrophy (D), congenital adrenal 
hyperplasia III (E), Williams-Beuren syndrome (F), glucocorticoid-remediable aldosteronism (G), 
Prader-Willi/Angelman syndrome (H/I), polycystic kidney disease (J), Charcot-Marie-Tooth 
disease type 1A (K), hereditary neuropathy with pressure palsies (L), Smith-Magenis syndrome 
(M), neurofibromatosis (N), pituitary dwarfism (O), cat eye syndrome (P), 
DiGeorge/velocardiofacial syndrome (Q), ichtyosis (R), Hunter syndrome (S), red-green colour 
blindness (T), Emery-Dreifuss muscular dystrophy (U), incontinentia pigmenti (V), haemophilia A 
(W), azoospermia (X). (From Bailey et al., 2002). 
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Figure 1.3 – CNV formation via homologous recombination 
In (A), genomic rearrangements between a pair of SD (black arrows) in direct orientation may 
result in a deletion (1) and/or a duplication (2) events, while a rearrangement between SD in 
opposite orientation result in an inversion (3). In (B), interchromosomal (left), interchromatid 
(middle) and intrachromatid (right) non-allelic homologous recombination (NAHR) events are 
shown, mediated by the SD pairs (yellow arrows) in direct orientation. Interchromosomal and 
interchromatid NAHR result in reciprocal duplication (dup) and deletion (del), whereas 
intrachromatid NAHR only results in deletion (From Gu et al., 2008). 
  
Figure 1.4 – Experimental observations of recurrent and non-recurrent CNVs 
The thick gray lines represent the copy number changes resulting from the rearrangements. In 
(A), recurrent rearrangements via non-allelic homologous recombination (NAHR) mechanism 
were generated. The yellow fat arrows flanking the region depict segmental duplications (SD), 
functioning as substrates for NAHR and result in CNVs with rearrangement breakpoints that are 
clustered within the SD. In (B), the breakpoints of the rearrangements are scattered, i.e. “non-
recurrent”. Traditionally, smallest region of overlap in such CNVs is used to identify critical gene 
for the associated phenotype. Some of the non-recurrent CNVs have grouping in one breakpoint 
(C), which is distinct from breakpoint clustering in (A). But it may reflect underlying genomic 
architecture that is important to the mechanism for CNV formation (Adapted from Gu et al., 2008).  
A 
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It is also known that increased copies of SD (CNV within SD) elevate the risk for 
recurrent rearrangements, e.g. in the 7q11.23 region that cause Williams-
Beuren syndrome (Cusco et al., 2008). Interestingly, several ancient haplotypes 
of SD regions have been found to either predispose or protect the genome from 
the occurrence of some recurrent pathogenic NAHR events. The H2 haplotype 
of the 17q21.31 region contains directly orientated SD, thus predisposing the 
individuals that inherit the H2 haplotype to a pathogenic 480kb deletion. In 
contrast, the H1 haplotype has the SD in inverted orientation, and thus 
protecting the individuals with such haplotype from the occurrence of 
pathogenic rearrangement between the flanking predisposing SD (Stefansson 
et al., 2005, Zody et al., 2008, Koolen et al., 2006, Shaw-Smith et al., 2006). 
Similarly, the S1 and S2 haplotypes of the 16p12.1 locus also either protect or 
predispose the individuals to a pathogenic rearrangement (Antonacci et al., 
2010, Girirajan et al., 2010, Girirajan and Eichler, 2010). See Figure 1.5.    
Studies have shown that some NAHR hotspots overlap allelic homologous 
recombination (AHR) hotspots in paralogous sequences, while some NAHR 
hotspots were found to be adjacent to AHR hotspots. Both mechanisms were 
found to share similar properties of the distribution of strand exchanges. The 
studies additionally revealed that these two mechanisms are very closely 
related in both the current and ancestral genomes (Raedt et al., 2006, Lindsay 
et al., 2006).  
1.3.3 Other mechanisms for CNV formation 
Recent findings from the 1000 Genomes Project suggest that in addition to the 
NAHR events, which constitute the majority of the large CNVs, the remaining 
CNVs were either generated by non-homologous end joining (NHEJ), fork 
stalling and template switching (FoSTeS) or retrotransposon activities (Mills et 
al., 2011). These findings are in agreement with another report by Kidd and 
colleagues (Kidd et al., 2010). The following sections of this chapter will briefly 
discuss the three other major mechanisms for CNV formation that are not 
mediated by SD. 
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Figure 1.5 – Genomic predisposition to pathogenic rearrangements 
The architectural features of SD and other genomic elements of chromosome 
17q21.31 (A) and 16p12.1 (B) are shown. The blue lines connect the SD pairs in 
inverted orientation, while the green lines connect those in direct orientation. The red 
arrows signify SDs that may participate in the NAHR event resulting in the 
pathogenic microdeletion (fusion of 2 SD blocks, depicted as dark red arrow). The 
genes in the regions are shown with the small arrows indicating the transcriptional 
orientation. H1 and S1 haplotypes contain the protective architectural configuration 
wherein the predisposing SDs are not in the same orientation, and thus not 
susceptible for pathogenic microdeletion. Whereas the H2 and S2 haplotypes have 
the predisposing SDs in the same orientation, thus make the corresponding 
17q21.31 and 16p12.1 loci vulnerable for recurrent pathogenic microdeletions (From 
Girirajan and Eichler, 2010).  
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Non-homologous end joining 
DNA repair mechanisms that use minimal or no homologies are also known to 
generate CNVs. Non-homologous end joining (NHEJ) occurs as a result of 
aberrant DNA repair of double-strand breaks (DSB). The breakpoints of NHEJ-
generated CNVs are frequently coincide with repetitive elements, e.g. long 
terminal repeats (LTRs) and long interspersed nuclear elements (LINEs), 
suggesting that their occurrence may be stimulated by such architectures 
(Lieber et al., 2003, Lee et al., 2007). DNA end-binding proteins Ku70 and Ku80 
have been shown to be required for NHEJ mechanism (Zhang et al., 2011, 
Guirouilh-Barbat et al., 2004). 
Fork stalling and template switching 
It is also known that replication stress is associated with CNV formations. 
Inhibitors of DNA polymerases (e.g. aphidicolin) were found to induce CNV 
formations (Arlt et al., 2009). Since double-strand breaks are known to result 
from replication stress and the majority of aphidicolin-induced CNVs were found 
to have microhomology or no homology at their breakpoints, non-homologous 
replication-based DNA repair mechanisms have been proposed as the main 
generating force for such CNVs (Arlt et al., 2009). One such mechanism has 
been proposed and termed Fork Stalling and Template Switching (FoSTeS), a 
replication-based DNA repair mechanism that is induced by double-strand 
breaks during mitosis (Lee et al., 2007, Zhang et al., 2009b).  Since there is a 
marked difference in the number of mitotic cell divisions in spermatogenesis 
compared to oogenesis, it has been hypothesized that such DNA repair 
mechanisms are more prevalent in male germline, particularly in older males, 
compared to female germline (Crow, 2000) – see Figure 1.6.  
Retrotransposon-mediated CNV formation 
The human genome has been shaped for hundreds of millions of years by 
mobile elements (i.e. transposable elements), which are discrete DNA 
sequences that make up ~45% of the genome and have unique capability to 
transport and duplicate themselves (Xing et al., 2007). Long interspersed 
nuclear elements 1 (LINE1 or L1), which cover ~17% of human genomic DNA, 
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are the only currently active class of mobile elements (Goodier and Kazazian, 
2008, Kazazian and Moran, 1998). Both germline and somatic L1 activities have 
been shown to significantly contribute to human structural variation (Beck et al., 
2011, Lupski, 2010). Additionally, L1-mediated deletions of the PDHX and EYA1 
genes have been shown to cause sporadic case of pyruvate dehydrogenase 
complex deficiency and branchioto-renal syndrome, respectively (Mine et al., 
2007, Morisada et al., 2010).  
 
Figure 1.6 – Comparison of cell divisions during oogenesis versus 
spermatogenesis 
In the life history of an egg of a human female, the total number of cell 
divisions is 24, all of which occur during the fetal development. In 
contrast, the number of cell divisions in the life history of a sperm in a 
male individual depends on the number of stem-cell divisions, which is 
increasing as the individual gets older. S = stem cells, G = gonial cell, M 
= meiotic cells. (From Crow, 2000) 
  
Crow, 2000 
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1.3.4 Genome-wide CNV detection methods 
The current methods for genome-wide CNV discovery and genotyping include 
microarrays and next-generation sequencing.  
Microarray approaches 
Microarray methods have been the workhorse of CNV discovery and genotyping 
in the past decade. In terms of throughput and cost, they are regarded as the 
preferred method of choice (Alkan et al., 2011). The two major array platforms 
for CNV detection are comparative genomic hybridization (CGH) and SNP 
arrays. These technologies infer gain or loss of copy number in comparison to a 
reference sample in the case of CGH arrays or a reference population in the 
case of SNP arrays.  
a) Comparative genomic hybridization (CGH) array 
CGH arrays are considered to be the best platform for CNV detection due to the 
reliability of their signals. This method uses comparative hybridization principle 
on test and reference samples that are differentially labelled with fluorescent 
dyes to a set of hybridization targets on an array platform (see Figure 1.7). The 
ratio of hybridization signals from the test and reference samples is then used 
as a proxy for copy number status (i.e. relative gain or loss). An important 
consideration for any CGH experiment is the effect of the reference sample on 
the copy number interpretation, e.g. a copy number loss in the reference sample 
can be interpreted as copy number gain in the test sample. Thus, depending on 
which reference sample is used, one report may identify a CNV as a gain, while 
another identifies it as a loss. This major limitation is thought to be the cause for 
the low level of concordance between copy number profile generated by the 
CGH arrays and massively parallel sequencing (Ju et al., 2010). Pooled DNAs 
have been used to partly overcome this limitation, but this approach is known to 
cause a decrease in the power for CNV detection, particularly in polymorphic 
CNV loci (Scherer et al., 2007).  Most current CGH arrays use long 
oligonucleotides as hybridization targets, although bacterial artificial 
chromosome (BAC) clones are still used in limited extent. BAC arrays also have 
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another major limitation i.e. the resulting CNV breakpoint resolution is very low. 
Initial CNV studies that use BAC arrays are known to provide a drastic 
overestimation of CNV size (Redon et al., 2006).   
 
 
 
b) SNP array 
CNV detection from SNP genotyping errors 
SNP genotyping data can be exploited to detect CNVs, particularly deletions. 
This was done by investigating erroneous SNP genotyping calls, e.g. patterns of 
null genotypes, apparent Mendelian inconsistencies and Hardy-Weinberg 
disequilibrium (McCarroll et al., 2006, Conrad et al., 2006) – see Figure 1.8. 
However, the majority of such observations in actuality resulted from technical 
artefacts and genotyping errors, and thus such approaches are very laborious, 
limited, and not practical.  
CNV detection from signal intensity data 
The more advanced methods of CNV detection on the SNP platforms use the 
signal intensity data from the SNP allelic probes to infer CNV. Therefore, CNV  
Figure 1.7 – Array-based comparative genomic hybridization  
Reference and test DNA samples are differentially labelled with 
fluorescent dyes (Cy5 and Cy3, respectively). They were then co-
hybridized to the arrays after repetitive-element binding is blocked by 
COT-1 DNA. After hybridization, the fluorescence ratio is determined 
and relative copy number is inferred. Typically, dye-swap experiment is 
performed, in order to detect spurious signals. (From Feuk et al., 
2006a) 
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Figure 1.8 – CNV mining from SNP genotyping data 
CNVs may leave a “footprint” in SNP genotyping data by causing physically clustered 
patterns of null genotypes, apparent Mendelian inconsistencies and apparent Hardy-
Weinberg disequilibrium. (Adapted from McCarroll et al., 2006) 
detection on SNP arrays is also based on hybridization, but it is fundamentally 
different from that of the CGH arrays. Hybridization on the SNP platform is 
performed on a single sample per array, and log-transformed ratios of clustered 
intensities were calculated at each marker across many arrays. It is important to 
note that the allelic probes that constitute the markers in the SNP platforms 
were designed and optimized for SNP genotyping (to detect single-nucleotide 
differences) either by single-base-extension methods (Illumina) or differential 
hybridization (Affymetrix). Thus, they are not optimized for CNV detection, 
although the newer generations of SNP platforms try to compensate this by 
including probes that are specifically designed to target CNVs (McCarroll et al., 
2008b, Peiffer et al., 2006, Cooper et al., 2008). However, the utilization of 
these CNV probes on the Illumina SNP platform proved to be limited (personal 
communications with Illumina technical support, Illumina, CA, USA), although 
this is not the case with the Affymetrix 6.0 platform, which has nearly 1 million 
CNV probes that can serve as a powerful tool when the CNV calling is 
performed using the algorithm designed and optimized specifically for the 
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platform (McCarroll et al., 2008b, Korn et al., 2008). Nevertheless, the signal 
intensity ratio from the allelic probes on the SNP arrays exhibit low signal-to-
noise ratio in all the currently available platforms, especially when compared to 
that of the CGH platforms.  
However, there are several key advantages of using the SNP platforms for CNV 
detection. First, it is generally considered to be a cost-effective option to do both 
SNP and CNV analyses on a single platform. And second, the use of SNP 
allele-specific probes can differentiate the different alleles as well as identifying 
regions of uniparental disomy (Alkan et al., 2011) – see Figure 1.9. 
Log R ratio (LRR) and B allele frequency (BAF) 
CNV detection on SNP arrays generally utilizes two metrics: log2 R ratio (LRR) 
and B allele frequency (BAF). LRR is calculated per-marker as the log2 ratio of 
the observed normalized intensity of the test sample to the expected intensity 
(i.e. the median signal intensity from a reference population or from the rest of 
the samples that are being analyzed). LRR generated from the SNP array 
shows a lower per-marker signal-to-noise ratio than the log2 ratio generated 
from array CGH (compare Figure 1.9 (a) and (b)). The BAF metric is calculated 
per marker as the ratio of normalized signal intensities from the two allelic 
probes. BAF serves as a powerful metric to increase CNV detection power in 
the SNP platforms and has a significantly higher per-marker signal-to-noise ratio 
compared to the LRR. The following are some examples of BAF values: in copy 
number neutral scenario (2 copies are present), the BAF observed would be 0 
(AA), 1/2 (AB) or 1 (BB). In the case of a duplication (e.g. the presence of 3 
copies), BAF of 0 (AAA), 1 (BBB), 1/3 (AAB) or 2/3 (ABB) will be observed. In 
the case of a heterozygous deletion (the presence of 1 copy), BAF values of 0 
(A/-) or 1 (B/-) will be observed. See examples of BAF plots at Figure 1.9 (b). 
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Figure 1.9 – Comparison of CNV detection by CGH versus SNP arrays 
The log ratio of signal intensities from array CGH data (a) has a much higher signal-to-noise 
ratio compared to that generated by the SNP arrays (b). B allele frequency (BAF) is a powerful 
metric available in most CNV detection methods on SNP arrays (shown as plots made of black 
dots in (b)). Examples of the expected log ratio and BAF values that signify 4 copies, 3 copies, 
2 copies, 1 copy and 0 copy are shown. Additionally, BAF values that signify copy number 
neutral events but suggest segmental uniparental disomy (segmental UPD) or whole-
chromosome UPD and identity by descent (IBD), resulting from a replacement of a segment of 
one chromosome by the other allele, is shown. A mosaic loss and gain scenarios are also 
shown. While in (c), the theoretical power of various commercially available platforms to detect 
CNV (by size) at any given location in the genome is shown (From Alkan et al., 2011).  
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Algorithms for automating CNV detection on SNP platforms 
There are many algorithms that have been written to automate CNV detection 
on the SNP platforms. QuantiSNP (Colella et al., 2007) and PennCNV (Wang et 
al., 2007) are among the most commonly used algorithms for CNV detection 
and optimized for the Illumina platform. Other algorithms include BirdSuite 
(optimized for the Affymetrix platform) (Korn et al., 2008), HMMSeg (Day et al., 
2007) and cnvPartition (developed by Illumina, CA, USA) (Winchester et al., 
2009). All of these algorithms have high false discovery rates in addition to other 
limitations, many of which will be discussed in the subsequent chapters of this 
thesis (Tsuang et al., 2010, Marenne et al., 2011, Dellinger et al., 2010). The 
QuantiSNP algorithm uses an Objective Bayes Hidden-Markov Model and CNV 
events are defined as excursions out of the normal states. Each event is 
associated with a Bayes factor, which is a ratio of two probabilities that 
compares the evidence for the region being in hidden state in comparison to 
those in which no part of this region is in this hidden state (Colella et al., 2007). 
Thus, the Bayes factor can be used as a detection threshold for “tuning” 
purposes in the analysis pipeline. This is very desirable because the quality of 
the signal intensity data is known to be exceedingly sensitive to the variability in 
experimental treatments. The PennCNV algorithm also implements a Hidden 
Markov Model, but it doesn’t provide a probabilistic or likelihood measure when 
calling CNVs. However, PennCNV has an option to utilize family information to 
generate trio-joint CNV calling, which is a preferred method to identify de novo 
CNVs in trio-design studies (Wang et al., 2007). 
c) Limitations of all microarray approaches 
Array-based methods have several inherent limitations: the requirement for the 
knowledge of the sequences under interrogations as the prerequisite for the 
array design, the problem of cross-hybridizations for highly homologous 
sequences, the inability to provide information on the locations of duplicated 
copies and a single base-pair resolution of CNV breakpoints is impossible to 
obtain.  Moreover, both CGH and SNP arrays suffer reduced sensitivity in 
single-copy gain detection (3:2 copy number ratio) in comparison to deletions 
(1:2 copy-number ratio). The BAF metrics on the SNP arrays, although 
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powerful, may not be sufficient when only few probes are available or in regions 
of Runs of Homozygosity (ROHs) (McQuillan et al., 2008).  This has caused 
ascertainment bias (more deletions than duplications are detected) in most CNV 
surveys that have been conducted on various array platforms, including in the 
study presented in this thesis. The array detection methods also assume diploid 
state in all locations of the reference genome. Therefore, CNV detection in SD 
regions is not reliable. Yet it is well-known that CNVs have strong positive 
correlation with SDs, and most CNV breakpoints (that are generated via NAHR) 
lie within SDs.  
Next-generation sequencing approaches 
The arrival of next-generation sequencing (NGS) technologies holds much 
promise to revolutionize the studies of structural variation. They are likely to 
supplant microarrays as the technology of choice in near future (Wheeler et al., 
2008, Bentley et al., 2008, McKernan et al., 2009, Korbel et al., 2007). The 
greatest challenge of NGS approaches lies in the computational and 
bioinformatics aspects of data analysis. There are four general methods for 
CNV detection (i.e. read-depth, read-pair, split-read and assembly), all of which 
focus on mapping sequence reads to the reference sequence and subsequently 
detecting discordant signatures that suggest the presence of a CNV. However, 
none of these approaches is comprehensive. When multiple algorithms and 
experimental methods are applied to the same DNA samples, a significant 
fraction of the validated CNVs remains unique to one of the approaches (Alkan 
et al., 2011, Mills et al., 2011, Kidd et al., 2010).  
The greatest limitation in using NGS is the nature of the data (i.e. short 
sequencing reads) that cause considerable read-mapping ambiguity due to the 
high complexity of the human genomic sequence. Although future technologies 
with longer sequence reads may help, it has been estimated that >1.5% of the 
human genome still cannot be covered uniquely with read lengths of 1kb 
(Schatz et al., 2010). Moreover, sequence coverage is a determining factor in 
achieving high sensitivity and specificity in CNV detection. But most projects 
(including the 1000 Genomes project) opt to sequence at low coverage for cost 
effectiveness (2010). Last but not least, storage and analysis of NGS data 
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requires a substantial investment in computational resources. And as the 
number of sequenced genomes increase, there is currently an urgent need for 
improvements in the efficiency of both data storing and processing.  
Nonetheless, the NGS technologies offer the possibility to detect multitude of 
classes of structural variation (including inversions and novel insertions) and 
achieve genome-wide analysis of a complete spectrum of genetic variation 
without a priori information. The ability of such technologies to distinguish 
paralogous copies of duplicated gene families also has been extremely valuable 
in studying the phenotypic effect and evolutionary roles of gene duplications 
(Sudmant et al., 2010). 
1.3.5 Targeted CNV detection methods 
Genome-wide techniques enable CNV discovery but facing the challenge of 
analyzing the data “blind” to the possible CNV locations, thus stringent threshold 
must be applied to reduce false-positive discoveries. CNV genotyping (targeted 
CNV detection methods) on the other hand, has the advantage of increased 
power to detect CNVs due to the more relaxed threshold that can be applied 
compared to those of CNV discovery methods. However, accurate CNV 
genotyping is still a major set-back in multiallelic CNV loci (Craddock et al., 
2010). Targeted CNV detection encompasses various techniques that include 
various PCR-based methods (e.g. MLPA, QF-PCR, PRT and qPCR), 
fluorescent in situ hybridization (FISH) and Southern blotting. The following 
sections will briefly discuss some of the PCR-based methods. 
Multiplex ligation-dependent probe amplification (MLPA) 
MLPA (Schouten et al., 2002) is a multiplex PCR method that can measure 
relative copy numbers in up to 50 different genomic sequences. The assay 
involves denaturation and hybridization of MLPA half-probes to genomic target, 
followed by ligation and PCR amplification of the ligated MLPA probes. The 
PCR products are subsequently separated using capillary electrophoresis and 
quantified to obtain relative dosage. Unlike detection power in the microarray 
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approaches that are limited by the size of the CNVs, MLPA can detect single 
base pair indels to whole chromosomal abnormalities in any given target, 
although it may not necessarily able to differentiate small and large CNVs. The 
information on CNV size is only attainable in an assay that has been designed 
to genotype previously characterized CNVs with known size. Like most assays, 
MLPA is very sensitive to DNA qualities and extraction methods. It cannot 
reliably genotype certain regions in the genome that are GC rich. MLPA assay 
also can be difficult to design in SNP-dense regions. Further information on 
design, reaction and analysis can be found in the Method chapter of this thesis. 
Quantitative Fluorescent – Polymerase Chain Reactions (QF-PCR) 
QF-PCR (von Eggeling et al., 1993) involves PCR amplification of genetic 
markers known as small tandem repeats (STRs) using fluorescently-labelled 
primers, followed by separation and detection using capillary electrophoresis 
and subsequent dosage analysis. A normal diploid sample will show two peaks 
in a 1:1 ratio when the marker is heterozygous or one peak when the marker is 
homozygous. The presence of an additional allele will result in three peaks in a 
1:1:1 ratio or as two peaks in a 2:1 or 1:2 ratio, which is indicative of a trisomy. 
However, test subjects who are homozygous or monosomic for a specific 
marker are indistinguishable; both will display as one peak, which can be a 
problem when testing for sex chromosome abnormalities. Incorporating 
additional X-chromosome STR markers is likely to reduce but not eliminate the 
likelihood of homozygosity. Therefore, using an additional marker that measure 
the relative dosage of an autosomal chromosome compared to the X 
chromosome can greatly increase the specificity and sensitivity of the assay. 
Paralogue ratio test (PRT) 
Paralogue ratio test (PRT) assay is a comparative PCR approach, which uses a 
single primer pair to amplify dispersed repeats that are shared in both test and 
reference loci (Armour et al., 2007). The PCR products are subsequently 
distinguished via the internal sequence differences and quantified to calculate 
relative dosage. This approach is inexpensive and reportedly capable of 
accurately genotyping multiallelic CNVs (Armour et al., 2007). However, the 
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major set-back of this approach is the reference locus that is variable for each 
assay. Moreover, the use of linked paralogous sequences and various 
dispersed repeats (e.g. LTRs and MERs) in the PRT assay design severely 
limits the use of such assay due to the complex nature of the repeat sequences 
as well as the limitation of the currently available reference sequence (e.g. the 
most current GRCh37 build still contains ~300 gaps (Dolgin, 2009)). 
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1.4 Congenital heart disease 
Congenital heart disease (CHD) is the most common form of congenital 
anomaly. The birth prevalence of CHD varies from 4/1,000 to 50/1,000 – see 
Figure 1.10 (Hoffman and Kaplan, 2002). CHD is the leading non-infectious 
aetiological cause of infant deaths in the Western hemisphere (Boneva et al., 
2001). In ~20% of the CHD cases, they occur as part of recognized 
chromosomal or Mendelian syndromes (Goodship et al., 1998, Freeman et al., 
1998, Wessel et al., 1994, Garg et al., 2003, Razzaque et al., 2007), while the 
remaining (~80%) of the cases have unknown aetiology and manifest as 
isolated (non-syndromic), non-Mendelian conditions. Nevertheless, significant 
familial recurrence risk has been demonstrated in such sporadic CHD cases, 
suggesting the presence of strong but complex genetic components in the 
occurrence of most CHD (Burn et al., 1998, Gill et al., 2003, Oyen et al., 2009). 
Some environmental risk factors have also been identified as the contributing or 
causal risk for CHD (Jenkins et al., 2007).  
 
Figure 1.10 – CHD prevalence per million live births 
A bargraph in logscale depicts the mean prevalence per million live births from the 
incidence data derived from various published studies, as described at Hoffman and 
Kaplan, 2002. 
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1.4.1 Cardiac morphogenesis 
CHD is the clinical manifestation of anomalies in the embryonic cardiac 
development. The heart is the first internal organ to form and function during 
embryogenesis. In brief, the human heart development begins with the 
specification of myocardial and endocardial progenitor cells during the 
establishment of heart-forming fields. The first heart field forms the cardiac 
crescent, while the second heart field lies medially to the crescent. Both heart 
fields then move to the midline, where the first heart field (that later contributes 
to the left ventricle) forms a linear heart tube, and in concert with the second 
heart field (that later contributes to the right ventricle and the outflow tracts) 
create a series of looping, bending and ballooning transformation events. 
Subsequently, a series of septation events create a four-chambered heart with 
parallel systemic and pulmonary circulations. A detailed description of cardiac 
morphogenesis is beyond the scope of this thesis. The simple overview of heart 
development can be found at Figure 1.11. Any type of insult at any stage of the 
developing heart may result in a spectrum of malformations observed in CHD 
patients (Buckingham et al., 2005, Epstein, 2010).   
 
Figure 1.11 – Heart development 
Cardiac development involves a progression from the cardiac crescent to the linear 
heart tube, which in turn undergoes a series of looping and transformation, followed by 
septation process to make a mature four-chambered heart. (From Epstein, 2010).  
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1.4.2 Types of congenital heart disease 
Numerous numbers of CHD classification systems have been proposed from 
either the anatomical or developmental origins, clinical, physiological or genetic 
overlaps (Tynan et al., 1979, Sauvage et al., 1973, Riehle-Colarusso et al., 
2007, Morgan, 1978, Franklin et al., 2002). Classifications of CHD are 
particularly challenging due to the diversity and complex phenotypic overlaps, 
as well as the heterogeneity in the underlying developmental mechanisms. For 
this thesis, CHD is classified broadly into cyanotic defects, septation defects 
and left-sided malformations (Bruneau, 2008). Infants with cyanotic defects 
have arterial oxygen desaturation, and most of them do not survive to adulthood 
without surgical interventions (Brickner et al., 2000b). The most common type of 
cyanotic CHD is tetralogy of Fallot (TOF) – see Figure 1.12A; others include 
transposition of the great arteries (TGA; see Figure 1.12B), pulmonary atresia 
(PA) and total anomalous pulmonary venous drainage (TAPVD). Defects of 
cardiac septations include ventricular septal defect (VSD; see Figure 1.12C), 
atrial septal defect (ASD; see Figure 1.12D) and atrioventricular septal defect 
(AVSD). Left-sided malformations are defects that cause obstruction to the 
systemic blood flow. Examples of such lesions include aortic stenosis (AS), 
coarctation of the aorta (CoA), interrupted aortic arch (IAA) and hypoplastic left 
heart syndrome (HLHS). Additionally, there are types of CHD that do not fit into 
any of these three categories. These include bicuspid aortic valve (BAV) and 
patent ductus arteriosus (PDA).  
The following sections will briefly discuss some of the CHD types that are most 
commonly found in the study cohort presented in this thesis: 
Tetralogy of Fallot 
Tetralogy of Fallot (TOF) is characterized by an obstruction of the right 
ventricular outflow tract and the resulting right ventricular hypertrophy, a large 
ventricular septal defect (opening in the interventricular septum), and an aorta 
that overrides the left and right ventricles – see Figure 1.12A (Brickner et al., 
2000b). TOF was first described by Niels Stenson in 1671, but its precise 
anatomical description was only introduced in 1784 by William Hunter at St. 
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Georges Hospital Medical School in London, and was refined by Etienne-Louis 
Fallot in 1888 in his publication of L’anatomie pathologique de la maladie blue. 
The term “tetralogy of Fallot”, however, was first introduced by Canadian Maude 
Abbott in 1924 (Apitz et al., 2009). TOF is often regarded as a family of 
diseases with a similar intracardiac anatomy. Its manifestation is highly variable 
in terms of anatomy, associated abnormalities and outcomes. Most patients with 
TOF have substantial right-to-left shunting due to the increased resistance to 
venous blood flow in the right ventricular outflow tract, which causes the 
cyanosis. While the severity of the obstruction that underlies the flow resistance 
in the right ventricular outflow tract determines the magnitude of the shunting, 
an increase or decrease of systemic vascular resistance can also decrease or 
increase the underlying right-to-left shunting (Brickner et al., 2000b). Before the 
paediatric cardiovascular surgical era, most TOF patients die during childhood. 
Only 66% survived passed 1 year of age, 40% passed 3 years of age, 11% 
passed 20 years of age, and mere 3% passed 40 years of age (Bertranou et al., 
1978). In contrast, the survival rates of TOF patients who received surgery were 
~92% at 5 year of age and ~85% at 36 years of age (Pigula et al., 1999, Murphy 
et al., 1993). 
Transposition of the great arteries 
Transposition of the great arteries (TGA) is a cardiac malformation in which the 
two major arteries are “transposed”: the aorta that normally arises from the left 
ventricle instead arises from the right ventricle, while the pulmonary artery 
arises from the left ventricle, instead of from the right ventricle (see Figure 
1.12B). This condition results in a separation of the pulmonary and systemic 
circulations: the venous blood from systemic circulation passes through the right 
atrium, right ventricle, aorta and back to systemic circulation, whereas the 
pulmonary venous blood passes through the left atrium, left ventricle, pulmonary 
artery and back to the pulmonary circulation. Therefore, infants with TGA have 
severe cyanosis. Without any form of communication between the two circuits, 
these patients will not survive. Two thirds of TGA cases have ductus arteriosus 
or foramen ovale, while the remaining cases have other associated defects that 
permit intracardiac mixing (e.g. atrial septal defect or ventricular septal defect) 
and their conditions are therefore less critical. Without interventions, the 
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mortality rate for infants with TGA is 90% by six months of age (Brickner et al., 
2000b). 
Ventricular septal defect 
Ventricular septal defect (VSD) is the most commonly found congenital cardiac 
anomaly in neonate and paediatric patients (see Figure 1.12C). VSD signifies 
an opening in the interventricular septum that led to shunting of blood between 
the two ventricles. In 25-40% of the cases, the defect closes spontaneously by 
the age of 10. The precise anatomic location of VSD varies, and the severity of 
the defect depends on the size of the opening and the pulmonary vascular 
resistance. Patients with small defects and normal pulmonary arterial pressure 
are usually asymptomatic (although at risk for infective endocarditis). Surgery is 
recommended for those with large defects, if the extent of pulmonary vascular 
resistance is not prohibitive (Brickner et al., 2000a). 
Atrial septal defect 
Atrial septal defect (ASD) represents one-third of the CHD found in adult 
patients. The defect is found 2-3 times more commonly in women than in men 
(Campbell, 1970, Feldt et al., 1971). ASD is also highly variable in terms of 
anatomy, associated abnormalities and outcomes. The defect is characterized 
by the shunting of blood between the two atria. The direction and magnitude of 
the shunting via the interatrial septum are determined by the extent of the defect 
as well as the relative compliance of the ventricles (Brickner et al., 2000a). 
Figure 1.12C illustrates a case of ASD with the left-to-right shunting.  
Patent ductus arteriosus 
The ductus arteriosus connects the descending aorta to the left pulmonary 
artery. This is normally found in the foetus, since it permits the pulmonary 
arterial blood to bypass the unexpanded lungs and enter the descending aorta 
for oxygenation in the placenta. Ductus arteriosus normally closes soon after 
birth, but in some infants, it does not close spontaneously (i.e. patent ductus 
arteriosus; PDA), causing the left-to-right shunting due to the flow from the aorta 
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to the pulmonary artery. PDA accounts for ~10% of all CHD cases. Although 
patients with mild PDA are usually asymptomatic, one third of PDA cases that 
are not surgically repaired eventually die of heart failure, pulmonary 
hypertension or endarteritis by the age of 40 (Brickner et al., 2000a, Campbell, 
1968).  
          
                             
Figure 1.12 – Types of congenital heart disease 
(From Brickner et al., 2000a and Brickner et al., 200b; legend on the next page) 
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trick 
Figure 1.12 – Types of congenital heart disease 
Panel (A) depicts tetralogy of Fallot (TOF), which is characterized by four defects: an 
obstruction of the right ventricular outflow tract (1), the resulting right ventricular 
hypertrophy (2) and an overriding aorta (3) that sits on top of a ventricular septal defect 
(VSD) (4). The obstruction of the right ventricular out tract determines the severity of 
the right to left shunting of the venous blood through the VSD (the arrow indicates the 
unoxygenated blood from the right ventricle crosses over to the left ventricle and up to 
the arterial circulation via the overriding aorta) - hence the cyanosis (bluish appearance 
to the skin, lips and fingernails). In the case of transposition of the great arteries (TGA), 
the aorta arises from the right ventricle and the pulmonary artery arises from the left 
ventricle – see (B). Thus, systemic and pulmonary circulations are completely 
separated. Infants with such condition will only survive if there is a communication 
between the two circuits, such as a patent ductus arteriosus (PDA). Panel (C) shows a 
case of ventricular septal defect (VSD). When the left ventricle contracts, it ejects some 
blood into the aorta as well as across the VSD into the right ventricle and pulmonary 
artery (left to right shunting). Panel (D) also shows a left to right shunting, but in the 
case of atrial septal defect (ASD). As shown by the arrows, the blood from the 
pulmonary veins enters the left atrium, and crosses into the right atrium and to the right 
ventricle). (From Brickner et al., 2000a and Brickner et al., 2000b). 
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1.4.3 Genetic factors for CHD 
The genetic elucidation of most complex human traits, including sporadic CHD 
(that account for ~80% of all CHD), has been limited at best. Most of what is 
known about genetic basis of CHD has come from studies of the remaining 
~20% occurrence of CHD, which consist of chromosomal disorders, Mendelian 
syndromes and rare familial forms of non-syndromic CHD. Nevertheless, 
variable penetrance and variable phenotypes have been observed, even in the 
case of rare familial single-gene disorders, suggestive of the importance of 
modifying genetic and environmental factors in CHD. In the subsequent 
sections, some of the known causative genetic factors of CHD will be briefly 
discussed. 
Genetic contributors for syndromic CHD 
1. Aneuploidies 
Aneuploidy is a chromosomal abnormality that is characterized by a deviation 
from the normal number (46) of human chromosomes. It is associated with 
significant mortality and morbidity in prenatal and early postnatal life. They 
occur in ~1/160 live births, but they are found in a much higher frequency with 
advanced maternal age. Trisomy 21 (Down syndrome; MIM 190685), trisomy 18 
(Edwards syndrome; MIM 601161) and trisomy 13 (Patau syndrome) account 
for the majority of autosomal chromosome alterations found in foetus that are 
carried to term. The clinical features of these trisomies are variable but CHD is a 
major component in all of them. Except for trisomy 21, the other autosomal 
trisomies are incompatible with survival (e.g. <10% of trisomy 13 and trisomy 18 
infants reach 1 year of age). On the other hand, individuals with sex 
chromosome aberrations generally have less severe clinical manifestations 
when compared to the autosomal trisomies. This can be attributed to genetic 
inactivation mechanism in all but one X chromosome (in cases where multiple 
copies of X chromosomes are present) as well as the relatively low gene 
content of the Y chromosome. Sex chromosome abnormalities in males include 
47,XXY (Klinefelter’s syndrome) and 47,XYY, while in females include 45,X 
(Turner’s syndrome) and 47,XXX (Triple X syndrome). Except for Turner’s 
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syndrome (45,X) that is normally diagnosed in newborns and often include 
CHD, the other sex chromosome aberrations are mostly diagnosed after 
puberty. Nevertheless, CHD occurs frequently in 47,XXY males, and 
occasionally in 47,XYY and 47,XXX cases (Wimalasundera and Gardiner, 2004, 
Driscoll and Gross, 2009, Polani, 1968, Adatia et al., 1987, Visootsak et al., 
2001, Pierpont et al., 2007). Table 1.2 shows the reported frequency of CHD 
occurrences in different types of aneuploidies. 
Table 1.2 – Aneuploidies associated with CHD 
Aneuploidy % CHD CHD types 
Trisomy 21 (Down syndrome) 40-50 
AVSD, VSD, ASD (also less commonly TOF 
and TGA) 
Trisomy 18 (Edwards syndrome) 90-100 
ASD, VSD, PDA, TOF, DORV, TGA, CoA, 
BAV, BPV, polyvalvular nodular dysplasia 
Trisomy 13 (Patau syndrome) 80 
ASD, VSD, PDA, HLHS, laterality defects, 
atrial isomerism 
45,X (Turner syndrome) 25-35 CoA, BAV, valvar AS, HLHS, aortic dissection 
47,XXY (Klinefelter’s syndrome) 50 MVP, PDA, ASD 
Trisomy 9 mosaicism 65-80 PDA, LSVC, VSD, TOF/PA, DORV 
Trisomy 8 mosaicism 25 VSD, PDA, CoA, PS, TAPVD, PTA 
Adapted from Pierpont et al., 2007. AVSD = atrioventricular septal defect, VSD = ventricular septal 
defect, ASD = atrial septal defect, PDA = patent ductus arteriosus, TOF = tetralogy of Fallot, DORV = 
double outlet right ventricle, TGA = transposition of the great arteries, CoA = coarctation of the aorta, 
BAV = bicuspid arterial valve, BPV = bicuspid pulmonary valve, HLHS = hypoplastic left heart syndrome, 
AS = aortic stenosis, MVP = mitral valve prolapsed, LSVC = persistent left superior vena cava, PA = 
pulmonary atresia, PS = pulmonary stenosis, TAPVD = total anomalous pulmonary drainage, PTA = 
persistent truncus arteriosus. 
From the reverse viewpoint, Table 1.3 is showing the frequency of aneuploidies 
in some of the most commonly observed CHD types. Some forms of CHD are 
more commonly observed in certain types of aneuploidies. The strongest 
association observed was found between atrioventricular septal defect (AVSD) 
and trisomy 21 (Evans, 1950). AVSD and ventricular septal defect (VSD) 
accounted for ~76% of CHD in trisomy 21 cases (Kidd et al., 1993). They were 
also frequently encountered in trisomy 13, trisomy 18 and in a lower frequency, 
45,X (Wimalasundera and Gardiner, 2004, Pierpont et al., 2000). Tetralogy of 
Fallot (TOF), double outlet right ventricle (DORV), common arterial trunk (CAT) 
and coarctation of the aorta (CoA) were frequently found in trisomy 21, trisomy 
18, trisomy 13 and 45,X neonates (Tennstedt et al., 1999, Boldt et al., 2002, 
Allan et al., 1994). Hypoplastic left heart syndrome was also frequently found in 
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trisomy 18, trisomy 13 and 45,X neonates, but not in trisomy 21 (Allan et al., 
1994, Tennstedt et al., 1999, Boldt et al., 2002), while heterotaxy has only been 
found to be associated with trisomy 18 (Lin et al., 2002). 
Table 1.3 – The percent rate of aneuploidy for individuals with CHD 
                                                                          Aneuploidy distribution 
CHD 
% overall 
aneuploidy rate 
Trisomy 21 
(%) 
Trisomy 18 
(%) 
Trisomy 13 
(%) 
45,X           
(%) 
Other (%) 
AVSD 46 79 13 - - 8 
VSD 46 43 45 2 4 6 
TOF 31 43 29 7 - 21 
CoA 33 18 24 24 12 22 
HLHS 7 - 56 22 11 11 
DORV 21 10 40 20 30 - 
Adapted from Wimalasundera and Gardiner, 2004. AVSD = atrioventricular septal defect, VSD = 
ventricular septal defect, TOF = tetralogy of Fallot, CoA = coarctation of the aorta, HLHS = hypoplastic left 
heart syndrome, DORV = double outlet right ventricle 
2. DiGeorge syndrome 
The most common recurrent pathogenic microdeletion found in humans 
encompasses a region in chromosome 22q11 that result in DiGeorge (MIM 
188400) or velocardiofacial (MIM 192430) syndrome (DG/VCFS) (Ryan et al., 
1997, Goodship et al., 1998, Cooper et al., 2011). The phenotypes of DG/VCFS 
patients often include CHD, the most frequently observed being interrupted 
aortic arch type B, tetralogy of Fallot, truncus arteriosus, conoventricular VSDs 
and other aortic arch anomalies. However, pulmonary stenosis, atrial septal 
defect, heterotaxy and hypoplastic left heart syndromes have also been 
observed in these patients. Other common clinical features of 22q11 deleted 
patients include palate anomalies, hypocalcaemia, feeding disorders, renal 
abnormalities, behavioural disturbances, speech and learning disabilities. There 
are two types of 22q11 deletions (~3Mb and ~1.5Mb) that are typically found in 
DG/VCFS patients. They are generated by the NAHR mechanism, mediated by 
the three major SD clusters in the region (that are commonly referred as 
LCR22) (Edelmann et al., 1999). The genomic span of DG/VCFS is a well-
known hotspot for recurrent rearrangements (see Figure 1.2).  
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3. Williams-Beuren syndrome 
Williams-Beuren syndrome (Williams syndrome; WBS [MIM 194050]) is an 
autosomal dominant disorder characterized by CHD (typically supravalvular 
aortic stenosis), infantile hypercalcaemia, characteristics facial features, skeletal 
and renal abnormalities, cognitive deficits and gregarious personality. 
Approximately 90% of patients with clinical diagnosis of WBS have recurrent 
microdeletions at chromosome 7q11.23 (Ewart et al., 1993, Wessel et al., 1994, 
Ferrero et al., 2007, Pierpont et al., 2007). Haploinsufficiency of ELN (MIM 
130160), which encodes the elastin gene, is believed to be responsible for the 
CHD manifestation in WBS patients with 7q11.23 deletions (Pober, 2010, 
Tassabehji et al., 1997). The genomic span of WBS deletions has also been 
recognized as one of the NAHR hotspots (see Figure 1.2). The deletions are 
mediated by the existing three major clusters of SD in the 7q11.23 region, 
resulting in the ~1.5Mb and ~1.8Mb recurrent deletions that were found in 95% 
and 5% of patients, respectively (Bayes et al., 2003). 
4. Alagille syndrome 
Alagille syndrome (MIM 118450) is an autosomal dominant disorder with clinical 
manifestations of abnormalities of the liver, heart, eye, skeleton, and a 
characteristic facial appearance. CHD occur in >90% of patients with Alagille 
syndrome (McElhinney et al., 2002). The most commonly observed CHD in 
Alagille patients are peripheral pulmonary artery hypoplasia, tetralogy of Fallot 
and pulmonary valve stenosis (Pierpont et al., 2007). Some patients with 
Alagille syndrome have deletions of chromosome 20p12 (Krantz et al., 1997), 
while others have mutations of JAG1 [MIM 601920] (McElhinney et al., 2002, Li 
et al., 1997a). JAG1 mutations causative for non-syndromic forms of pulmonary 
stenosis and tetralogy of Fallot also have been identified (Krantz et al., 1999, 
Eldadah et al., 2001). 
5. Noonan syndrome 
Noonan syndrome is an autosomal dominant syndromic disorder characterized 
by typical facial dysmorphisms, short stature, webbed neck, cardiac anomalies, 
deafness, motor delay, and a bleeding diathesis. CHD occur in 80-90% of 
Chapter 1: Introduction 
34 
 
affected individuals, the most commonly observed being pulmonary valvar 
stenosis and hypertrophic cardiomyopathy (Noonan, 1994, Marino et al., 1999). 
Noonan syndrome can be caused by a mutation in either of the following genes: 
PTPN11 (MIM 163950; 176876) on chromosome 12q24.13, SOS1 (MIM 
610733; 182530) on chromosome 2p22.1, KRAS (MIM 609942; 190070) on 
chromosome 12p12.1, RAF1 (MIM 61553; 164760) on chromosome 3p25.2, 
NRAS (MIM 613224; 164790) on chromosome 1p13.2 and BRAF (MIM 613706; 
164757) on chromosome 7q34.  
6. Holt-Oram syndrome 
Holt-Oram syndrome (MIM 142900) is an autosomal dominant syndrome that is 
characterized with CHD and abnormalities in the upper limb extremities. This 
syndrome can be either be inherited in a Mendelian fashion or occurs 
sporadically. CHD are found in ~95% of the cases, with secundum atrial septal 
defect as the most commonly observed phenotype. However, a wide variety of 
other CHD have also been identified in these patients, including ventricular 
septal defect and mitral valve prolapse (Smith et al., 1979, Newbury-Ecob et al., 
1996). The Holt-Oram syndrome is caused by mutations in the TBX5 gene (MIM 
601620) on chromosome 12q24.1 (Basson et al., 1997, Li et al., 1997b). 
Interestingly, mutations responsible for CHD are clustered in a different region 
of the protein than mutations responsible for the limb defects, thus suggesting 
the presence of different downstream targets of the same gene in different 
tissues (Basson et al., 1999).  
Genetic contributors for non-syndromic CHD 
1. Rare variants with high penetrance 
Many causative single-gene mutations have been identified in a minority of non-
syndromic CHD occurrences, mostly from genetic linkage analyses of rare 
family pedigrees. Mutations in cardiac transcription factor NKX2.5 (MIM 600584) 
were discovered in 4 kindred with atrial septal defects and cardiac conduction 
abnormalities (Schott et al., 1998). Further screening in non-Mendelian 
(sporadic) CHD cases also identified sequence alterations in the same gene 
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that were not present in control subjects in patients with tetralogy of Fallot, 
tricuspid valve anomalies, hypoplastic left heart syndrome and other types of 
CHD (Goldmuntz et al., 2001, Benson et al., 1999, Elliott et al., 2003, Wessels 
and Willems, 2010). Additionally, mutations of GATA4 (MIM 600576), another 
cardiac transcription factor, were also identified in 2 families with septal defects 
without apparent syndromic features (Garg et al., 2003).  Other familial CHD 
that involve other genes, e.g. ZIC3 (MIM 300625), NKX2.6 (MIM 611770), 
MYH6 (MIM 160710), ACTC1 (MIM 102540) and NOTCH1 (MIM 190198) have 
also been characterized, while other mutations were identified by various 
candidate gene approaches.  For example, a sequencing study performed in 
our group of exonic and splice-site regions of candidate gene TBX1 (MIM 
602054) identified a 57bp exonic deletion that was found to significantly reduce 
the transcriptional activity of the protein in a TOF patient with right-sided aortic 
arch (Griffin et al., 2010). For a comprehensive list of some of the published 
high penetrant mutations in CHD, see Table 1.4. It is important to note that the 
causal relationship to sporadic CHD in some of the private mutations identified 
by the candidate gene approach is difficult to establish definitively, although 
their contribution to CHD risk is very likely. Moreover, as evident from the data 
shown in Table 1.4, a single genetic defect can result in a broad range of 
cardiac defects, while various genetic defects may in turn result in the same 
type of heart malformation. These findings thus highlight the multifactorial 
aetiology of CHD, in addition to identifying the common molecular pathways that 
are associated with the occurrence of CHD during cardiac development. Many 
of the genes implicated are transcriptional regulators and ligand receptors that 
are known to be important for cardiac morphogenesis; the identifications of 
these genes thus helped in underlining the transcriptional networks and signal 
transduction pathways that are frequently targeted by genetic and environment 
perturbation that lead to CHD.   
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Table 1.4 – High penetrance mutations that cause various types of CHD 
Genes CHD type Mutations 
Ligand receptors   
NOTCH1 BAV/AS 
R1108X, H1505del, T596M, P1797H, P1390T, 
A683T, G661S 
CFC1 Heterotaxy R112C, R189C 
 TGA Splice donor site duplication intron 4 
 TOF IVS4+2T>C 
 PTA IVS4+2T>C 
 AVSD IVS4+2T>C 
LEFTY2 Heterotaxy R314X, S342K 
ACVR2B Heterotaxy R40H, V494I 
GDF1 TOF G162D, D309P, P312T 
ALK2 ASD L343P 
 TGA C227X, A318T 
 DORV C267Y 
 AVSD G262S, R68H 
NODAL Heterotaxy 
E203K, G260R, R275C, V284F, 
R234_P241delinsLTS, IVS1-1G>T, IVS2+1G>A 
TDGF1 TOF P125L 
JAG1 PS G274D 
 TOF E228fs 
Transcription factors   
GATA4 ASD S52F, G296S, S358del, E359fs, Q316E, A411V 
 TOF E216D, D425N, A118_A119insA, P407Q 
 VSD 
A411V, E359K, A6V, S46del, A125_A126insAA, 
S429T, A422V 
GATA6 PS N466H 
NKX2.5 ASD 
Q149X, R189G, T178M, Y259X, Q170X, Q198X, 
Q160P, IVS1+1G>T+AT, c.215_221del7, A75fs, 
A88fs, R190C, Y256X, Q170X, E160P, K104fs, 
A127E, R142C, Q817H, N188K, R189G, Y191C, 
c.701_702ins5, C264X, E109X 
 TOF R25C, Q22P, R216C, R142C, A323T, Q149X 
 CoA R25C 
 HLHS T178M 
 IAA P275T 
 Heterotaxy c.215_221del7 
 TGA A63V 
 DORV N291del 
 VSD Y191C, Q149X, Y259X, E109X 
 Ebstein A42P 
TBX20 ASD I152M 
 VSD I152M 
 PDA I152M 
 DCM Q195X 
 MS/HLV Q195X 
 ASD 1121M 
CITED2 VSD S170_G178del 
 ASD G178_S179del, S198_G199del 
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FOXH1 TOF D350G, P336L, S339G 
ZIC3 Heterotaxy Various mutations 
 TGA W255G, K467X, K405E 
 ASD/PS A217P 
TBX5 
ASD, VSD, 
AVSD 
G80R 
TBX1 VSD A379_G381del 
 IAA A466_A476dup c.1399-1428dup 
 
TOF with R-
sided AA 
c.129_185del57 
ANKRD1 TAPVD T116M 
Adapted from Wessels and Willems, 2010. Mutations in the open reading frame are described at the 
protein level. AS = aortic stenosis; ASD = atrial septal defect, AVSD = atrioventricular septal defect, BAV = 
bicuspid aortic valve, CoA = coarctation of the aorta; DCM = dilated cardiomyopathy; DORV = double 
outlet right ventricle; HLHS = hypoplastic left heart syndrome; HLV = hypoplastic left ventricle; IAA = 
interrupted aortic arch; MS = mitral stenosis; PA = pulmonary atresia; PDA = patent ductus arteriosus; PS 
= pulmonary valve stenosis; PTA = persistent truncus arteriosus; TAPVD = total anomalous pulmonary 
venous drainage; TGA = transposition of the great arteries, TOF = tetralogy of Fallot; R-sided AA = right-
sided aortic arch, VSD = ventricular septal defect. 
2. Common variants with low penetrance 
Common variants with low penetrance and modest effects have been proposed 
to contribute to the manifestation of various complex traits, including sporadic 
CHD. They may act as disease modifiers (in concert with rare high penetrant 
variants) or as disease susceptibility factors. It has been argued, however, that 
common variants are unlikely to contribute to the susceptibility of severe 
congenital phenotypes such as CHD. Up until the modern surgical era that 
revolutionized the neonatal and paediatric CHD management, the mortality 
rates for CHD were extremely high. Therefore, variants that confer even a 
modest additional risk for such conditions will be expected to be eliminated by 
natural selection.  
Nevertheless, in a recent GWAS that was led by our group in a cohort of TOF 
and ancestry-matched controls, SNPs with genome-wide significance were 
identified within a locus on chromosome 12q24, which were subsequently 
replicated in another independent cohort (per allele OR = 1.27 [95% CI 1.13-
1.42]; P = 7.7 x 10-11) (Cordell et al., 2012, unpublished manuscript). 
Intriguingly, the strongest candidate gene within the 12q24 region is PTPN11, a 
regulator for Ras/MAPK signaling, whose gain of function mutations are known 
to cause Noonan syndrome, a condition in which 90% of the affected individuals 
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have CHD as a component of their phenotypes (as discussed in previous 
section) (Noonan, 1994, Marino et al., 1999). It has been hypothesized that the 
emergence of the risk haplotype in the 12q24 locus is driven by the 
advantageous selection that occurred during the expansion of population 
density in Europe, due to its effect of enhanced resistance to infection (Cordell 
et al., 2012, unpublished manuscript). Coincidently, the common variants of the 
PTPN11 gene had been previously identified to be associated with TOF from a 
candidate genes study, also conducted in our group (Goodship et al., 2012). 
1.4.4 Environmental factors for sporadic CHD 
Maternal pregestational diabetes 
Several environmental risk factors have been shown to influence the risk for 
CHD. Maternal pregestational diabetes has been associated with 3-20 fold 
increased risk, depending on the type of CHD. Most frequently observed CHD 
associated with maternal pregestational diabetes include laterality, looping 
defects, transposition of the great arteries, atrioventricular septal defect and 
outflow tract defects (Jenkins et al., 2007, Becerra et al., 1990). The evidence 
for the relationship between glycemic control during cardiogenesis and CHD 
has been well-established, and strict glycemic control before conception and 
during pregnancy has been shown to reduce CHD risk levels comparable to 
those of general population (Ray et al., 2001, Cousins, 1991). However, the 
precise pathogenic mechanism by which maternal diabetes cause CHD is still 
unclear. It has been proposed that abnormal glucose levels disrupt the 
expression of a regulatory gene that led to embryotoxic apoptotic cellular 
changes (Phelan et al., 1997). 
Maternal phenylketonuria 
Untreated maternal phenylketonuria has also been associated with 6-fold 
increased risk for CHD, the most commonly observed being coarctation of the 
aorta, tetralogy of Fallot, patent ductus arteriosus and hypoplastic left heart 
syndrome (Lenke and Levy, 1980, Levy et al., 2001). Strict diet control before 
and during pregnancy has been shown to reduce risk (Rouse and Azen, 2004). 
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Other factors 
Other definitive environmental risk factors for CHD include maternal rubella and 
exposure to drugs (Jenkins et al., 2007). 
1.5 General aim 
The general aim of this thesis is to investigate the role of CNVs in the genetic 
aetiology of sporadic CHD.  
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CHAPTER 2: MATERIALS AND METHODS 
2 Materials and Methods 
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2.1 Study Subjects 
2.1.1 Sample collections and inclusion criteria 
Non-syndromic CHD patients of European ancestry (51% male and 49% 
female, median age = 10 years, lower and upper quartiles = 1 and 25 years) 
with their parents and siblings (when available) were recruited from multiple 
centres in the UK (Newcastle, Bristol, Leeds, Liverpool, Nottingham, Leicester 
and Oxford), Germany (Erlangen), Belgium (Leuven) and Australia (Sydney) as 
part of the CHeartED and Wellcome Trust Case Control Consortium 
collaborations. Less than 1% of CHD cases recruited had affected first degree 
relatives. Ethical approval was granted from the local institutional review boards 
and informed consent was obtained from all participants (or from a 
parent/guardian in cases where the subjects were too young to consent 
themselves). Case ascertainment in Bristol, Leeds and Liverpool was principally 
focused on TOF, while case ascertainment in other centres included all CHD 
phenotypes. TOF was therefore relatively over-represented in the cohort.  DNA 
samples from cases were extracted from blood (85%) and saliva (15%) at each 
of the participating centres.  
2.1.2 French population cohort 
Control subjects consisted of unrelated healthy individuals of European ancestry 
from a French population cohort. All samples were extracted from whole blood.  
2.1.3 WTCCC2 control cohort 
WTCCC2 control cohort consists of 3000 individuals from the 1958 British Birth 
Cohort and 3000 individuals from the UK Blood Service. CNV data was 
obtained from personal communication with Dr. Matthew Hurles (Wellcome 
Trust Sanger Institute, Cambridge, UK). The 1958 British Birth Cohort DNA 
samples were cell line derived and the DNAs from the UK Blood Service 
individuals were extracted from blood (Craddock et al., 2010).  
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2.2 CNV detection on SNP arrays 
2.2.1 QC procedures 
Exclusion of cases with known causative chromosomal aberrations  
All patients were screened for DiGeorge, Williams-Beuren and other major 
chromosomal aberrations (e.g. trisomy 21 and trisomy 18) known to cause 
CHD; patients found with such anomalies were excluded from further study.  
SNP and intensity QC 
A total of 2896 CHD patients, 747 unaffected family members and 856 
unrelated controls were typed on the Illumina 660W-Quad SNP platform at the 
Centre National de Génotypage (Evry Cedex, France) and normalized total 
intensity and genotype data were obtained from the genotyping centre. Per 
sample SNP QC analyses were carried out in PLINK (Purcell et al., 2007) and 
samples with genotyping call rates <98.5%, average heterozygosity outside the 
range of [0.31, 0.33], gender mismatches and those that failed to cluster with 
the CEU individuals (Utah residents with Northern and Western European 
ancestry from Phase II HapMap) were excluded. Genomewide identity-by-
descent (IBD) sharing was calculated on all probands and only one from each 
pair of related probands (mean proportion of alleles shared IBD >0.1) was 
included in the analyses. Quality-control parameters were calculated from the 
intensity data and samples were excluded when they failed one of the following 
criteria: a standard deviation of autosomal log R ratio (LRR) > 3.0, GC wave 
factor of the LRR outside the range of [-0.1, 0.1] (Wang et al., 2007), and a 
standard deviation of B-allele frequency (BAF) >0.15 after GC correction 
(Colella et al., 2007). The results of the SNP and intensity QC procedures were 
collated, and individuals that passed all QC were included in the subsequent 
analyses. Finally, 2256 CHD cases (phenotype distribution is listed in Table 
2.1), 697 unaffected family members and 841 unrelated controls were 
incorporated in the subsequent studies reported in this thesis. The WTCCC2 
controls were typed on Affymetrix 6.0 arrays. Further details on genotyping and 
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QC criteria (n=5919 passed QC) on this cohort has been reported in a published 
study (Craddock et al., 2010) (http://www.wtccc.org.uk/ccc2). 
2.2.2 CNV calling algorithms 
CNV detection on the Illumina 660W platform was performed using both 
PennCNV (Wang et al., 2007) and QuantiSNP (Colella et al., 2007) calling 
algorithms. CNV detection on the Affymetrix 6.0 platform was performed using 
the Birdseye algorithm from the Birdsuite (Korn et al., 2008) package. All CNV 
coordinates were mapped to NCBI build 36.1 (hg18). For case-control CNV 
burden comparison and targeted CNV detection in the 1q21.1. locus, the 
QuantiSNP (Colella et al., 2007) algorithm was used as the primary CNV calling 
algorithm and the Bayes factors output was used as a detection threshold, as 
described in each relevant result chapters; while PennCNV individual calling 
(Wang et al., 2007) was used as a confirmatory method. For rare de novo CNV 
detection in family trios (probands and their respective unaffected parents), 
CNV calls were generated with PennCNV trio joint calling, which is the preferred 
method to call de novo CNVs (Wang et al., 2007), while QuantiSNP was used 
for confirmation.  
2.2.3 Contribution from collaborators in the Statistical Genetics Group 
The SNP QC analyses were performed by Prof. Heather J. Cordell. I obtained 
the results of her PLINK analyses that are pertinent to the projects described in 
this thesis and used them to identify certain individuals that needed to be 
excluded from my CNV analyses, as described in section 2.2.1. Dr. Ian J. 
Wilson ran the PennCNV and QuantiSNP algorithms on the normalized intensity 
data of all individuals that were genotyped on the Illumina 660W platform and 
Dr. Rebecca Darlay ran the Birdseye algorithm on the intensity data of 
individuals that were typed on the Affymetrix 6.0 platforms. Dr. Wilson also 
wrote an R script to generate LRR and BAF plots from the raw intensity data 
obtained from the genotyping centre. I obtained the resulting text files containing 
2,064,706 PennCNV calls, 2,720,143 QuantiSNP calls and 148,627 Birdseye 
calls (prior to any QC) that correspond to NCBI Build 36.1 positions 
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(chromosome start and end) and the associated specific parameters obtained 
from each algorithm (e.g. Bayes factors or LOD scores). Unless noted 
otherwise, I performed all the downstream CNV analyses (described in section 
2.2.4 onwards), including further QC, mapping to RefSeq genes and all pipeline 
designs and executions as well as the subsequent statistical tests that are 
described further in this thesis. 
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Table 2.1 – Phenotype distribution in 2256 CHD patients 
CHD type n 
Aortic arch abnormalities 161 
Aortic valve abnormalities 127 
Atrial septal defect 293 
Atrioventricular septal defect 60 
Common arterial trunk 22 
Congenitally corrected transposition of the great arteries  36 
Coronary artery anomaly 2 
Double inlet left ventricle or right ventricle 23 
Double outlet left ventricle 1 
Double outlet right ventricle 16 
Ebstein malformation 14 
Heterotaxy 7 
Hypoplastic left heart syndrome 14 
Left isomerism 13 
Mitral valve abnormalities 23 
Other  53 
Partial anomalous pulmonary venous drainage 12 
Patent ductus arteriosus 63 
Pulmonary atresia with intact ventricular septum 18 
Pulmonary atresia with ventricular septal defect 17 
Pulmonary stenosis 76 
Right isomerism 11 
Situs inversus/dextrocardia 5 
Tetralogy of Fallot 808 
Total anomalous pulmonary venous drainage 7 
Transposition of the great arteries  165 
Tricuspid valve abnormalities 32 
Univentricular heart 14 
Ventricular septal defect 163 
Total 2256 
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2.2.4 CNV analyses 
A highly stringent threshold (Bayes factor >100) was used as a filtering criterion 
in the primary global CNV burden analyses. For targeted detection in the 1q21.1 
locus that has a dense coverage in the Illumina 660W platform, a lower 
threshold (Bayes factor >50) was applied. Due to the limitations of the currently 
available detection technologies, all CNV calls >500kb and those occurring in all 
known pathogenic NAHR hotspots (Mefford and Eichler, 2009) were examined 
manually (in the context of platform coverage, segmental duplications and other 
properties of the region) in order to determine the approximate breakpoints, 
which cannot be done in an automated fashion. 
Rare de novo CNV detection in family trios was performed using much less 
stringent calling criteria in order to maximize capture; Bayes factor was not used 
as a filtering criterion. However, all putative CNV calls generated from this less 
stringent pipeline were subjected to verification by one or more independent 
experimental methods. All putative de novo CNVs and the flanking regions were 
examined manually in all three individuals of the trio unit (see Figure 2.1). Calls 
that appeared to be inherited on manual examination were excluded. And 
putative de novo calls that were artificially split (due to the limitation of the 
platform and the algorithms) were joined and confirmed with an independent 
method.  
CNVs were further analyzed using custom R scripts and the “join genomic 
interval” script on Galaxy (Goecks et al., 2010) in conjunction with conditional 
overlap filter as described in Figure 2.2. CNVs were visualized in the UCSC 
Genome Browser.  
2.2.5 Database mining 
The various analyses described in this thesis depended on the availability of 
many public databases. The coordinates for RefSeq genes transcription 
boundaries, segmental duplications (Bailey et al., 2002), cytogenetic bands, and 
SNP array content were downloaded from the hg18 UCSC Genome Browser 
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(http://genome.ucsc.edu) (Kent et al., 2002, Karolchik et al., 2004). The 
Database of Genomic Variants (DGV) (Iafrate et al., 2004) was downloaded 
from the UCSC Genome Browser as well as from http://projects.tcag.ca/. Gene 
descriptions were obtained using Gene ID conversion tool on the RefSeq IDs at 
the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
Bioinformatics Resources v6.7 (Dennis et al., 2003). The Online Mendelian 
Inheritance in Man (OMIM) database was downloaded from the ftp server 
grcf.jhmi.edu (McKusick, 2007). The haploinsufficiency scores were obtained 
from a published source (Huang et al., 2010). The fetal heart gene expression 
data was downloaded from the Bgee: Database for Gene Expression Evolution 
(http://bgee.unil.ch) (Bastian et al., 2008). The hg18 coordinates for the 
predicted human heart-specific enhancer sequences were obtained from a 
published source (Narlikar et al., 2010). 
Chapter 2: Materials and Methods 
48 
 
           F
ig
u
re
 2
.1
 –
 M
a
n
u
a
l 
e
x
a
m
in
a
ti
o
n
 r
e
v
e
a
ls
 l
im
it
a
ti
o
n
s
 o
f 
C
N
V
 d
e
te
c
ti
o
n
 a
lg
o
ri
th
m
  
(s
e
e
 l
e
g
e
n
d
 o
n
 t
h
e
 f
o
llo
w
in
g
 p
a
g
e
) 
A   
  
  
  
 
 B   
  
  
 
    C
 
     D
 
Chapter 2: Materials and Methods 
49 
 
Figure 2.1 – Manual examination reveals limitations of CNV detection algorithm 
Figure 2.1 – Manual examination reveals limitations of CNV detection algorithm 
There are major limitations in all the currently available algorithms for CNV detection 
on the SNP platform. The LRR and BAF plots of the proband, mother and father are 
shown. The blue hatch indicates PennCNV trio joint calls in the respective individuals. 
The blue hatched area that is highlighted in red indicates putative de novo call 
(occurs in the proband, but not in the mother and the father). However, examination 
of the flanking regions reveals that the duplication is in fact inherited. PennCNV calls 
from the father (D) suggests a duplication that span the putative de novo region (red 
highlight) in the proband (C). It is evident from the BAF plots that the algorithm failed 
to recognize the presence of a duplication whenever there is a stretch of homozygous 
SNPs, thus causing the artificial splits in different regions of the proband and the 
father; hence the inaccurate breakpoints and miscalling of the de novo duplication 
(red highlight). To verify this, CGH was performed on the proband (shown in A), which 
reveals the true duplication breakpoints in the proband, and thus confirming the 
shared breakpoints between the proband and the father, suggesting that the 
duplication is not de novo, but transmitted from the father to the proband. 
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Figure 2.2 – Conditional overlap filter 
Conditional overlap filters take into account three ways (purple bars) in which a CNV 
call may intersect the CNV under study (blue bar). To identify all the “purple calls” 
that have >20% overlap with the “blue CNV”, BED files from both data sets were 
joined using join script under “operate on genomic intervals” tool in Galaxy (Goecks 
et al., 2010). The script joins any two sets of genomic coordinates that intersect into 
one lane. If ‘A’ and ‘B’ are the start and end coordinates of a CNV under study and 
‘c’ and ‘d’ are the start and end coordinates of the “purple CNV” that intersect with 
the “blue CNV”, the following expression was computed to designate the output of 
joined coordinates into two categories: If (d-A)>(0.2(B-A)) and (d-B)>(0.2(B-A)) and 
(d-c)>(0.2(B-A)), the call was assigned as “>20% overlap call,” or else “<20% 
overlap,” in which case they were subsequently filtered out. 
2.2.6 CNV validation  
Affymetrix 6.0 SNP arrays, comparative genomic hybridization (CGH) arrays 
and multiplex ligation dependent amplification (MLPA) were used to confirm 
CNV calls that were made on the discovery platform (Illumina 660W). Calls in a 
random subset of CHD patients (n = 198) that had been analyzed both on the 
discovery platform and on the Affymetrix 6.0 platform was compared. All rare de 
novo CNVs >30kb, CNVs in candidate loci and recurrent CNVs that were 
suspected to be artefacts on the discovery platform (due to certain properties of 
the genomic regions) were subjected to confirmation by CGH, subject to DNA 
availability and adequate coverage on the CGH platform. All remaining CNVs 
were validated using MLPA.  
  
A B
c d
c’ d’
c’’ d’’
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2.3 Comparative Genomic Hybridization (CGH) 
CGH experiments were performed using 4x44K (ISCA v.2) and 2x105K Agilent 
(CA, USA) arrays purchased from BlueGnome (Cambridge, UK). All reagents 
and protocols were provided by BlueGnome (Cambridge, UK) 
(http://www.cytochip.com).  
2.3.1 DNA purification by ethanol precipitation 
DNAs were obtained from multiple centres (see section 2.1.1) at various 
concentrations. DNAs were quantified upon receipt using a ND-8000 
spectrophotometer (NanoDrop Technologies, DE, USA). The corresponding 
volume needed for 1.5μg of DNA from each individual was determined and 
added to separate 1.5ml microcentrifuge tubes (Eppendorf, Hamburg, 
Germany). Then the following components were added to each sample in the 
following order: Milli-Q water (Millipore, MA, USA) to make the final volume of 
150μl, 15μl of 3M Sodium Acetate (Sigma-Aldrich, MO, USA), and 500μl of 
99.7% Ethanol (Sigma-Aldrich, MO, USA) that had been previously chilled at -
20⁰C. Tubes were inverted several times, and kept at dry ice for 15 min. 
Afterwards they were centrifuged at 13000rpm at 4⁰C for 30 min 
(Microcentrifuge 5417R, Eppendorf, Hamburg, Germany). Supernatant was 
then discarded, and 500μl of 70% Ethanol (Sigma-Aldrich, MO, USA) was 
added to wash the pellet, followed by centrifugation at 13000rpm for 5 min at 
4⁰C (Microcentrifuge 5417R, Eppendorf, Hamburg, Germany). Supernatant was 
discarded, and followed by centrifugation for 1 min at 13000rpm 
(Microcentrifuge 5417R, Eppendorf, Hamburg, Germany) to collect the 
remaining ethanol at the bottom of the tubes, which was then removed with 
P200 micropipette (Gilson, WI, USA). Tubes with DNA pellets were left with lids 
open at room temperature for 1 hr. Pellets were examined to ensure dryness, 
and 12 – 25μl of nuclease-free H2O (Ambion, TX, USA) was added and left at 
room temperature for 1 to 2 hr, during which the tubes were flicked gently 
periodically and then stored at -20⁰C overnight. On the next day, DNA 
concentrations were quantified at 260/280nm absorbance with ND-8000 
Spectrophotometer (NanoDrop Technologies Inc., DE, USA). Successful 
purification step required >1μg DNA recovery and 260/280 absorbance ratio 
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between 1.8 to 2.0 and 260/230 ratio ≥ 2.0. When one of these criteria was not 
met, the experiment was repeated. 
2.3.2 Fluorescent dUTP labelling  
Random primers, 5x Buffer, 10x dNTPs, Cy3 and Cy5 from the labelling kit (cat# 
4134-1, BlueGnome, Cambridge, UK) , as well as previously purified DNA 
(section 2.3.1) were thawed on ice and protected from exposure to light. All 
reactions were performed on ice unless otherwise indicated. The patient’s 
purified DNA and the corresponding sex-matched purified reference DNA (cat# 
G1471 or G1521 for male and female DNA, respectively), purchased from 
Promega (Madison, WI, USA), were assigned and marked at separate wells at a 
96-wells plate (ThermoFisher Scientific, MA, USA). The appropriate volume for 
1μg purified DNA of each patient and the corresponding reference was added, 
followed by the addition of water to make the final volume of 26μl. To each well, 
5μl of random primers (BlueGnome, Cambridge, UK) were added and mixed. 
Afterwards, the plate was covered with film (ThermoFisher Scientific, MA, USA) 
and centrifuged at 170g for 1 min (Microcentrifuge 5430, Eppendorf, Hamburg, 
Germany), then transferred to a pre-heated thermocycler (DNA engine Tetrad2, 
BioRad, CA, USA) at 95⁰C for 10 min, followed by incubation on ice for 5 min.  
The following Cy3 and Cy5 master mixes were prepared per 8 patient samples:  
Table 2.2 – CGH labelling master mixes 
Reagents  
(Blue Gnome, Cambridge, UK) 
Cy3 master 
mix 
Cy5 master 
mix 
5xBuffer 85μl 85μl 
10x dNTP 42.5μl 42.5μl 
Cy3 dUTP 25.5μl - 
Cy5 dUTP - 25.5μl 
exo-Klenow fragment 8.5μl 8.5μl 
Total 161.5μl 161.5μl 
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To each well, 19μl of either Cy3 master mix or Cy5 master mix for patient and 
reference DNA, respectively, was added. Plate was resealed with film 
(ThermoFisher Scientific, MA, USA), centrifuged at 170g for 1 min 
(Microcentrifuge 5430, Eppendorf, Hamburg, Germany) and loaded to a 
preheated thermocycler (DNA engine Tetrad2, BioRad, CA, USA) for incubation 
at 37⁰C for 2 hr, followed by 65⁰C for 10 min and cooled to 4⁰C. 
2.3.3 Purification of labelled DNAs 
Fluorescently-labelled genomic DNA was purified using Amicon Ultracel-30 
(AU-30) membrane filters (Millipore, MA, USA). For each reaction, an Amicon 
AU-30 membrane filter was fitted into a 1.5mL microcentrifuge tube (included in 
the AU-30 membrane purchase, Millipore, MA, USA). To each filter, 430μl of TE 
(pH 8.0) (Sigma-Aldrich, MO, USA) was added, followed by the addition of 
labelled DNA (~50μl) from section 2.3.2. Filters were capped and centrifuged at 
8000g for 10 min (Microfuge 1-14, Sigma-Aldrich, MO, USA) at room 
temperature. Flow-through was discarded and 480μl of TE (pH 8.0) (Sigma-
Aldrich, MO, USA) was added to the same filters, and centrifuged at 8000g for 
10 min (Microfuge 1-14, Sigma-Aldrich, MO, USA). Afterwards, each of the AU-
30 membrane filters (Millipore, MA, USA) was placed upside down to a new 
1.5ml microcentrifuge tube (Millipore, MA, USA) with its cap already removed, 
before final centrifugation at 16000g for 2 min (Microfuge 1-14, Sigma-Aldrich, 
MO, USA) at room temperature. Membrane filters were then discarded, and 
purified labelled DNAs were placed into the SpeedVacTM DNA 120 vacuum 
dryer (Thermo Fisher, MA, USA) for 30 min with high setting (heater on) and 
protected from light. After the pellets were completely dry, they were 
resuspended in nuclease-free H2O (Ambion, TX, USA) with the appropriate 
volumes: 21μl for the 4x44 array experiments or 41μl for the 2x105 array 
experiments. Resuspension was allowed to occur in room temperature 
(protected from light) for 1 hr prior to storage at -20⁰C overnight. The samples 
were then thawed, and the DNA yield and the dye (Cy3 and Cy5) incorporation 
were determined using ND-8000 spectrophotometer (NanoDrop Technologies, 
DE, USA). The expected yield was 150-250 ng/μl DNA with Cy3 incorporation 
between 7.0-11.0 pmol/μl or Cy5 incorporation between 6.0-9.0 pmol/μl for the 
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4x44 array experiments, or half the amount for the 2x105 array experiments. 
The Cy3-labelled patient DNAs were then combined with the corresponding 
Cy5-labelled reference DNAs and stored at -20⁰C, protected from light.  
2.3.4 Array hybridization  
COT human DNA and a 100μl aliquot of 10x blocking agent (Blue Gnome, 
Cambridge, UK) were thawed on ice. Then the following hybridization mixes 
were made at room temperature: 
Table 2.3 – CGH hybridization mix 
Reagents 4x44 
arrays 
2x105 
arrays 
Labelled DNA solution 39μl 79μl 
COT human DNA 5μl 25μl 
10x blocking agent 11μl 26μl 
2x Hi-RPM Buffer (kept 
at room temperature) 55μl 130μl 
Total 110μl 260μl 
Samples were incubated for 3 min at 95⁰C, followed by 30 min at 37⁰C, and 
then cooled to room temperature. An appropriate gasket slide (Blue Gnome, 
Cambridge, UK) was placed at each hybridization chamber base (Agilent, CA, 
USA), and 100μl (for 4x44 arrays) or 245μl (for 2x105 arrays) of the 
hybridization mix was applied to each sub-array using a “drag-and-dispense” 
method; see Figure 2.3. 
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Figure 2.3 – Drag-and-dispense pipetting method 
Starting close to one end of the inner gasket-well area, the 
sample is slowly dispensed while moving the pipette to the 
opposite end of the well without touching the slide. 
(www.chem.agilent.com). 
Afterwards, oligo array was carefully aligned and gently dropped onto the 
gasket slide with the array-side down (numeric barcode facing upwards and the 
Agilent barcode facing downwards), as shown in Figure 2.4 (A). The 
hybridization chamber cover was placed onto the chamber base, and then 
assembled with the clamp, as shown in Figure 2.4 (B).  
                           A                
                           B    
Figure 2.4 – CGH oligo array, chamber and clamp assembly 
              (www.chem.agilent.com) 
The assembled chamber was rotated clockwise 3 times to wet the slides and 
the mobility of the bubbles was examined. When stationary bubbles were 
detected, the chamber was tapped on a hard surface until all bubbles appeared 
mobile. Then the assembled chamber was placed in the rotator rack of a pre-
warmed Agilent G2545A hybridization oven at 65⁰C for 40 hrs (Agilent, CA, 
USA). 
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2.3.5 Array wash 
Each hybridization chamber was disassembled and the gasket and oligo array 
“sandwich” was submerged in the Wash Buffer 1 (Blue Gnome, Cambridge, UK) 
contained in a glass staining dish. The “sandwich” was separated with a plastic 
twister (included in the purchase of hybridization chambers, Agilent, CA, USA) 
and the oligo array was placed (with array-side facing out) to the slide rack 
(Agilent, CA, USA) that has been submerged in Wash Buffer 1 in a separate 
glass container that has been placed on a VWR-375 magnetic plate stirrer 
(VWR, PA, USA). Buffer was stirred for 5 min at room temperature, while 
covered with aluminium foil (Bacofoil, Baco, Telford, UK). Afterwards, the slide 
rack was transferred to another glass container filled with pre-warmed Wash 
Buffer 2 (BlueGnome, Cambridge, UK) at 37⁰C for 1 min.  Then the slide rack 
was very slowly lifted (in roughly 10 – 12 sec duration), allowing the liquid to 
draw droplets off the array surface, and placed on two layers of fibre-free 
blotting papers (Hollingsworth & Vose, ThermoFisher Scientific, MA, USA) for 5 
min to dry.  
2.3.6 Scanning and analyses 
A GenePix 4000B laser scanner (Axon Instruments, Inc., CA, USA) was used to 
excite the hybridized fluorophores and scan the images from each oligo array, 
using the default setting and following the instruction from the manufacturer. 
Scan images were quantified and normalized using the BlueFuse Multi software 
(BlueGnome, Cambridge, UK); default settings were applied and the content of 
the array was mapped to hg18 (NCBI Build 36.1). CNV calls were then further 
visualized in the UCSC Genome Browser (http://genome.ucsc.edu). 
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2.4 Multiplex Ligation-dependent Probe Amplification (MLPA) 
2.4.1 MLPA design 
A MLPA probe consists of left primer oligo (LPO) and right primer oligo (RPO), 
containing left hybridizing sequence (LHS) and right hybridizing sequence 
(RHS), respectively (see Figure 2.5). Probes were designed following the MRC 
Holland guidelines (http://www.mlpa.com) using the H-MAPD software (Zhi and 
Hatchwell, 2008) (http://bioinform.arcan.stonybrook.edu/mlpa2/cgi-bin/mlpa.cgi) 
with the default settings. Hg18 target sequence (in FASTA format) was inputted 
to the software, and the resulting list of candidate probes were subjected to 
BLAT search (Kent, 2002) in order to ensure specificity and to obtain genomic 
positions. Candidate probes that overlapped known SNPs from dbSNP 126, 
128, 129 and 130 (Sherry et al., 2001) and/or segmental duplications (Bailey et 
al., 2001), as well as regions of CpG islands (when appropriate) (Gardiner-
Garden and Frommer, 1987) - identified by using UCSC Extended DNA utility 
(Karolchik et al., 2004, Kent et al., 2002) - were excluded. The candidate probe 
with the highest score given by the H-MAPD software from each CNV locus with 
the suitable first nucleotide of the LHS (T for the shortest probes, G for probes 
with intermediate length and C for the longest probes), has a maximum of 2 G/C 
nt within the 5 nt of the 3’ end of the LHS and a maximum of 3 G/C nt directly 
adjacent to the primer recognition sequence in both LHS and RHS, was chosen 
for synthesis. When the software failed to result in probe designs that fulfil all 
the criteria listed above, probes were designed manually. In this case, minimum 
requirements for Tm (>70⁰C) and ∆G (>0) were determined with RAW 
(http://www.mlpa.com) and UNAfold (http://mfold.rna.albany.edu/) software, 
respectively. When necessary, stuffer sequence from Lambda genomic 
sequence (http://www.mlpa.com) was used to satisfy length requirement.  
A minimum of two probes per CNV locus under investigation was designed. 
Each MLPA assay contained a total of eleven synthetic probes with size ranging 
from 100 – 140 nucleotides with a minimum of 4nt size difference between all 
probes that were used in a given assay, in order to allow optimum peak 
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separation by capillary electrophoresis. The list of synthesized probe sequences 
can be found in the Appendix. 
 
 
              (modified from www.mlpa.com) 
Figure 2.5 – MLPA probe components 
2.4.2 MLPA assay 
MLPA assay was carried out as previously described (Schouten et al., 2002). All 
reagents used for MLPA reactions were obtained from the MRC Holland P200 
kit (Amsterdam, the Netherlands). Custom design synthetic oligonucleotide 
probes (25nM standard desalting) were ordered from Integrated DNA 
Technology (IA, USA), with the exception of synthetic probes ≥60nt in length, in 
which case ultramerTM (IDT, IA, USA) probes were ordered from the same 
company. 100ng of genomic DNA in 5μl TE (pH 8.0) (Sigma-Aldrich, MO, USA) 
was added into a 96-wells plate (ThermoFisher Scientific, MA, USA) and loaded 
to a preheated thermocycler (DNA engine Tetrad2, BioRad, CA, USA) to 
denature for 30 min at 95⁰C and then cooled down to 25⁰C. This was followed 
by the addition of 35fmoles of synthetic custom design probes (IDT, IA, USA), 
1μl of P200 probe mix and 1.5μl of MLPA buffer (MRC Holland, Amsterdam, the 
Netherlands) at 25⁰C. MLPA probes were then allowed to hybridize to their 
corresponding genomic DNA targets for 16 hours at 60⁰C. Hybridized probes 
were ligated with 1U of Ligase-65 (MRC Holland, Amsterdam, the Netherlands) 
for 15 min at 54⁰C, followed by ligase deactivation for 5 min at 98⁰C. 
Afterwards, 5μl of the ligated products were added to 15μl of 2:13 dilution of 
PCR buffer (MRC Holland, Amsterdam, the Netherlands) in H2O at 4⁰C, and the 
temperature was raised to 60⁰C before the remaining PCR reagents (2.5nmoles 
of dNTPs, 10pmol FAM-labelled universal primers and 2.5U of SALSA 
Polymerase) (MRC Holland, Amsterdam, the Netherlands) were added to make 
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the final reaction volume to 25μl while protected from direct exposure to light. 
PCR reaction was performed in 33 cycles (95⁰C for 30 sec, 60⁰C for 30 sec and 
72⁰C for 1 min), followed by a final extension at 72⁰C for 20 min and cooled to 
25⁰C (or stored at 4⁰C). Afterwards, 0.8μl of 2:1 dilution of the final MLPA 
product in H2O was added to a well-mixed 0.3μl of GS500-ROX size standard 
(Applied Biosystems, CA, USA) and 14μl Hi-Di formamide (Applied Biosystems, 
CA, USA), which were then incubated for 3 min at 98⁰C, followed by 15 min at 
4⁰C (while protected from light), before subsequently loaded to the ABI 3730xl 
capillary electrophoresis (Applied Biosystems, CA, USA) using the default 
settings.  
2.4.3 MLPA analyses 
The ABI 3730xl output (.fsa) files were loaded to the GeneMarker v.1.85 
software (SoftGenetics, PA, USA) and analyzed with the recommended settings 
by the software manufacturer. The MRC Holland P200 kit (Amsterdam, the 
Netherlands) contains 14 control probes that target various regions in the 
genome (see Table 2.4) as well as Q and D fragments that may indicate 
insufficient DNA amount and incomplete denaturation, respectively. Signals 
from these probes were used to determine the quality of the MLPA experiments 
and used for internal normalization. Population normalization was applied when 
appropriate, and the peak areas were used to calculate relative dosage.   
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Table 2.4 – Profile of M13 clone-derived probes from MRC Holland P200 kit 
cytoband Gene 
probe 
length 
hyb 
length 
chr  hyb-start hyb-end 
4q25 CFI 226 76 4 110907205 110907280 
5p15.2 DNAH5 244 67 5 13819133 13819199 
7q31.2 CFTR 172 72 7 117094314 117094385 
10p13 OPTN 214 61 10 13182654 13182714 
12q24.33 PIWIL1 220 70 12 129422034 129422103 
13q12.11 GJB6 196 61 13 19703026 19703086 
14q22.2 GCH1 178 73 14 54401797 54401869 
14q32.33 XRCC3 184 55 14 103251532 103251586 
17p11.2 FLCN 250 61 17 17071984 17072044 
18q11.1 ROCK1 233 70 18 16840434 16840503 
20p12.2 JAG1 202 64 20 10570384 10570447 
20p13 PANK2 190 58 20 3841229 3841286 
Xq26.2 GPC3 208 67 X 132497926 132497992 
Yq11.21 UTY 238 64 Y 14101048 14101111 
Probe sequences were obtained from the manufacturer and hg18 position coordinates were 
determined using BLAT software (http://genome.ucsc.edu). Hyb = hybridizing, chr = chromosome  
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2.5 Quantitative Fluorescence (QF) -PCR 
2.5.1 QF-PCR assay 
QF-PCR was used to confirm possible aneuploidies that involve the sex 
chromosomes that were inferred from the SNP array and/or MLPA data. It was 
also used to screen additional TOF cases for Trisomy X occurrences. All 
reactions were performed using reagents provided by the Devyser Resolution 
XY kit (Devyser AB, Hagersten, Sweden).  QF-PCR experiments were 
performed following the instruction from the manufacturer (Devyser AB, 
Hagersten, Sweden). First, Reaction Master Mix was prepared by adding 500μl 
of the Devyser Resolution mix to a tube of PCR activator (all provided by the 
Devyser Resolution XY kit, Devyser AB, Hagersten, Sweden), and mixed well 
by pipetting up and down with P1000 (Gilson, WI, USA) followed by vortexing 
for 5 sec (Velp Scientifica, Usmate, Italy). At each PCR reaction well in a 96-
wells plate (ThermoFisher Scientific, MA, USA), 5μl of 5ng/μl genomic DNA was 
added into 20μl of Reaction Master Mix and loaded to a preheated thermocycler 
(DNA engine Tetrad2, BioRad, CA, USA). Denaturation step was initiated at 
95⁰C for 15 min, and afterwards 26 PCR cycles (consisting of 30 sec at 94⁰C, 
90 sec at 59⁰C and 90 sec at 72⁰C) was performed. This was followed by final 
denaturation step at 72⁰C for 30 min, and cooled to 4⁰C.  
The final PCR product (1.5μl) was then added to a mixture of 0.4μl of GS500-
ROX size standard (Applied Biosystems, CA, USA) and 15μl Hi-Di formamide 
(Applied Biosystems, CA, USA), and incubated for 3 min at 98⁰C, followed by 
15 min at 4⁰C, before subsequently loaded to the ABI 3730xl capillary 
electrophoresis (Applied Biosystems, CA, USA) using the default settings.  
2.5.2 QF-PCR analyses 
The output (.fsa) files were analyzed using the GeneMarker v.1.85 software 
(SoftGenetics, PA, USA), utilizing the panel template that was kindly provided 
by the Devyser company (Hagersten, Sweden). Analyses were performed using 
the Trisomy detection setting. The peak areas were used to calculate the 
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relative dosage and the results were interpreted in conjunction with the marker 
content information from the Devyser Resolution XY kit (Devyser AB, 
Hagersten, Sweden) as listed in Table 2.5. 
Table 2.5 – Devyser Resolution XY marker overview 
Marker ID Location 
Marker size range 
(bp) 
Dye colour 
X1 Xq26.2 120 - 170 Green 
X2 Xq13.1 230 - 260 Green 
X3 Xq26.2 262 - 315 Yellow 
X4 Xq21.33 290 - 340 Blue 
X5 Xq26.1 392 - 430 Green 
X6 Xq28 430 - 500 Blue 
X8 Xq21.31 100 - 140 Blue 
Y1 Yp11.31 235 (+/- 3bp) Blue 
Y2 Yq11.223 346 - 380 Blue 
XY1 
Xp22.22 
Yp11.2 
X = 105 
Y = 111 
(+/- 2,5bp) 
Green 
XY2 
Xq21.3 
Yp11.31 
180 - 222 Blue 
7X 
7q34 
Xq13 
7 = 182 
X = 202 
(+/- 3bp) 
Green 
T2 
Xq23 
2p23.2 
X = 114 
2 = 118 
(+/- 3bp) 
Yellow 
Devyser AB (Hagersten, Sweden), http://www.devyser.com 
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2.6 Statistical analyses 
2.6.1 CNV burden and gene-content analyses 
The frequency of CNVs in case and control groups was compared with a two-
sided Fisher’s test. CNV length and the number of genes spanning each CNV in 
cases versus controls were assessed with two-sided permutation tests, which 
compare the observed t statistic (normalized difference between means) with 
the t statistics from 10,000 random replicates of relabeling of cases and 
controls, which is more accurate than the normal t-test for non-normal 
distributions.  Haploinsufficiency scores of the genes spanned by CNVs in 
cases and controls were obtained from a published source (Huang et al., 2010) 
and compared with a two-tailed Mann Whitney U test, a non-parametric test that 
is used to examine whether there is a difference in the median of two 
independent distributions.  All tests were performed using R statistical package, 
with the exception of permutation tests, which were performed using PAST 
statistical software.  
As the study included substantial numbers of CHD patients with a relatively 
homogeneous phenotype (TOF), it was decided a priori to carry out subgroup 
analyses in the group with TOF and the group with other types of CHD.  There 
were insufficient numbers of CHD patients with any other homogeneous 
phenotype to permit additional valid subgroup analyses. 
2.6.2 Parental origin bias ascertainment 
The parental origin of each de novo CNV in the analyses of CHD trios was 
determined by examining the mismatches between the allelic ratio (B-allele 
frequency) of each SNP in the proband and both parents within each CNV 
region. This analysis was performed in collaboration with Dr. Ian J. Wilson from 
the Statistical Genetics Group. I subsequently performed a binomial probability 
distribution using R statistical package to compare the CNV frequency from 
each parental origin and obtained a two-tailed p-value.  
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2.6.3 Frequency of 1q21.1 rearrangements in cases versus controls 
The frequency of 1q21.1 rearrangements was compared in cases versus 
controls using Stata 11 to obtain odds ratios (OR) with 95% confidence intervals 
(CI) by Cornfield approximation and two-sided Fisher’s test p-values.  
2.6.4 Frequency of GJA5 duplications in cases versus controls 
The frequency of small GJA5 duplications was compared by maximum 
likelihood estimation using two binomial distributions, corrected for a small 
degree of excess IBD sharing in two of the probands by Prof. Heather J. Cordell 
(details of the calculation can be found in the Appendix).   
2.6.5 Population attributable risk (PAR) 
Population attributable risk (PAR) was calculated in R using the formula: 
100(P(OR-1))/(1+(P(OR-1))), in which P = proportion of control population with 
the CNVs and OR = odds ratio.  
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CHAPTER 3: CHD PATIENTS WITH KNOWN CAUSE 
3 Preliminary analyses to identify CHD patients with known 
causative CNVs 
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3.1 Abstract 
Some chromosomal abnormalities are associated with CHD. These include 
aneuploidies such as trisomy-21 (Down’s), trisomy-18 and Klinefelter’s (XXY) 
syndrome, in addition to some well-described multi-system abnormalities that 
frequently include CHD as the primary component (DiGeorge and Williams-
Beuren syndrome). Since the goal of the present study is to explore the role of 
CNVs as genetic risks in the CHD cases that exhibit classic complex trait 
features (representative of ~80% of total CHD occurrences), CHD patients with 
known genetic causes need to be removed to ensure sample homogeneity in 
the study. The misclassification of patients that were recruited in this study can 
be attributed to one of the following factors: some of the participating centres 
routinely screened for these conditions, while others did not, and the phenotypic 
manifestation of some of these conditions (e.g. intellectual disability and other 
forms of developmental delays) also can be difficult to recognize in newborns. 
For these reasons, a preliminary CNV study to identify such patients was 
conducted. Nine cases with trisomy-21, one trisomy-18, three Klinefelter’s 
(47,XXY), four Triple-X (47,XXX), two Williams-Beuren deletions and twenty-two 
carriers of DiGeorge anomalies were identified and excluded, as appropriate, 
from further studies described in this thesis. 
3.2 Aims 
The aim of this preliminary study is to identify CHD cases with known cause and 
excluded them from further analyses. 
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3.3 Results 
3.3.1 Identification of patients with whole chromosomal aberrations  
QuantiSNP calls from all individuals were screened for indications of whole 
chromosomal anomalies. Since the marker coverage on the sex chromosomes 
are limited both in the Illumina 660W platform and all the MLPA kits that are 
routinely used in our centre, calls that are suggestive for whole chromosomal 
aberrations involving the X and Y chromosomes from any of those datasets 
were further confirmed with QF-PCR (see figure 3.1 and 3.2). For the remaining 
cases that were indicative of whole chromosomal aberrations (per QuantiSNP 
calls), the LRR and BAF plots were generated, and these were subsequently 
confirmed by manual inspections (see Figure 3.3). In total, nine trisomy-21 (MIM 
190685), one trisomy-18 (MIM 601161), three Klinefelter’s (47,XXY) and four 
trisomy-X (47,XXX) syndrome cases were identified (see Table 3.1). 
Table 3.1 – CHD cases with whole chromosomal aberrations 
Patient ID Phenotype Aneuploidy 
OX-2681.1 PS 
Trisomy 21 
GOCHD-219.1 Other 
GOCHD-3905.1 VSD 
GOCHD-2931.1 MV anomaly 
OX-2882.1 AVSD 
SYD-2353.1 AVSD 
SYD-1111.1 AVSD 
SYD-2045.1 AVSD 
SYD-1258.1 ASD 
SYD-1665.1 VSD Trisomy 18 
FCH-317.1 VSD 
XXY FCH-291.1 VSD 
CHA-772.1 TOF 
CHA-134.1 TOF 
XXX 
CHA-160.1 TOF 
ERL-11273.1 TOF 
GOCHD-1379.1 TOF 
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Figure 3.1 – Detection of a Klinefelter’s (47,XXY) abnormality by QF-PCR 
The above is the result of GeneMarker (SoftGenetics, PA, USA) analysis on a QF-PCR 
experiment performed with the Devyser Resolution XY kit (Devyser AB, Hagersten, 
Sweden). The peak area ratios are definitive for a 47,XXY chromosomal abnormality: 
XY1 and XY2 markers are showing 2:1 and 1:2 allelic ratio, respectively, X1, X2, X3, 
X4, X5, X6 and X8 markers showed 1:1 heterozygous alleles and Y1 and Y2 markers 
showing homozygous alleles. See Table 2.5 in Methods for overview of all marker 
details. 
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Figure 3.2 - Detection of a Triple-X abnormality by QF-PCR 
The above is the result of GeneMarker (SoftGenetics, PA, USA) analysis on a QF-
PCR experiment performed with the Devyser Resolution XY kit (Devyser AB, 
Hagersten, Sweden). The peak area ratios are definitive for 47,XXX chromosomal 
abnormality: X1, X4 and X6 markers are showing allelic ratios of 1:1:1 and X2, X3, 
X5 and X8 are showing 1:2 allelic ratios. Additionally, XY2 marker is giving a 1:2 
allelic ratio. All are indicative of the presence of 3 copies of the X chromosomes. 
See Table 2.5 in Methods for overview of all marker details. 
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Figure 3.3 - BAF plots for trisomy-18 and trisomy-21 
The B-allele frequency (BAF) plots along the entire 
chromosome 18 (A) and chromosome 21 (B) in SYD-1665 
and SYD-1258, respectively, are shown, indicating the 
presence of three whole copies of the corresponding 
chromosomes. The black dots indicate the allelic ratio from 
the markers that are targeting the SNPs along the 
corresponding chromosomes and the red dots are the 
intensity data generated from the CNV probes, thus not 
informative in these plots. 
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3.3.2 Identification of DiGeorge and Williams-Beuren CNVs 
QuantiSNP and PennCNV calls within the minimal regions for DiGeorge (MIM 
188400) (chr22:17,409,194-18,626,079) and Williams-Beuren (MIM 194050) 
(chr7:72,388,826-73,780,026) syndrome were examined. Patients that showed 
abnormalities in such locations were confirmed with MLPA (MRC Holland P023-
B2 DiGeorge kit) or array CGH (as described in the methods). The list of 
patients identified that were subsequently excluded from further analyses can 
be found in Table 3.2. 
Table 3.2 – Patients with DiGeorge and 
Williams-Beuren CNVs 
Patient ID Aberrations 
SYD-569.1 
DiGeorge     
CHA-930.1 
CHA-585.1 
CHA-586.1 
CHA-914.1 
FCH-390.1 
FCH-464.1 
GOCHD-2132.1 
GOCHD-4620.1 
GOCHD-5708.1 
NOTT-444.1 
FCH-526.1 
FCH-492.1 
FCH-203.1 
NOTT-545.1 
NOTT-238.1 
GOCHD-1257.1 
GOCHD-5912.1 
GOCHD-5916.1 
SYD-2343.1 
SYD-2379.1 
LEU-30.1 
OX-1334.1 Williams-
Beuren  CHA-505.1 
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3.4 Discussion 
Aneuploidies are known to cause multi-system abnormalities that often include 
CHD (Patterson, 2009, Tucker et al., 2007, Tomita-Mitchell et al., 2012, 
Wimalasundera and Gardiner, 2004, Devriendt and Vermeesch, 2004). 
Additionally, patients with DiGeorge and Williams-Beuren anomalies often 
manifest CHD as one of the primary phenotypes (Ryan et al., 1997, Ferrero et 
al., 2007, Devriendt and Vermeesch, 2004, Tomita-Mitchell et al., 2012). In fact, 
a recent report showed that the prevalence of DiGeorge deletion syndrome is 
currently under-recognized in the adult patients with TOF and pulmonary atresia 
(van Engelen et al., 2010). This chapter describes a systematic screen for 
chromosomal and syndromic abnormalities that are known to be causative for 
CHD, in a cohort that was primarily designed to recruit sporadic, non-syndromic 
CHD patients with unknown cause. This screen was performed because not all 
participating patient recruitment centres routinely test for these abnormalities. 
Such syndromic cases were found in our CHD cohort, although at a much lower 
frequency (1.6%) than the rate of occurrence that is normally observed in the 
CHD population (~20%). The presence of the syndromic patients may in part be 
attributable to the fact that this study recruited newborns (in addition to children 
and adults with CHD – see Figure 3.4). Such approach was undertaken in order 
to be certain of ascertaining a broad spectrum of CHD phenotypes, and not just 
those patients who survive to adulthood. However, oftentimes CHD is the only 
phenotypic component that is evident in the newborns with such abnormalities, 
and thus the syndromic diagnosis may not have been made at the time some of 
the patients were recruited.  
The findings of four Triple-X occurrences, all identified in TOF females, were 
nonetheless surprising. Triple-X has been previously reported in TOF (Rauch et 
al., 2010), but the association has not been firmly established. Triple-X girls are 
generally taller in stature, but otherwise may be healthy and have normal 
physical features. Most of them are fertile and have normal sexual development. 
However, it is well established that they have increased risk for learning 
disabilities and developmental delays (Otter et al., 2010). The incidence of 
47,XXX in females with TOF in this study is significantly higher than the 
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reported population frequency (Nielsen and Wohlert, 1991) (4/412 and 
18/17038, respectively, P = 0.002 by two-tailed Fisher’s exact test). Further 
replication in another cohort would be needed in order to definitively establish 
the association between 47,XXX abnormality and TOF. 
             
Figure 3.4 – Age distribution in CHD cohort 
To conclude, 37 patients with chromosomal abnormalities known to cause CHD 
were identified, and such patients were excluded, as appropriate, from further 
studies that are described in this thesis.  
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4 Chapter 4: Global Rare CNVs in CHD 
4 Global Rare Copy Number Variants Contribute to Sporadic 
Congenital Heart Disease  
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4.1  Abstract  
Macroscopically visible copy number variants (CNVs) are known to cause many 
Mendelian disorders, most involving intellectual disability and multi-system 
developmental abnormalities. More recently, submicroscopic CNVs that occur 
with <1% frequency have been shown to contribute to the risk of complex 
psychiatric and neurological phenotypes.  The contribution of submicroscopic 
CNVs to the risk of sporadic CHD, however, remains incompletely defined. This 
chapter describes the genome-wide CNV analyses on data generated from the 
Illumina 660W platform in 808 patients with TOF, 1448 patients with non-TOF 
CHD and 841 ancestry-matched unrelated controls. Increased global rare genic 
deletion burden was identified in CHD patients (P = 0.001). Rare deletions in 
CHD patients spanned more genes (P = 0.001) that were associated with higher 
haploinsufficiency scores (P = 0.03) compared to controls. The rare deletions 
were also enriched with genes involved in Wnt signaling pathway (P = 1x10-5), 
the significance of which is well-known for cardiac development. Additionally, a 
novel association of 15q11.2 deletions with CHD risk was identified. This 
chapter concludes that at least 4% of the population risk of CHD is attributable 
to rare genic deletions.   
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4.2 Background 
The causative nature of microscopically visible CNVs (>5Mb) has long been 
recognized in syndromic developmental phenotypes. The role of 
submicroscopic CNVs in such phenotypes has also been established, but it is 
complicated by the fact that such CNVs are known to occur abundantly in 
healthy controls (Iafrate et al., 2004, Sebat et al., 2004, Redon et al., 2006). 
Moreover, the technology that allows detection of CNVs in this size range has 
only been available in the past decade. These technological advancements 
nevertheless had led to the discovery of the association of common CNV loci 
with several autoimmune phenotypes (Gonzalez et al., 2005, Hollox et al., 2008, 
Fanciulli et al., 2007, Fellermann et al., 2006, McCarroll et al., 2008a); in line 
with what is known about the enrichment of immunity genes within common 
CNV loci (Nguyen et al., 2006, Feuk et al., 2006a). However, the recent effort by 
the Wellcome Trust Consortium in a large genomewide association study of 
common CNVs (copy number polymorphisms, CNPs) with minor allele 
frequency (MAF) >5% in 16000 cases of eight common diseases and 3000 
controls did not result in any novel finding, although several of the previously 
identified associations in autoimmune phenotypes were confirmed (Craddock et 
al., 2010).   
Previous studies have shown that the population frequency of a given CNV is 
inversely correlated with gene density and size of the CNV. Rare CNVs, 
particularly rare genic CNVs, are short-lived in the population and subject to 
strong purifying selection (Itsara et al., 2009, Conrad et al., 2010). In recent 
years, increasing attention has been directed towards exploring the contribution 
of rare CNVs (generally considered to be those with <1% population frequency) 
of submicroscopic size to the susceptibility of various complex traits. However, 
association analysis of individual rare CNVs is much less straightforward, as the 
standard approaches cannot be used due to the low power to detect association 
even in large sample sizes. Nonetheless, these variants are collectively 
common, although they are individually rare (Itsara et al., 2009, McCarroll et al., 
2008b). Thus, many studies adopted the analysis strategy that assesses the 
combined effects of rare variants across the genome (Pinto et al., 2010, Sebat 
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et al., 2007, 2008, Girirajan et al., 2011, Xu et al., 2008, Cooper et al., 2011). 
There have been reports of the increased collective burden of rare CNVs in 
developmental and psychiatric phenotypes (2008, Cooper et al., 2011, Girirajan 
et al., 2011, Zhang et al., 2009a).  
Recently, Cooper and colleagues examined the burden of large CNV with <1% 
frequency in 15767 children that had been referred for genetic evaluation of 
intellectual disability, including 575 cases with CHD as a component of their 
phenotypes (Cooper et al., 2011).  A significantly increased burden of CNVs 
>400kb (P = 6.45 x 10-5) was shown among children with CHD in comparison to 
children with autism spectrum disorder.  However, the case population in their 
study included many cases with recognized deletion syndromes that typically 
include CHD (e.g. Williams’ and DiGeorge syndromes). Also, mainly large 
deletions were studied and the population was not primarily ascertained for 
CHD.  
4.3 Aims 
This chapter aims to address the disease risk associated with the global burden 
of CNVs >100kb in a case population that is non-syndromic, non-Mendelian (i.e. 
sporadic), and ascertained on the basis of CHD. It aims to explore the functional 
annotation enrichments associated with CHD risk as well as to identify novel 
dosage-sensitive genes that are involved in CHD pathogenesis.   
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4.4 Results 
4.4.1 CNV validation and inclusion criteria  
Stringent filtering measures were applied for case-control genome-wide CNV 
burden analyses (size >100kb with Bayes factor >100) in order to ensure 
comparability of detection between individuals ascertained from multiple 
centres, particularly due to a batch-effect identified in two shipping batches 
during the QC procedures as well as a low validation rate in shorter CNVs (50% 
validation rate for CNVs >30kb, as described in Chapter 6). Initially, 4551 
autosomal CNV calls (1217 deletions and 3334 duplications) met these 
inclusion criteria on the discovery platform (Illumina 660W). Independent 
experiments (utilizing Affymetrix 6.0 SNP platform, array CGH or MLPA) were 
subsequently performed to investigate the validity of 87 deletion calls and 216 
duplication calls - 87% were randomly selected, and the remainder were 
targeted on CNVs in candidate loci (described in chapter 7) and recurrent calls 
that were suspected to be artefacts. The resulting positive validation rates were 
85% and 34% for deletions and duplications, respectively. Based on this 
validation data, a number of regions that could not be genotyped reliably were 
identified (see Table 4.1). After excluding these regions, 74/74 (100%) of 
deletion calls and 62/62 (100%) of duplication calls were successfully validated 
by Affymetrix 6.0, array CGH or MLPA. In total, 1077/1217 (88%) deletion calls 
and 775/3334 (23%) duplication calls that met the initial filtering criteria 
remained (after excluding the unreliable regions) and they were incorporated in 
the final analyses.  
4.4.2 CNV burden in CHD cases and controls 
Preliminary analyses of CNVs with <1% frequency 
Previous publications from other groups have adopted an analysis strategy that 
mainly focuses on measuring disease risk attributable to CNVs with <1% 
frequency. As a preliminary approach, this strategy was used to analyze CNVs 
in our cohort. CNVs with <1% frequency were identified in 2256 CHD cases and 
841 unrelated controls, and CNV burden was compared between cases and 
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controls (Table 4.2). While the burden of CNVs with <1% frequency that were 
>400kb in the control individuals of the present study and the study by Cooper 
et al. were highly comparable (10.8% vs. 11.5%; P = 0.6 by Fisher’s exact test), 
the CNV burden that was observed in the sporadic, non-syndromic CHD cohort 
(1.3 fold, P = 0.04) was almost two-fold lower than those observed in the case 
cohort in the study by Cooper et al. (2.7 fold; P = 7.6x10-40), which was largely 
composed of individuals with intellectual disability (ID) (Cooper et al., 2011).  
Table 4.1 - Unreliable regions that were excluded from analyses 
CHR START END COMMENT 
1 953726 1498897 artefacts in GC-rich region 
7 913761 1122949 artefacts in GC-rich region 
7 27087213 27254061 artefacts in GC-rich region 
8 144621302 144772135 artefacts in GC-rich region 
8 145595447 145728221 artefacts in GC-rich region 
9 138277725 138650091 artefacts in GC-rich region 
10 134885864 135054789 artefacts in GC-rich region 
12 131103204 131701256 artefacts in GC-rich region 
16 956057 1132214 artefacts in GC-rich region 
17 76704184 77138316 artefacts in GC-rich region 
19 748078 943903 artefacts in GC-rich region 
21 45644509 45788806 artefacts in GC-rich region 
2 89078673 89855977 low validation rate due to SD 
14 105079689 105945405 low validation rate due to SD 
   CHR = chromosome; SD = segmental duplications 
Table 4.2 – Burden of genome-wide CNVs with <1% frequency 
 Present study Cooper et al., 2011 
CNV 
size  
%         
CHD cases 
(n=2256) 
%  
Controls 
(n=841) 
OR P 
%  
ID cases 
(n=15767) 
%  
Controls 
(n=8329) 
OR P 
>100kb 31.0 29.1 1.1 0.33 NA NA - - 
>400kb 13.6 10.8 1.3 0.04 25.7 11.5 2.7 10
-158 
>1.5Mb 1.9 1.2 1.6 0.21 11.3 0.6 20.3 10
-266 
OR = odds ratio, P = p-value by two-sided Fisher’s exact test 
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Analysis strategy 
Based on the results of the preliminary analysis as well as the previously 
published studies that suggest that 1) CNVs that are genic and rarer (e.g. single 
occurrences or private) have much bigger contribution to disease risk, and 2) 
indications that deletions and duplications may have different roles in disease 
mechanism (2008, Pinto et al., 2010, Soemedi et al., 2012, Crespi et al., 2010, 
Hannes et al., 2009), a novel analysis strategy was introduced in this study. The 
frequency of deletions and duplications was examined independently between 
TOF (n=808), non-TOF CHD (n=1448) and ancestry-matched unrelated controls 
(n=841) in the following sets: all CNVs, genic CNVs, rare CNVs, rare genic 
CNVs, common CNVs and common genic CNVs. Genic CNVs were defined as 
those that overlap with RefSeq transcription boundaries. Rare CNVs were 
defined as those that occur with <1% frequency and have minimum (<20%) 
overlap with CNVs in the compared group; in effect CNVs unique to the case or 
control group. Common CNVs were defined as those that are shared (>20% 
overlap) between case and control groups. 
Association of rare deletions with CHD risk 
No difference was observed in overall deletion burden between case and 
control groups (see Table 4.3). However, a significantly higher rare deletion 
burden was found in CHD cases, particularly in rare genic deletion burden (1.7 
fold, P = 0.02 for TOF; 1.8 fold, P = 0.001 for other CHD), which correspond to 
population attributable risks (PAR) of 3.04% and 3.78% for TOF and other CHD, 
respectively. In contrast, no difference was observed in the frequency of 
common deletions between cases and controls. A greater difference was seen 
in the frequency of large (>500kb) rare deletions between cases and controls 
(2.3 fold, P = 0.04 for TOF; 2.5 fold, P = 0.01 for other CHD), which was yet 
more marked when only >1Mb deletions were considered (3.8 fold, P = 0.03 for 
TOF; 3.9 fold, P = 0.02 for other CHD). No difference was found in the 
frequency of large common deletions.  There was no difference in the frequency 
of either rare or common duplications (see Table 4.4). There was, however, an 
excess of large genic duplications in TOF cases as compared to controls (1.9 
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fold, P = 0.01); this effect being solely due to a single locus (1q21.1) whose role 
on TOF risk is further discussed in Chapter 5 of this thesis. 
Table 4.3 – Deletion Frequency in cases and controls 
Size CNV category 
% 
TOF 
% 
CHD 
% 
CTRL 
TOF/CTRL 
fold 
change 
P 
CHD/CTRL 
fold   
change 
P 
>
1
0
0
k
b
 
all 28.5 29.8 28.9 1.0 0.870 1.0 0.669 
all genic 12.7 14.2 10.8 1.2 0.251 1.3 0.024 
rare 10.6 10.5 8.3 1.3 0.111 1.3 0.092 
rare genic 7.3 8 4.4 1.7 0.015 1.8 0.001 
common 21 21.8 21.8 1.0 0.764 1.0 1.000 
common genic 5.8 6.6 6.5 0.9 0.609 1.0 1.000 
>
5
0
0
k
b
 
all 3.2 3.6 2.1 1.5 0.221 1.7 0.059 
all genic 2.8 3.2 1.8 1.6 0.189 1.8 0.059 
rare 2.5 2.6 1.1 2.3 0.038 2.5 0.014 
rare genic 2.2 2.2 1.0 2.3 0.047 2.3 0.031 
common 0.7 1.0 1.1 0.7 0.607 1.0 1.000 
common genic 0.6 1.0 0.8 0.7 0.774 1.2 0.825 
>
1
M
b
 
all 1.4 1.7 0.7 1.9 0.228 2.4 0.059 
all genic 1.4 1.7 0.7 1.9 0.228 2.3 0.058 
rare 1.4 1.4 0.4 3.8 0.031 3.9 0.017 
rare genic 1.4 1.3 0.4 3.8 0.031 3.7 0.025 
common 0 0.4 0.4 0.0 0.250 1.2 1.000 
common genic 0 0.4 0.4 0.0 0.250 1.2 1.000 
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Table 4.4 – Duplication frequency in cases and controls 
Size CNV category 
% 
TOF 
% 
CHD 
% 
CTRL 
TOF/CTRL 
fold 
change 
P 
CHD/CTRL 
fold   
change 
P 
>
1
0
0
k
b
 
all 22.6 20.0 20.7 1.1 0.339 1.0 0.706 
all genic 19.2 17.3 16.3 1.2 0.138 1.1 0.563 
rare 10.4 10.5 10.2 1.0 0.936 1.0 0.887 
rare genic 8.8 8.7 8.1 1.1 0.658 1.1 0.641 
common 13.6 11.3 12.1 1.1 0.378 0.9 0.589 
common genic 11 9.8 9.5 1.2 0.330 1.0 0.884 
>
5
0
0
k
b
 
all 8.2 6.6 6.3 1.3 0.154 1.1 0.793 
all genic 7.7 6.3 5.2 1.5 0.045 1.2 0.313 
rare 5.0 4.5 3.1 1.6 0.060 1.5 0.120 
rare genic 5.0 4.1 2.6 1.9 0.014 1.6 0.078 
common 3.1 2.4 3.2 1.0 1.000 0.8 0.286 
common genic 3.0 2.3 2.6 1.1 0.765 0.9 0.671 
>
1
M
b
 
all 3.3 2.1 1.9 1.8 0.088 1.1 0.878 
all genic 3.3 2.0 1.8 1.9 0.059 1.1 0.755 
rare 2.4 1.5 1.1 2.2 0.056 1.4 0.568 
rare genic 2.4 1.3 1.1 2.2 0.056 1.2 0.696 
common 1.0 0.8 0.8 1.2 0.799 0.9 0.812 
common genic 1.0 0.8 0.7 1.4 0.599 1.1 1.000 
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4.4.3 Properties and functional impact of CNVs 
CNV size in cases and controls 
The size of deletions and duplications in cases and controls was compared (see 
Table 4.5). Larger deletions were observed in cases compared to controls (1.3 
fold, P = 0.024 and 1.6 fold, P = 0.022 for TOF and other CHD, respectively) but 
no difference was observed in the length of duplications.  
Table 4.5 – CNV size in cases versus controls 
Copy 
number 
Group 
mean length 
(bp) 
case/control   
ratio P 
deletions 
TOF 285657 1.3 0.024 
CHD 337288 1.6 0.022 
CTRL 213262   
duplications 
TOF 517326 1.1 0.312 
CHD 472382 1.0 0.793 
CTRL 462125   
P was generated with a two-sided permutation test with 10,000 replicates.  
Genic content in rare CNVs associated with CHD risk 
There were significant differences in the numbers of genes that were spanned 
by both deletions and duplications, in both TOF and other CHD cases when 
compared to controls (Table 4.6). In both case groups, these effects were driven 
by rare CNVs.  For rare deletions there was a 2.6 fold higher number of genes 
(P = 0.006) for TOF and a 3.7 fold higher number of genes (P = 0.001) for other 
CHD.  For rare duplications, there was a 2.8 fold higher number of genes (P = 1 
x 10-4) for TOF and a 1.9 fold higher number of genes (P = 0.006) for other 
CHD.  The number of genes spanned by common CNVs did not differ between 
cases and controls. The recurrent genes overlapped by both rare deletions and 
rare duplications in CHD patients can be found in Table 4.7 – 4.8. 
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Table 4.6 – Number of genes per CNV in cases versus controls 
Copy 
number 
CNV 
category 
TOF 
mean 
CHD 
mean 
CTRL 
mean 
TOF/CTRL CHD/CTRL 
ratio P ratio P 
d
e
le
ti
o
n
s
 all 1.7 2.5 1.0 1.7 0.009 2.5 3x10-4 
rare 3.5 5.1 1.4 2.6 0.006 3.7 0.001 
common 0.8 1.1 0.8 1.0 0.982 1.3 0.325 
d
u
p
lic
a
ti
o
n
s
 
all 4.5 3.7 2.8 1.6 0.005 1.3 0.031 
rare 6.1 4.1 2.2 2.8 1x10-4 1.9 0.006 
common 3.2 3.4 3.3 1.0 0.829 1.0 0.878 
                                               P was generated with a two-sided permutation test with 10,000 replicates 
Haploinsufficiency of genes spanned by rare CNVs in CHD 
Genes encompassed by deletions in CHD cases were associated with higher 
haploinsufficiency scores (P = 0.02) – see Figure 4.1. This effect was also due 
to the genes encompassed by rare deletions (P = 0.03), and not by common 
deletions (P =0.40). No difference was observed in the haploinsufficiency scores 
of the genes encompassed by duplications in cases compared to controls (P = 
0.44). The list of genes spanned by rare deletions with high haploinsufficiency 
scores can be found in Table 4.9. 
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Figure 4.1 - Haploinsufficiency score distribution in deletions and 
duplications identified in CHD cases and controls 
Box plots showing the distribution of haploinsufficiency (HI) scores of 
the genes spanned by all deletions (A) and duplications (B) detected in 
2256 CHD and 841 unaffected controls. The means are indicated as 
black diamonds. Deletions in CHD cases are more likely to contain 
genes that were predicted or known to be haploinsufficient (high HI 
scores) than controls (P = 0.02), as shown in (A). The outliers (red 
asterisks) refer to six genes (PRKAB2, BCL9, PMP22, TPK1, LINGO2, 
PTPRD, and TEK) with high HI scores that were spanned by rare 
heterozygous deletions in controls. However, their occurrences are 
known to be extremely rare (<0.2% frequency in our controls). In 
contrast, there is no significant difference (P = 0.44) in the distribution 
of HI scores between the genes that were intersected by duplications 
in cases and controls, as shown in (B) 
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Functional annotation enrichment in rare CNVs 
In order to identify pathway or ontology overrepresentation in functional regions, 
Genomic Region Annotation Enrichment analysis (GREAT version 1.8.2 
(McLean et al., 2010)) was performed on rare deletions and rare duplications in 
2256 CHD patients. Analysis was performed using default settings and the 
entire genome as background. GREAT analysis on rare deletions resulted in 
statistically significant enrichment (2.9 fold enrichment, P = 1.2 x 10-5) for genes 
in Wnt signalling pathway (PANTHER database (Mi et al., 2005)), which 
implicated 13 genes in this pathway (CDH18 [MIM 603019], CDH2 [MIM 
114020], CTBP1 [MIM 602618], CTNNB1 [MIM 116806], FAT1 [MIM 600976], 
LRP5L, NFATC1 [MIM 600489], PCDH15 [MIM 605514], PCDHB7 [MIM 
606333], PCDHB8 [MIM 606334], PRKCB [MIM 176970], PRKCQ [MIM 
600448], and WNT7B [MIM 601967]); there was involvement of Wnt genes in 
28/238 (12%) of the CHD cases with the rare deletions. Phenotypes of these 
patients were TOF (11), atrial septal defect (7), transposition of the great 
arteries (3), atrioventricular septal defect (2), coarctation of the aorta (2), aortic 
stenosis (1), congenitally corrected transposition of the great arteries (1), and 
ventricular septal defect (1). No significant enrichment was found for any other 
functional category. There was no pathway or gene-ontology overrepresentation 
in the rare duplications.  
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Table 4.7 – Recurrent genes spanned by rare deletions 
Cyto-
band 
RefSeq 
gene 
CHD 
(n=2256) 
CHD phenotype 
Controls 
(n=841) 
(Cooper et al., 2011) 
Cardio 
(n=575) 
Controls   
(n = 8329) 
1p31.1 PTGER3 1 CAT 0 2 1 
1p31.1 USP33 1 CAT 0 1 0 
1p31.1 FAM73A 1 CAT 0 1 0 
1p31.1 NEXN 1 CAT 0 1 0 
1q21.1 PRKAB2 3 TGA, MV, ASD 1 3 2 
1q21.1 PDIA3P 3 TGA, MV, ASD 1 3 2 
1q21.1 FMO5 3 TGA, MV, ASD 1 3 2 
1q21.1 CHD1L 3 TGA, MV, ASD 1 3 2 
1q21.1 BCL9 3 TGA, MV, ASD 1 3 2 
1q21.1 ACP6 3 TGA, MV, ASD 1 3 2 
1q21.1 GJA5 3 TGA, MV, ASD 1 3 2 
1q21.1 GJA8 3 TGA, MV, ASD 1 3 2 
1q44 OR14A16 1 TOF 0 1 4 
1q44 OR11L1 1 TOF 0 1 2 
1q44 TRIM58 1 TOF 0 1 2 
1q44 OR2W3 1 TOF 0 1 3 
2p22.1 SLC8A1 1 TOF 0 1 0 
2q13 MIR4267 1 CoA 0 2 2 
2q13 BUB1 1 TOF 0 2 2 
2q13 ACOXL 2 TOF, ASD 0 2 1 
2q13 BCL2L11 2 TOF, ASD 0 2 1 
2q13 MERTK 1 TOF 0 2 3 
2q13 TMEM87B 1 TOF 0 2 1 
2q13 FBLN7 1 TOF 0 2 2 
2q13 ZC3H8 1 TOF 0 2 1 
3p22.1 ULK4 3 TOF, ASD, VSD 0 0 7 
3p14.2 FHIT 3 TOF, VSD(2) 0 0 8 
3q25 MME 2 TOF, VSD 0 0 0 
4q34.1 GALNT7 1 TOF 0 1 0 
4q34.1 HMGB2 1 TOF 0 1 0 
4q34.1 SAP30 1 TOF 0 1 0 
4q34.1 SCRG1 1 TOF 0 1 0 
4q34.1 HAND2 1 TOF 0 1 0 
4q34.1 NBLA00301 1 TOF 0 1 0 
4q34.1 FBXO8 1 TOF 0 1 0 
4q35.2 LOC401164 2 TOF(2) 0 0 11 
5p15.33 AHRR 1 AVSD 0 1 1 
5p15.33 C5orf55 1 AVSD 0 1 0 
5p15.33 EXOC3 1 AVSD 0 1 0 
5p15.33 SLC9A3 1 AVSD 0 1 13 
5p14.3 CDH18 1 TOF 0 1 2 
5q31.3 PCDHB2 2 ASD, VSD 0 0 1 
5q31.3 PCDHB3 2 ASD, VSD 0 0 2 
5q31.3 PCDHB4 2 ASD, VSD 0 0 1 
5q31.3 PCDHB5 2 ASD, VSD 0 0 1 
5q31.3 PCDHB6 2 ASD, VSD 0 0 2 
5q31.3 PCDHB17 2 ASD, VSD 0 0 1 
5q31.3 PCDHB16 2 ASD, VSD 0 0 2 
5q31.3 PCDHB9 2 ASD, VSD 0 0 2 
5q31.3 PCDHB10 2 ASD, VSD 0 0 2 
7p22.2 SDK1 1 TOF 0 1 9 
8p23.3 CLN8 1 AVSD 0 1 4 
8p23.3 MIR596 1 AVSD 0 1 2 
8p23.3 ARHGEF10 1 AVSD 0 1 3 
8p23.3 KBTBD11 1 AVSD 0 1 9 
8p23.3 MYOM2 1 AVSD 0 1 14 
8p23.2 CSMD1 1 AVSD 0 2 6 
8p23.1 MCPH1 2 TOF, AVSD 0 1 0 
8p23.1 ANGPT2 1 TOF, AVSD 0 1 0 
8p23.1 AGPAT5 2 TOF, AVSD 0 1 0 
8p23.1 XKR5 2 TOF, AVSD 0 1 0 
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8p23.1 DEFB1 2 TOF, AVSD 0 1 1 
8p23.1 DEFA6 2 TOF, AVSD 0 1 0 
8p23.1 DEFA4 2 TOF, AVSD 0 1 6 
8p23.1 DEFA10P 2 TOF, AVSD 0 1 1 
8p23.1 DEFA1B 1 AVSD 0 1 1 
8p23.1 DEFA3 1 AVSD 0 1 1 
8p23.1 DEFA1 1 AVSD 0 1 1 
8p23.1 DEFA5 1 AVSD 0 1 0 
8p23.1 SGK223 3 TOF, AVSD, BAV 0 2 3 
8p23.1 CLDN23 3 TOF, AVSD, BAV 0 3 0 
8p23.1 MFHAS1 3 TOF, AVSD, BAV 0 3 9 
8p23.1 ERI1 3 TOF, AVSD, BAV 0 2 1 
8p23.1 TNKS 3 TOF, AVSD, BAV 0 3 0 
8p23.1 MIR597 2 TOF, AVSD 0 3 0 
8p23.1 LOC157627 2 TOF, AVSD 0 3 0 
8p23.1 MIR124-1 2 TOF, AVSD 0 3 0 
8p23.1 MSRA 2 TOF, AVSD 0 3 4 
8p23.1 PRSS55 2 TOF, AVSD 0 3 1 
8p23.1 RP1L1 2 TOF, AVSD 0 3 1 
8p23.1 MIR4286 2 TOF, AVSD 0 3 0 
8p23.1 C8orf74 2 TOF, AVSD 0 3 2 
8p23.1 SOX7 2 TOF, AVSD 0 3 0 
8p23.1 PINX1 2 TOF, AVSD 0 3 0 
8p23.1 MIR1322 2 TOF, AVSD 0 3 0 
8p23.1 XKR6 2 TOF, AVSD 0 3 0 
8p23.1 MIR598 2 TOF, AVSD 0 3 0 
8p23.1 MTMR9 2 TOF, AVSD 0 3 0 
8p23.1 TDH 2 TOF, AVSD 0 3 0 
8p23.1 C8orf12 3 TOF, AVSD, VSD 0 3 1 
8p23.1 FAM167A 3 TOF, AVSD, VSD 0 3 1 
8p23.1 BLK 3 TOF, AVSD, VSD 0 3 0 
8p23.1 GATA4 4 TOF(2), AVSD, VSD 0 3 0 
8p23.1 NEIL2 4 TOF(2), AVSD, VSD 0 3 0 
8p23.1 FDFT1 4 TOF(2), AVSD, VSD 0 3 0 
8p23.1 CTSB 4 TOF(2), AVSD, VSD 0 3 0 
8p23.1 DEFB136 2 TOF, AVSD 0 1 0 
8p23.1 DEFB135 2 TOF, AVSD 0 1 0 
8p23.1 DEFB134 2 TOF, AVSD 0 1 0 
10q22.3 SFTPD 1 Other 0 1 2 
10q22.3 LOC219347 1 Other 0 1 1 
10q22.3 ANXA11 1 Other 0 1 1 
10q23.1 MAT1A 1 Other 0 1 0 
10q23.1 DYDC1 1 Other 0 1 0 
10q23.1 DYDC2 1 Other 0 1 0 
10q23.1 C10orf58 1 Other 0 1 0 
10q23.1 TSPAN14 1 Other 0 1 3 
10q23.1 SH2D4B 1 Other 0 1 0 
10q23.1 NRG3 2 ASD, Other 0 1 6 
10q23.1 GHITM 2 ASD, Other 0 0 0 
10q23.1 C10orf99 2 ASD, Other 0 0 0 
10q23.1 CDHR1 2 ASD, Other 0 0 1 
10q23.1 LRIT2 2 ASD, Other 0 0 0 
10q23.1 LRIT1 2 ASD, Other 0 0 0 
10q23.1 RGR 2 ASD, Other 0 0 0 
10q26.3 C10orf93 2 AVSD, TGA 0 1 1 
10q26.3 GPR123 1 AVSD 0 1 4 
10q26.3 CYP2E1 2 AVSD, ASD 0 0 6 
10q26.3 SYCE1 2 AVSD, ASD 0 0 12 
11p15.4 OR52R1 2 TOF, VSD 0 0 14 
11p15.4 OR51F2 2 TOF, VSD 0 0 14 
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11p15.4 OR51S1 2 TOF, VSD 0 0 14 
11p15.4 OR51T1 2 TOF, VSD 0 0 11 
11q13.1 MACROD1 2 TGA, AVSD 0 0 2 
11q13.1 FLRT1 2 TGA, AVSD 0 0 0 
11q13.1 STIP1 2 TGA, AVSD 0 1 4 
11q13.1 FERMT3 2 TGA, AVSD 0 1 4 
11q13.1 TRPT1 2 TGA, AVSD 0 1 4 
11q13.1 NUDT22 2 TGA, AVSD 0 1 4 
11q13.1 DNAJC4 2 TGA, AVSD 0 1 9 
11q13.1 VEGFB 2 TGA, AVSD 0 1 10 
11q13.1 FKBP2 2 TGA, AVSD 0 1 4 
11q13.1 PPP1R14B 2 TGA, AVSD 0 0 4 
11q13.1 PLCB3 2 TGA, AVSD 0 0 4 
11q13.1 BAD 2 TGA, AVSD 0 0 3 
11q13.1 GPR137 2 TGA, AVSD 0 0 2 
11q13.1 KCNK4 2 TGA, AVSD 0 0 2 
11q13.1 C11orf20 2 TGA, AVSD 0 0 2 
11q13.1 TRMT112 2 TGA, AVSD 0 0 2 
11q13.1 PRDX5 2 TGA, AVSD 0 0 2 
11q13.1 CCDC88B 2 TGA, AVSD 0 0 2 
13q34 RASA3 1 TGA 0 1 11 
15q11.2 TUBGCP5 12 
CoA(3), VSD(2), ASD(2),     
L-sided (3), TOF, TAPVD 
0 6 22 
15q11.2 CYFIP1 12 
CoA(3), VSD(2), ASD(2),      
L-sided (3), TOF, TAPVD 
0 6 21 
15q11.2 NIPA2 12 
CoA(3), VSD(2), ASD(2),      
L-sided (3), TOF, TAPVD 
0 6 19 
15q11.2 NIPA1 12 
CoA(3), VSD(2), ASD(2),      
L-sided (3), TOF, TAPVD 
0 6 19 
15q13.3 FAN1 2 IL, PDA 0 2 0 
15q13.3 MTMR10 2 IL, PDA 0 2 0 
15q13.3 TRPM1 2 IL, PDA 0 2 7 
15q13.3 MIR211 2 IL, PDA 0 2 7 
15q13.3 CHRNA7 3 IL, PDA, PS 0 2 4 
16p12.1 UQCRC2 1 TOF 0 1 3 
16p12.1 PDZD9 1 TOF 0 2 3 
16p12.1 C16orf52 1 TOF 0 2 3 
16p12.1 VWA3A 1 TOF 0 2 3 
16p12.1 EEF2K 1 TOF 0 2 3 
16p12.1 POLR3E 1 TOF 0 2 3 
16p12.1 CDR2 1 TOF 0 2 3 
16q23.1 WWOX 2 CoA(2) 0 0 6 
16q24.3 FANCA 2 PS, BAV 0 0 2 
16q24.3 SPIRE2 3 PS, BAV, ASD 0 0 9 
16q24.3 TCF25 3 PS, BAV, ASD 0 0 3 
16q24.3 MC1R 2 PS, ASD 0 0 1 
16q24.3 TUBB3 2 PS, ASD 0 0 1 
16q24.3 DEF8 2 PS, ASD 0 0 3 
18q23 ATP9B 2 TGA, CCTGA 0 1 2 
18q23 NFATC1 2 TGA, CCTGA 0 1 9 
22q11.21 DGCR10 1 ASD 0 16 2 
22q11.21 ZNF74 1 VSD 0 10 0 
22q11.21 SCARF2 1 VSD 0 10 0 
22q11.21 KLHL22 1 VSD 0 10 0 
22q11.21 MED15 1 VSD 0 10 0 
22q11.21 PI4KA 1 VSD 0 10 1 
22q11.21 SERPIND1 1 VSD 0 10 1 
22q11.21 SNAP29 1 VSD 0 10 1 
22q11.21 CRKL 1 VSD 0 10 1 
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22q11.21 AIFM3 1 VSD 0 10 1 
22q11.21 LZTR1 1 VSD 0 10 1 
22q11.21 THAP7 1 VSD 0 10 1 
22q11.21 FLJ39582 1 VSD 0 10 1 
22q11.21 P2RX6 1 VSD 0 10 1 
22q11.21 SLC7A4 1 VSD 0 10 1 
22q11.22-
q11.23 
RTDR1 1 CAT 0 2 1 
22q11.22 GNAZ 1 CAT 0 2 0 
22q13.31 LOC100271722 1 AS 0 1 0 
22q13.31 C22orf26 1 AS 0 1 0 
22q13.31 LOC150381 1 AS 0 1 0 
22q13.31 MIRLET7A3 1 AS 0 1 0 
22q13.31 MIRLET7B 1 AS 0 1 0 
AS = Aortic valve stenosis, ASD = Atrial septal defect, AVSD = Atrioventricular septal defect, BAV = Bicuspid aortic valve, 
CAT = Truncus arteriosus    , CCTGA = Congenitally corrected transposition of the great arteries, CoA = Coarctation of the 
aorta, IL = Left isomerism, L-sided = Complex left-sided malformation, MV = Miltral valve abnormalities, PDA = Patent 
ductus arteriosus, PS = Pulmonary valve stenosis, TAPVD = Total anomalous pulmonary venous drainage, TGA = 
Transposition of the great arteries, VSD = Ventricular septal defect. 
Table 4.8 – Recurrent genes spanned by rare duplications 
Cyto band RefSeq gene 
CHD 
(n=2256) 
CHD phenotype 
Controls 
(n=841) 
(Cooper et al., 2011) 
Cardio 
(n=575) 
Controls   
(n = 8329) 
1p36.32 ACTRT2 1 TOF 0 1 0 
1p36.32 FLJ42875 1 TOF 0 1 0 
1p36.32 PRDM16 1 TOF 0 1 0 
1p36.32 MIR4251 1 TOF 0 1 0 
1q21.1 HFE2 2 TOF 0 2 6 
1q21.1 TXNIP 2 TOF 0 2 6 
1q21.1 POLR3GL 2 TOF 0 2 6 
1q21.1 ANKRD34A 2 TOF 0 2 6 
1q21.1 LIX1L 2 TOF 0 2 6 
1q21.1 GNRHR2 2 TOF 0 2 6 
1q21.1 PEX11B 2 TOF 0 2 6 
1q21.1 ITGA10 2 TOF 0 2 6 
1q21.1 ANKRD35 2 TOF 0 2 6 
1q21.1 PIAS3 2 TOF 0 2 6 
1q21.1 NUDT17 2 TOF 0 2 6 
1q21.1 POLR3C 2 TOF 0 2 6 
1q21.1 RNF115 2 TOF 0 3 15 
1q21.1 CD160 2 TOF 0 2 14 
1q21.1 PDZK1 2 TOF 0 2 14 
1q21.1 PRKAB2 8 TOF 0 1 0 
1q21.1 PDIA3P 8 TOF 0 1 0 
1q21.1 FMO5 8 TOF 0 1 2 
1q21.1 CHD1L 8 TOF 0 1 2 
1q21.1 BCL9 8 TOF 0 1 1 
1q21.1 ACP6 10 TOF 0 1 1 
1q21.1 GJA5 12 TOF(11), PA 0 1 3 
1q21.1 GJA8 10 TOF 0 1 2 
2p21 UNQ6975 1 DORV 0 1 1 
2p21 SRBD1 1 DORV 0 1 2 
2p21 PRKCE 1 DORV 0 1 1 
2p16.3 NRXN1 1 TGA 0 1 0 
3p14.2 FHIT 2 HLHS, ASD 0 0 3 
3q29 TFRC 1 VSD 0 1 1 
3q29 LOC401109 1 VSD 0 1 2 
3q29 ZDHHC19 1 VSD 0 1 1 
3q29 OSTalpha 1 VSD 0 1 1 
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3q29 PCYT1A 1 VSD 0 1 1 
3q29 TCTEX1D2 1 VSD 0 1 1 
4q22.1 FAM190A 2 ASD, PDA 0 1 4 
4q22.1-q22.2 GRID2 1 ASD 0 1 2 
6q12 EYS 1 CoA 0 1 5 
7q36.2 DPP6 1 TOF 0 1 8 
7q36.2 LOC100132707 1 TOF 0 1 0 
7q36.2 PAXIP1 1 TOF 0 1 0 
7q36.2 LOC202781 1 TOF 0 1 0 
7q36.2 HTR5A 1 TOF 0 1 0 
8p23.2 CSMD1 1 ASD 0 1 6 
8p23.1 ERI1 1 TOF 0 1 0 
8p23.1 PPP1R3B 1 TOF 0 1 0 
8p23.1 TNKS 1 TOF 0 1 0 
8p23.1 MIR597 1 TOF 0 1 0 
8p23.1 MSRA 1 BAV 0 1 1 
8p23.1 PRSS55 1 BAV 0 1 1 
8p23.1 RP1L1 1 BAV 0 1 1 
8p23.1 MIR4286 1 BAV 0 1 1 
8p23.1 C8orf74 1 BAV 0 1 0 
8p23.1 SOX7 1 BAV 0 1 0 
8p23.1 PINX1 1 BAV 0 1 0 
8p23.1 MIR1322 1 BAV 0 1 0 
8p23.1 XKR6 1 BAV 0 1 0 
8p23.1 MIR598 1 BAV 0 1 0 
8p23.1 MTMR9 1 BAV 0 1 0 
8p23.1 TDH 1 BAV 0 1 0 
8p23.1 FAM167A 1 BAV 0 1 0 
8p23.1 BLK 1 BAV 0 1 2 
8p23.1 GATA4 1 BAV 0 1 0 
8p23.1 NEIL2 2 BAV, VSD 0 1 0 
8p23.1 FDFT1 2 BAV, VSD 0 1 0 
8p23.1 CTSB 2 BAV, VSD 0 1 1 
8p23.1 DEFB136 2 BAV, VSD 0 0 2 
8p23.1 DEFB135 2 BAV, VSD 0 0 2 
8p23.1 DEFB134 2 BAV, VSD 0 0 2 
8p11.21 HGSNAT 2 TGA 0 0 6 
8p11.1 POTEA 3 TGA, TOF, HLHS 0 1 11 
8q11.23 NPBWR1 2 AS, PDA 0 0 0 
8q21.3 SLC7A13 1 TOF 0 2 3 
9p24.1 KDM4C 1 PS 0 1 11 
9q34.3 COL5A1 1 PS 0 1 1 
10q21.3 CTNNA3 3 TOF, SI, ASD 0 0 4 
10q21.3 LRRTM3 3 TOF, SI, ASD 0 0 0 
11q14.1 MIR4300 2 BAV, AS 0 0 2 
12p13.31 CD163 1 TOF 0 1 0 
12p13.31 APOBEC1 1 TOF 0 1 0 
12p13.31 GDF3 1 TOF 0 1 1 
12p13.31 DPPA3 1 TOF 0 1 1 
12p13.31 CLEC4C 1 TOF 0 1 0 
12p13.31 NANOGNB 1 TOF 0 1 0 
12p11.1 SYT10 8 
TOF(3), IL, PS, 
ASD, PDA, Other 
0 2 9 
13q12.11 LATS2 1 CoA 0 1 0 
13q12.11 SAP18 1 CoA 0 1 0 
13q12.11 MRP63 1 CoA 0 1 0 
15q13.3 ARHGAP11A 3 TOF, VSD, TGA 0 0 3 
15q13.3 SCG5 4 TOF, VSD, TGA 0 0 4 
15q13.3 GREM1 4 TOF, VSD, TGA 0 0 3 
15q13.3 FMN1 4 TOF, VSD, TGA 0 0 3 
15q14 RYR3 2 TOF, TGA 0 0 4 
15q14 AVEN 2 TOF, TGA 0 0 4 
15q14 CHRM5 2 TOF, TGA 0 0 3 
Chapter 4: Global Rare CNVs in CHD 
92 
 
15q14 C15orf24 2 TOF, TGA 0 0 3 
15q14 PGBD4 2 TOF, TGA 0 0 3 
15q14 C15orf29 2 TOF, TGA 0 0 2 
15q14 TMEM85 2 TOF, TGA 0 0 2 
15q14 SLC12A6 2 TOF, TGA 0 0 2 
15q25.3 AKAP13 2 BAV, TOF 0 0 16 
16p13.11 C16orf45 3 VSD, CoA, TAPVD 0 0 11 
16p13.11 KIAA0430 3 VSD, CoA, TAPVD 0 0 12 
16p13.11 NDE1 3 VSD, CoA, TAPVD 0 0 12 
16p13.11 MIR484 3 VSD, CoA, TAPVD 0 0 12 
16p13.11 MYH11 3 VSD, CoA, TAPVD 0 0 12 
16p13.11 ABCC1 3 VSD, CoA, TAPVD 0 1 13 
16p13.11 ABCC6 3 VSD, CoA, TAPVD 0 1 13 
16p12.3 XYLT1 2 TOF, TGA 0 0 2 
17q12 ZNHIT3 2 TOF, VSD 0 1 4 
17q12 MYO19 2 TOF, VSD 0 1 4 
17q12 PIGW 2 TOF, VSD 0 1 4 
17q12 GGNBP2 2 TOF, VSD 0 1 4 
17q12 DHRS11 2 TOF, VSD 0 1 3 
17q12 MRM1 2 TOF, VSD 0 1 3 
17q12 LHX1 2 TOF, VSD 0 1 3 
17q12 AATF 2 TOF, VSD 0 1 3 
17q12 MIR2909 2 TOF, VSD 0 1 3 
17q12 ACACA 2 TOF, VSD 0 1 3 
17q12 C17orf78 2 TOF, VSD 0 1 3 
17q12 TADA2A 2 TOF, VSD 0 1 3 
17q12 DUSP14 2 TOF, VSD 0 1 3 
17q12 SYNRG 2 TOF, VSD 0 1 3 
17q12 DDX52 2 TOF, VSD 0 1 3 
17q12 HNF1B 2 TOF, VSD 0 1 3 
18p11.32 COLEC12 2 TOF, CoA 0 0 5 
18p11.32 CETN1 2 TOF, CoA 0 0 6 
18p11.32 CLUL1 2 TOF, CoA 0 0 8 
18q22.1 CDH19 2 TOF, VSD 0 0 1 
20p12.3 PLCB1 1 VSD 0 1 4 
20q13.2 NFATC2 2 TOF, VSD 0 0 0 
20q13.2 ATP9A 2 TOF, VSD 0 0 0 
20q13.2 SALL4 2 TOF, VSD 0 0 0 
AS = Aortic valve stenosis, ASD = Atrial septal defect, BAV = Bicuspid aortic valve, CoA = Coarctation of the aorta, DORV = 
Double outlet right ventricle, HLHS = Hypoplastic left heart syndrome, IL = Left isomerism, PA = Pulmonary atresia, PDA = 
Patent ductus arteriosus, PS = Pulmonary valve stenosis, SI = Situs inversus, TGA = Transposition of the great arteries, VSD 
= Ventricular septal defect. 
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Table 4.9 – Deleted genes with high haploinsufficiency scores in CHD 
Gene symbol Gene name MIM ID 
HI 
score 
MAPK1 mitogen-activated protein kinase 1 176948 0.999 
ERBB4 
v-erb-a erythroblastic leukemia viral oncogene homolog 4 
(avian) 
600543 0.993 
DLG1 discs, large homolog 1 (Drosophila) 601014 0.991 
CTBP1 C-terminal binding protein 1 602618 0.99 
BMPR1A bone morphogenetic protein receptor, type IA; similar to ALK-3 601299 0.98 
RPL10L ribosomal protein L10-like n/a 0.975 
NUP205 nucleoporin 205kDa 614352 0.966 
PPM1F protein phosphatase 1F (PP2C domain containing) n/a 0.961 
KRR1 
KRR1, small subunit (SSU) processome component, homolog 
(yeast) 
612817 0.956 
GATA4 GATA binding protein 4 600576 0.951 
CRKL v-crk sarcoma virus CT10 oncogene homolog (avian)-like 602007 0.943 
HMGB2 high-mobility group box 2 163906 0.936 
CDH2 cadherin 2, type 1, N-cadherin (neuronal) 114020 0.934 
HDAC9 histone deacetylase 9   606543 0.923 
CECR6 cat eye syndrome chromosome region, candidate 6 n/a 0.9 
PCDH7 protocadherin 7  602988 0.889 
PTBP1 polypyrimidine tract binding protein 1 600693 0.875 
LDB3 LIM domain binding 3 605906 0.865 
MSX1 msh homeobox 1 142983 0.862 
CALD1 caldesmon 1 114213 0.836 
PDE4B 
phosphodiesterase 4B, cAMP-specific (phosphodiesterase E4 
dunce homolog, Drosophila) 
600127 0.826 
MYH11 myosin, heavy chain 11, smooth muscle 160745 0.823 
LRRC4C leucine rich repeat containing 4C 608817 0.817 
PAK2 p21 protein (Cdc42/Rac)-activated kinase 2 605022 0.815 
THBS2 thrombospondin 2 188061 0.804 
BCL9 B-cell CLL/lymphoma 9 602597 0.791 
RPS21 ribosomal protein S21 180477 0.79 
MED15 mediator complex subunit 15 607372 0.789 
DEPDC1B DEP domain containing 1B n/a 0.786 
STK38L serine/threonine kinase 38 like n/a 0.781 
WAPAL wings apart-like homolog (Drosophila) 610754 0.781 
MME membrane metallo-endopeptidase 120520 0.778 
MTPN myotrophin; leucine zipper protein 6 606484 0.772 
PCYT1A phosphate cytidylyltransferase 1, choline, alpha 123695 0.768 
GPM6A glycoprotein M6A 601275 0.766 
FOXC1 forkhead box C1 601090 0.763 
PRKAB2 protein kinase, AMP-activated, beta 2 non-catalytic subunit 602741 0.74 
OSBPL8 oxysterol binding protein-like 8 606736 0.738 
WRNIP1 Werner helicase interacting protein 1 608196 0.733 
BPGM 2,3-bisphosphoglycerate mutase 613896 0.725 
TNKS 
tankyrase, TRF1-interacting ankyrin-related ADP-ribose 
polymerase 
603303 0.721 
HAND2 heart and neural crest derivatives expressed 2 602407 0.72 
GADD45A growth arrest and DNA-damage-inducible, alpha 126335 0.719 
STIP1 stress-induced-phosphoprotein 1 605063 0.717 
USP33 ubiquitin specific peptidase 33 n/a 0.714 
SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 142360 0.704 
GPC5 glypican 5 602446 0.694 
SERBP1 SERPINE1 mRNA binding protein 1 607378 0.686 
PPFIBP1 PTPRF interacting protein, binding protein 1 (liprin beta 1)  603141 0.672 
ZZZ3 zinc finger, ZZ-type containing 3 n/a 0.659 
DNAJB4 DnaJ (Hsp40) homolog, subfamily B, member 4 611327 0.652 
CNOT4 CCR4-NOT transcription complex, subunit 4 604911 0.652 
ICMT isoprenylcysteine carboxyl methyltransferase 605851 0.651 
SACS spastic ataxia of Charlevoix-Saguenay (sacsin) 604490 0.651 
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CEP135 centrosomal protein 135kDa 611423 0.649 
RABGGTB Rab geranylgeranyltransferase, beta subunit 179080 0.645 
TUSC3 tumor suppressor candidate 3 601385 0.645 
FUBP1 far upstream element (FUSE) binding protein 1 603444 0.641 
PDE6B phosphodiesterase 6B, cGMP-specific, rod, beta 180072 0.638 
KLHL22 kelch-like 22 (Drosophila) n/a 0.634 
RGS7BP regulator of G-protein signaling 7 binding protein 610890 0.629 
SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1 611540 0.627 
WSCD1 WSC domain containing 1 n/a 0.622 
HPGD hydroxyprostaglandin dehydrogenase 15-(NAD) 601688 0.622 
WWOX WW domain containing oxidoreductase 605131 0.616 
LRRTM1 leucine rich repeat transmembrane neuronal 1 610867 0.613 
EXOC2 exocyst complex component 2 n/a 0.612 
ZDHHC17 zinc finger, DHHC-type containing 17 607799 0.611 
PCDH17 protocadherin 17 611760 0.608 
MSH3 mutS homolog 3 (E. coli) 600887 0.605 
SNTB1 
syntrophin, beta 1 (dystrophin-associated protein A1, 59kDa, 
basic component 1) 
600026 0.605 
PLCB3 phospholipase C, beta 3 (phosphatidylinositol-specific) 600230 0.6 
DIDO1 death inducer-obliterator 1 604140 0.594 
MSH4 mutS homolog 4 (E. coli) 602105 0.586 
GLDC glycine dehydrogenase (decarboxylating) 238300 0.586 
AGPAT5 
1-acylglycerol-3-phosphate O-acyltransferase 5 
(lysophosphatidic acid acyltransferase, epsilon) 
n/a 0.585 
CDH18 cadherin 18, type 2 603019 0.585 
NDST4 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 n/a 0.584 
STK32B serine/threonine kinase 32B n/a 0.581 
ESRRA estrogen-related receptor alpha 601998 0.579 
ANKRD13C ankyrin repeat domain 13C n/a 0.575 
DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 607987 0.569 
CNOT6 CCR4-NOT transcription complex, subunit 6 608951 0.565 
MLLT3 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila); translocated to, 3 
159558 0.561 
HAS2 hyaluronan synthase 2 601636 0.557 
SLC7A4 
solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 4 
603752 0.554 
HOMER2 homer homolog 2 (Drosophila) 604799 0.55 
ST6GALNAC5 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 5 
610134 0.547 
FUS fusion (involved in t(12;16) in malignant liposarcoma) 137070 0.546 
NDE1 nudE nuclear distribution gene E homolog 1 (A. nidulans) 609449 0.543 
PRDX5 peroxiredoxin 5 606583 0.54 
KDR 
kinase insert domain receptor (a type III receptor tyrosine 
kinase) 
191306 0.538 
ADRM1 adhesion regulating molecule 1 610650 0.534 
PYCARD PYD and CARD domain containing 606838 0.533 
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 605174 0.533 
SLC27A2 solute carrier family 27 (fatty acid transporter), member 2 603247 0.53 
ZC3H6 zinc finger CCCH-type containing 6 n/a 0.527 
RPS6KA4 ribosomal protein S6 kinase, 90kDa, polypeptide 4 603606 0.525 
EDIL3 EGF-like repeats and discoidin I-like domains 3 606018 0.525 
GLRA3 glycine receptor, alpha 3 600421 0.523 
KIAA1609 KIAA1609 n/a 0.523 
SNCG synuclein, gamma (breast cancer-specific protein 1) 602998 0.52 
ANGPT2 angiopoietin 2 601922 0.511 
LRRC40 leucine rich repeat containing 40 n/a 0.505 
LRFN5 leucine rich repeat and fibronectin type III domain containing 5 612811 0.496 
UQCRC2 ubiquinol-cytochrome c reductase core protein II 191329 0.491 
ZC3H18 zinc finger CCCH-type containing 18 n/a 0.49 
CLOCK clock homolog (mouse) 601851 0.49 
TFRC transferrin receptor (p90, CD71) 190010 0.489 
TMEM55A transmembrane protein 55A 609864 0.485 
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LRRC7 leucine rich repeat containing 7 614453 0.485 
NIPA1 non imprinted in Prader-Willi/Angelman syndrome 1 608145 0.483 
KCNAB2 
potassium voltage-gated channel, shaker-related subfamily, 
beta member 2 
601142 0.481 
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit 607244 0.479 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 182305 0.478 
LRRC33 leucine rich repeat containing 33 n/a 0.477 
CTNNA2 catenin (cadherin-associated protein), alpha 2 114025 0.476 
SLC35D1 
solute carrier family 35 (UDP-glucuronic acid/UDP-N-
acetylgalactosamine dual transporter), member D1 
610804 0.475 
CSRP2 cysteine and glycine-rich protein 2 601871 0.475 
SOX7 SRY (sex determining region Y)-box 7 612202 0.468 
ASB5 ankyrin repeat and SOCS box-containing 5 n/a 0.467 
RNF180 ring finger protein 180 n/a 0.465 
CTNND2 
catenin (cadherin-associated protein), delta 2 (neural 
plakophilin-related arm-repeat protein) 
604275 0.464 
ZNF141 zinc finger protein 141 194648 0.461 
GRID1 glutamate receptor, ionotropic, delta 1 610659 0.461 
ARID3A AT rich interactive domain 3A (BRIGHT-like) 603265 0.456 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1 motif, 5 605007 0.443 
GNAZ 
guanine nucleotide binding protein (G protein), alpha z 
polypeptide 
139160 0.442 
C8orf42 chromosome 8 open reading frame 42 n/a 0.439 
NECAB1 N-terminal EF-hand calcium binding protein 1 n/a 0.437 
PHLDA1 pleckstrin homology-like domain, family A, member 1 605335 0.434 
THAP7 THAP domain containing 7 609518 0.433 
NELL2 NEL-like 2 (chicken) 602320 0.432 
VGLL4 vestigial like 4 (Drosophila) n/a 0.431 
POLR3E polymerase (RNA) III (DNA directed) polypeptide E (80kD) n/a 0.424 
GRM5 glutamate receptor, metabotropic 5 604102 0.422 
C20orf11 chromosome 20 open reading frame 11 611625 0.421 
C16orf45 chromosome 16 open reading frame 45 n/a 0.415 
ADAMTS19 ADAM metallopeptidase with thrombospondin type 1 motif, 19 607513 0.413 
AP3B2 adaptor-related protein complex 3, beta 2 subunit 602166 0.412 
FGFRL1 fibroblast growth factor receptor-like 1 605830 0.411 
VEGFC vascular endothelial growth factor C 601528 0.406 
XKR6 XK, Kell blood group complex subunit-related family, member 6 n/a 0.405 
VEGFB vascular endothelial growth factor B 601398 0.396 
CYTL1 cytokine-like 1 607930 0.396 
CHD5 chromodomain helicase DNA binding protein 5 610771 0.395 
FHIT fragile histidine triad gene 601153 0.395 
The genes with HI scores (Huang et al., 2010) that were above the mean of total scores in all genes hit by rare 
deletions in CHD patients are listed. 
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Non-genic CNVs in highly conserved regions overlapping predicted 
human heart-specific enhancer sequences 
In 2256 CHD cases, twelve large (>500kb) rare CNVs were identified in highly 
conserved non-coding regions that contain previously predicted (Narlikar et al., 
2010) human heart-specific enhancer sequences (see Table 4.10) with no 
overlapping CNVs identified in 841 unrelated controls. Three of the loci (8q21.13, 
13q21.31 and 18q23) were found to be recurrent. The coding RefSeq genes within 
the vicinity (≤200kb) of the CNVs are HAND2 [MIM 602407] (see Figure 4.2), 
FBXO8 [MIM 605649], and CEP44 at 4q34.1, SALL3 [MIM 605079] and GALR1 
[MIM 600377] at 18q23, CSMD3 [MIM 608399] at 8q23.3, and TSG1 at 6q16.3. 
Table 4.10 - Rare non-genic CNVs >500kb that are likely to be pathogenic 
ID Phenotype 
copy 
number 
cyto band 
hg18 start 
coordinate 
size 
CHA-788.1 Tetralogy of Fallot del 4q34.1 174801597 504840 
SYD-1107.1 
Double inlet left 
ventricle 
dup 6q16.1 94610606 634130 
NOTT-266.1 Coarctation of the aorta del 6q16.3-q21 104286807 612781 
FCH-56.1 Isomerism right del 8q21.13 83141204 511096 
FCH-57.1 Atrial septal defect del 8q21.2-q21.13 83170552 1871607 
SYD-1847.1 Atrial septal defect dup 8q23.2-q23.3 111714363 1470169 
NOTT-732.1 Atrial septal defect dup 11p12 37046345 580618 
OX-1352.1 
Atrioventricular septal 
defect 
dup 
13q21.31-
q21.32 
63251062 982826 
FCH-10.1 Tricuspid atresia del 13q21.31 63330923 503322 
FCH-324.1 
Transposition of the 
great aorta 
del 13q21.31 63330923 503322 
FCH-295.1 
Partial anomalous 
pulmonary venous 
drainage 
dup 18q23 73264159 1408553 
NOTT-603.1 Ventricular septal defect del 18q23 73514135 713321 
Above is the list of rare CNVs detected in CHD patients that do not encompass any known 
genes, but spanned highly conserved regions, overlapped previously predicted human 
heart-specific enhancer sequences (Narlikar et al., 2010), and were absent in controls.  
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Figure 4.2 – Conservation of non-genic deletion span upstream of HAND2 
A 500kb deletion that did not span any known genes was identified in a TOF patient, 
~100kb upstream of HAND2 (a candidate gene for CHD, known for its role in cardiac 
development). The deletion span is significantly conserved in mammals and across 
the vertebrates (shown).  Transcription factor binding site conservation in the region 
is also shown. (http://genome.ucsc.edu) 
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4.4.4 15q11.2 deletions are associated with CHD 
Locus-specific enrichment was queried in 2256 CHD patients compared to 1538 
controls. The frequency of deletions and duplications within each cytogenetic 
band in cases and unrelated controls were compared with two-sided Fisher’s 
exact test, automated using an R script that I wrote, and resulted in one locus 
reaching statistical significance. Twelve deletions in the 15q11.2 locus were 
identified in CHD patients, while only one such deletion was identified in 
controls (P = 0.02, OR = 8.2). The deletions encompassed a minimal region 
between breakpoints (BP) 1 and 2 of the Prader-Willi/ Angelman syndrome 
region in chromosome 15q11.2, i.e. adjacent to but not including the established 
critical region for Prader-Willi/Angelman syndrome (see Figure 4.3). The 
minimally deleted region spans four RefSeq genes: TUBGCP5 (MIM 608147), 
CYFIP1 (MIM 606322), NIPA2 (MIM 608146) and NIPA1 (MIM 608145) – see 
Figure 4.4. The phenotypes of these patients were complex left-sided 
malformations (n=3), coarctation of the aorta (n=3), atrial septal defect (n=2), 
ventricular septal defect (n=2), total anomalous pulmonary venous drainage 
(n=1) and TOF (n=1) (see Table 6.1 for details).  
  
Figure 4.3 – The common 
breakpoints in the Prader-
Willi/Angelman syndrome 
(PW/AS) region. 
The breakpoints of the two 
types of Prader-Willi/Angelman 
syndrome are shown: BP1-BP3 
for the type I deletion and BP2-
BP3 for the type II deletion. 
Thus, the critical region for 
PW/AS lies between BP2 and 
BP3.  
 
Doornbos et al., 2009 
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Figure 4.4 - Recurrent rare deletions in 15q11.2 
Twelve deletions (shown as red bars in the UCSC Genome Browser) were identified in 
three patients with complex left-sided malformations (L-sided), three patients with 
coarctation of the aorta (CoA), two patients with ventricular septal defect (VSD), two 
patients with atrial septal defect (ASD), one patient with total anomalous pulmonary 
venous drainage (TAPVD) and one patient with TOF. RefSeq genes, segmental 
duplications and coverage of the Illumina 660W platform in the region are shown. The 
smallest deletions encompass four RefSeq genes: TUBGCP5, CYFIP1, NIPA2 and 
NIPA1. 
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Table 4.11 – Phenotype characteristics of 15q11.2 deleted patients 
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4.5 Discussion 
This chapter describes the largest study of CHD genetics thus far, involving a 
genome-wide investigation of CNVs >100kb in sporadic, non-syndromic CHD.  
Rare deletions, particularly rare genic deletions, are enriched in CHD, and they 
account for 3-4% of the population attributable risk of TOF and other CHD. Rare 
CNVs spanning higher number of genes confer higher risk of CHD, and rare 
deletions in CHD patients encompass genes with higher haploinsufficiency 
scores. Additionally, there is an overrepresentation of the Wnt signalling genes 
that span the rare deletions in CHD.   
A recent study by Cooper and colleagues reported a significant excess (OR = 
2.7, P = 5.9 x 10-158) of CNVs >400kb with <1% frequency in 15767 cases with a 
general diagnosis of intellectual disability and various congenital malformations 
that had been referred to Signature Genomics Laboratories, LLC for genetic 
evaluation, in comparison to 8329 unaffected adult controls (Cooper et al., 
2011). Their study confirmed what was previously known about the causative 
nature of many large CNVs in various developmental multi-system 
abnormalities. Interestingly, they discovered that this effect was much more 
pronounced in cases with cardiovascular defects and craniofacial anomalies in 
comparison to cases with autism and epilepsy (P = 6.45 x 10-5). They identified 
such CNVs in ~25% of the cases with CHD (Cooper et al., 2011).  By contrast, 
13.6% of the CHD cases in the present study had CNVs in this category, with 
highly comparable frequency of controls between the two studies (11.5% in 
Cooper et al.; 10.8% in the present study).  This likely reflects the different 
ascertainment of the two cohorts, which in the study of Cooper et al. was chiefly 
through referral with a diagnosis of intellectual disability or developmental delay 
and in the present study was through paediatric and adult congenital heart 
disease clinics.  Thus, the results of the present investigation are likely to 
provide more representative estimates of the contribution of CNVs to the 
population burden of CHD.  
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Another seminal work in sporadic schizophrenia that involved a cohort of 3391 
cases and 3181 matched controls, identified an increased burden (1.15 fold, P = 
3x10-5) of rare CNVs with frequency <1% and length >100kb in cases compared 
to controls (2008). Interestingly, they found a greater effect in single-occurrence 
CNVs (1.45 fold, P = 5x10-6). They further showed that the increased burden 
was attributed to rare genic CNVs (P = 5x10-6) but not to non genic CNVs (P = 
0.16). Additionally, they found higher number of genes encompassed by CNVs 
in cases compared to controls (1.41 fold, P = 2x10-6). A more recent study by 
Pinto and colleagues examined CNVs >30kb with frequency <1% and observed 
no difference in the global CNV burden between 996 autism cases and 1287 
ancestry-matched controls (Pinto et al., 2010). Nevertheless, they observed a 
1.19 fold increase (P = 0.012) in the number of genes spanned by rare genic 
CNVs. Thus, the results from these previous studies complement the findings 
presented in this chapter in providing the evidence of the pathogenicity of global 
rare CNVs and their contribution to common complex diseases, including but 
not limited to CHD. In agreement with previous studies, the present findings 
suggest that the more genes spanned by a CNV, the greater is its potential to 
be pathogenic. No multiple testing was performed in the CNV burden analysis in 
this study, thus the results presented in this chapter need to be interpreted 
accordingly. 
Additionally, I have shown a higher haploinsufficiency score (Huang et al., 2010) 
of the genes spanned by rare deletions in CHD cases. Haploinsufficient genes 
have formerly been shown to have biased evolutionary and functional 
properties. They are much more highly conserved, highly expressed during 
early development and highly tissue specific (Huang et al., 2010, Blekhman et 
al., 2008) Furthermore, an overrepresentation of Wnt signaling pathway genes 
was found in rare deletions identified in CHD cases. Wnt signalling regulates 
diverse cellular processes from gene transcription and cell proliferation, 
migration, polarity and cell division (Gessert and Kuhl, 2010, Henderson et al., 
2006).  They are involved at all stages of cardiac specification, differentiation 
and development (Gessert and Kuhl, 2010). Several model organisms with 
mutations in Wnt signalling pathway genes are known to exhibit CHD (Tian et 
al., 2010, Zhou et al., 2007). Yet evidence to date for the involvement of the Wnt 
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pathway in human CHD has been sparse. Thus, my work has provided among 
the first such evidence. 
The non-coding segments of the genome generally present minimal mutational 
hazard, as this present study also suggests. Yet such regions can also be highly 
conserved (Bejerano et al., 2004). Studies have shown that CNVs that involve 
non-coding regions can profoundly affect the expression of copy number neutral 
genes in the vicinity (Henrichsen et al., 2009, Guryev et al., 2008, Stranger et 
al., 2007, Merla et al., 2006, Molina et al., 2008, Feuk et al., 2006b, McCarroll et 
al., 2008a). Therefore, some of the rare CNVs that occur in highly conserved 
regions, particularly when they are large (>500kb), are likely to contribute to 
CHD risk. 12/2256 (0.5%) of cases with such CNVs were identified, and all span 
previously predicted human heart-specific enhancer sequences (Narlikar et al., 
2010), thus elevating their candidacy as contributing factors to the risk of CHD. 
A personal communication with Dr. Axel Visel (Lawrence Berkeley National 
Laboratory, CA, USA) also revealed that the recent ChIP-seq experiment 
conducted by his group (May et al., 2012) detected significant binding activities 
within the non genic deletion span identified in this study at 4q34.1, ~100kb 
upstream of HAND2 (Figure 4.2). These activities were reported to be present in 
human fetal heart tissues, but not in adult heart tissues. This data thus suggest 
the presence of an enhancer activity that is specific to the heart development 
stage in the deletion span, therefore highly likely to be relevant to CHD. 
Furthermore, HAND2 is known for its pivotal roles in cardiac development 
(Srivastava et al., 1997, Srivastava, 1999, Tsai et al., 1999). Additional 
functional experiments would be needed to confirm this hypothesis. Presently, 
these CNVs serve as anecdotal findings. Closer examination of such regions in 
future studies is warranted.  
In the search for locus specific enrichments, BP1-BP2 deletions of the 15q11.2 
locus (adjacent to but not including the critical region of the Prader-
Willi/Angelman syndrome [MIM 176270 and 105830]), were found to be 
associated with CHD risk (OR = 8.2, P = 0.02). These deletions implicated four 
RefSeq genes: TUBGCP5, CYF1P1, NIPA2 and NIPA1; none of which have 
been previously associated with CHD. However, TUBGCP5 (MIM 608147) and 
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NIPA1 (MIM 608145) were reported to be expressed in the fetal heart (Bgee 
database, http://bgee.unil.ch/), thus increasing their candidacy as the causative 
gene for CHD. Of note, half of the patients with the deletions had left-sided 
cardiac lesions. Further studies will be required to determine the significance of 
the apparent subphenotypic predominance.  Previously, the same 15q11.2 
deletions were identified in 1/182 patients with left ventricular outflow tract 
obstruction (Kerstjens-Frederikse et al., 2011) and in 6/575 cases with CHD (P 
= 0.004 by two-sided Fisher’s exact test when compared to 19/8329 
occurrences in controls) (Cooper et al., 2011). However, the penetrance of 
15q11.2 deletions is incomplete; only two out of nine patients with the BP1-BP2 
deletions reported by Doornbos and colleagues had CHD (Doornbos et al., 
2009) and such deletions also occur in healthy controls (Cooper et al., 2011). 
While the association of 15q11.2 deletions with CHD risk is clear, it is a paradox 
that Prader-Willi Angelman syndrome patients with type I deletions reportedly 
do not typically manifest CHD (Kim et al., 2012, Varela et al., 2005). Differences 
in patient ascertainment between the studies may account for this discrepancy. 
Deletions of the 15q11.2 locus have been previously associated with idiopathic 
generalized epilepsies (de Kovel et al., 2010), schizophrenia (Stefansson et al., 
2008) and behavioural disturbances (Doornbos et al., 2009, Murthy et al., 
2007). And point mutations in NIPA1, one of the genes in the critical region, are 
known to cause autosomal dominant spastic paraplegia (Rainier et al., 2003).  
Considering the limitations of the currently available CNV detection technologies 
(Tsuang et al., 2010, Alkan et al., 2011), I adopted a conservative approach in 
the global CNV analyses. All of the case and control subjects were typed on the 
same platform at the same genotyping centre and highly stringent CNV calling 
criteria were used in order to ensure comparability in detection between 
samples originating from multiple clinical centres. Furthermore, extensive 
manual inspection and validation experiments were undertaken in order to 
identify the regions that cannot be accessed reliably with the present detection 
platform and such regions were excluded from the analyses.  This approach 
thus effectively minimized false positive discoveries, albeit at the expense of a 
higher false negative rate. 
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This study presents no evidence of the involvement of common CNVs in the risk 
of sporadic CHD. However, it should be noted that many of the common CNV 
loci, particularly regions of segmental duplications (Bailey and Eichler, 2006), 
are not yet accessible with all the currently available detection technologies. 
Segmental duplications have vital roles in gene evolution and they shape the 
landscapes of human genetic variation that influence disease susceptibility; they 
mediate the majority of the known rearrangements that result in pathogenic 
chromosomal imbalances. For these reasons, it is currently premature to 
dismiss their potential contribution to the risk of CHD. 
In conclusion, this chapter summarizes the contribution of global CNVs to the 
risk of sporadic CHD. It establishes the association between rare deletions and 
CHD that is responsible for ~4% of the population attributable risk, and between 
higher gene content and disease risk. This study also highlights the presence of 
an upward bias in the haploinsufficiency scores of the genes spanned by rare 
deletions in CHD. Additionally, novel associations of 15q11.2 BP1-BP2 
deletions and the Wnt signalling pathway with CHD risk were identified. The 
dataset generated in this chapter may therefore serve as a rich source for 
discovering novel genes for CHD, which may be the subject of future research.   
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Chapter 5: Phenotype specific effect of 1q21.1 
rearrangements 
5 Phenotype-Specific Effect of Chromosome 1q21.1 
Rearrangements and GJA5 Duplications 
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5.1 Abstract 
Recurrent rearrangements that occur via non-allelic homologous recombination 
(NAHR) between 145.0 - 146.4 Mb of chromosome 1q21.1 have been 
associated with variable phenotypes exhibiting incomplete penetrance, including 
CHD. However, the gene or genes within the ~1Mb critical region responsible 
for each of the associated phenotypes remains unknown. In this chapter, the 
1q21.1 locus was examined in 949 patients with TOF, 1488 patients with other 
forms of CHD and 6760 ancestry-matched controls using SNP genotyping 
arrays (Illumina 660W and Affymetrix 6.0) and multiplex ligation-dependent 
probe amplification (MLPA).  Duplication of 1q21.1 was found to be more 
common in cases of TOF than in controls (OR 34.7 [95% CI 10.2-119.0]; P = 
2.3x10-8), but deletion was not.  By contrast, deletion of 1q21.1 was more 
common in cases of non-TOF CHD than in controls (OR 5.5 [95% CI 1.4-22.0]; 
P = 0.04), while duplication was not.  Additionally, smaller duplication variants 
(100-200kb) of lower frequency were identified within the critical region of 
1q21.1 in cases of TOF that spanned a single gene in common, GJA5. These 
smaller duplications were enriched in cases of TOF in comparison to controls 
(OR=10.7 [95% CI 1.8-64.3], P = 0.01]. These findings demonstrate that 
duplication and deletion at chromosome 1q21.1 exhibit a degree of phenotypic 
specificity in CHD, and implicate GJA5 as the gene responsible for the CHD 
phenotypes observed with copy number imbalances at this locus. 
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5.2 Background 
Rearrangement hotspots in the human genome that occur via nonallelic 
homologous recombination (NAHR) are associated with recurrent copy number 
imbalances (Mefford and Eichler, 2009, Itsara et al., 2009); many of which are 
known to be pathogenic – see Table 5.1. One such locus is situated at 
chromosome 1q21.1. There are two adjacent pathogenic regions in the 1q21.1 
locus: a ~500kb region (144.1 – 144.6Mb) that is associated with 
thrombocytopenia with absent radii (TAR) deletion syndrome, and the ~1Mb 
distal region (145.0 – 146.4 Mb) that is subjected for the more common 
rearrangements known to be associated with variable phenotypes exhibiting 
incomplete penetrance (Mefford et al., 2008, Brunetti-Pierri et al., 2008, 
Christiansen et al., 2004, Szatmari et al., 2007). Both deletions and duplications 
of distal 1q21.1 have been observed in syndromic (Christiansen et al., 2004, 
Mefford et al., 2008, Brunetti-Pierri et al., 2008) and non-syndromic CHD 
patients (Christiansen et al., 2004, Greenway et al., 2009).  
A recent study identified distal 1q21.1 copy number imbalances in 5 out of 512 
sporadic, isolated TOF cases (Greenway et al., 2009). Although these results 
were highly statistically significant when compared to controls (P = 0.0002), 
these findings still await replication in another independent TOF cohort.  
Moreover, the gene or genes responsible for TOF risk at this locus remain 
unknown among the RefSeq genes that are situated within the critical region. 
Among these genes (Table 5.2), gap junction protein α-5 (GJA5 [MIM 121013], 
Connexin40) has previously been proposed as the candidate gene for several 
cardiac disease phenotypes, including CHD (Gu et al., 2003, de Wit et al., 2000, 
Nao et al., 2003, Lamarche et al., 2001). Both Gja5 heterozygous (18%) and 
homozygous-null (33%) mice exhibit complex heart defects, including 
conotruncal and endocardial cushion defects (Gu et al., 2003). However, no 
GJA5 point mutation or GJA5-specific copy number variant has been found in 
CHD patients to date (Greenway et al., 2009, Mefford et al., 2008).  
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5.3 Aims 
This chapter aims to examine the 1q21.1 locus in a case-control study involving 
2437 isolated CHD patients and 6760 controls, in order to estimate more 
precisely the contribution of 1q21.1 rearrangements to CHD risk, and to identify 
the causative gene for CHD at this locus.  
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Table 5.1 – Rearrangement hotspots and their associated phenotypes 
 
Mefford and Eichler, 2009 
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Table 5.2 – RefSeq genes within the known critical region of distal 1q21.1 
RefSeq ID str chr txn start txn end Common name 
NR_024442 - chr1 144957518 144981223 LOC728989 
NM_005399 - chr1 145093308 145110753 PRKAB2 
NR_002305 + chr1 145116053 145118152 PDIA3P 
NM_001144829 - chr1 145122507 145163854 FMO5 
NM_001461 - chr1 145124461 145163854 FMO5 
NM_001144830 - chr1 145124461 145163854 FMO5 
NM_004284 + chr1 145180914 145234067 CHD1L 
NR_038423 - chr1 145320537 145456323 LOC100289211 
NM_004326 + chr1 145479805 145564639 BCL9 
NM_016361 - chr1 145585791 145609258 ACP6 
NM_181703 - chr1 145694955 145699338 GJA5 
NM_005266 - chr1 145694955 145712108 GJA5 
NM_005267 + chr1 145841569 145848019 GJA8 
Str = strand, chr = chromosome, txn = transcription 
5.4 Results 
5.4.1 CNV analyses on SNP array data  
QuantiSNP calls (Bayes factor >50) that were generated from the Illumina 660W 
data on the 1q21.1 locus were examined in a total of 949 TOF cases, 1488 non-
TOF CHD cases and 841 controls. PennCNV calls on the same Illumina dataset 
were examined for confirmation. Birdseye calls on a subset of TOF patients 
(n=198) that were typed on both Illumina 660W and Affymetrix 6.0 platforms 
were also used for comparison and confirmation. The number of markers that 
are available within the ~1Mb critical region of the distal 1q21.1 locus on the 
Illumina 660W and Affymetrix 6.0 platforms are 235 and 640, respectively. CNV 
calls were examined in relation to the segmental duplication blocks that exist in 
the region as well as the corresponding pattern of platform coverage. Calls that 
appeared to be artificially split (due to the limitation of the platform and the 
algorithms) were joined. Raw calls prior to joining can be found in Figure 5.1 
and 5.2. 
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5.4.2 CNV analyses using MLPA 
MLPA probes were designed to detect copy number imbalance within the critical 
region of distal 1q21.1. Twenty probes (ranging from 100-140bp final product 
size) that targeted GJA5 (10), CHD1L (2), ACP6 (2), GJA8 (2), PRKAB2 (2), 
TXNIP (1), and ANKRD34A (1) were synthesized. Nine 1q21 probes were used 
for each MLPA assay in addition to two control synthetic probes targeting copy 
number neutral regions. All probe sequences can be found in the Appendix. 
MLPA analyses on the 1q21.1 locus were performed in 574 TOF probands (433 
of which were also typed on the Affymetrix 6.0 and/or Illumina 660W arrays) and 
473 non-TOF CHD probands (433 of which were also typed on the Illumina 
660W arrays). An example of MLPA result is shown in Figure 5.3. And the 
overlaps between detection methods are summarized in Figure 5.4.  
5.4.3 Concordance between methods of CNV detection 
When the results from the various methods of detection were compared, 100% 
concordance was observed in CNVs detected in the 1q21.1 locus between the 
four methods of detection utilized in this study (Table 5.3). All CNVs that were 
detected from the Illumina 660W arrays in individuals that had not also been 
analyzed with another independent method (n=9) were successfully confirmed 
with MLPA.  
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FIGURE S1
GJA5
Figure 5.1 – LRR and BAF plots of 1q21.1 duplications  
(legend on the next page) 
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trick 
Figure 5.1 – LRR and BAF plots of 1q21.1 duplications 
Areas that are hatched in blue are PennCNV calls. Black dots represent SNP probes 
and red dots represent copy number probes. Limitations of the calling algorithms and 
the platform design cause splits in the CNV callings, particularly at the sites of the 
gaps in the platform coverage (shown in the Illumina 660W track). Most of the gaps 
coincide with the segmental duplication regions. All duplications were confirmed with 
MLPA (location of the probes are shown). However, a larger artificial split that 
extended beyond the coverage gap was observed in ERL-11640.1. It is likely that this 
was caused by a stretch of homozygous SNPs (as shown in the BAF plot of the 
proband). The candidate gene GJA5 is located within this split and thus was not 
called as a duplicated region by any of the algorithms (as shown). However, MLPA 
data confirmed a 2.2Mb duplication that included GJA5 in this proband, as shown in 
Figure 5.4.  
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Figure 5.2 - LRR and BAF plots of 1q21.1 deletions 
Areas hatched in red are PennCNV heterozygous deletion calls. Black dots represent 
SNP probes and red dots represent copy number probes. All deletions were 
confirmed with MLPA. The location of the markers in the Illumina 660W arrays and 
MLPA assays are shown. Segmental duplication blocks and RefSeq genes are also 
shown. 
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Figure 5.3 – MLPA analysis on ERL-11640.  
(A) MLPA assay consisted of custom-designed synthetic probes 
targeting genes in the critical region of distal 1q21.1 (GJA5, CHD1L, 
PRKAB2, GJA8 , ACP6) and control probes from the MRC Holland P200 
kit was used to examine dosage change in ERL-11640.1 (blue peaks) as 
compared to a normal control (red peaks). Analysis was performed using 
GeneMarker software (SoftGenetics, PA, USA). The corresponding 
dosage histogram is shown in (B). Plot of test/control ratio of peak areas 
is shown in (C). The first eleven dots correspond to custom-designed 
(100-140bp) synthetic probes (the two green dots represent synthetic 
probes targeting copy number neutral regions and the red dots represent 
probes in 1q21.1 locus that show dosage increase observed in the five 
genes within the critical region of 1q21.1 that were tested, including 
GJA5). The last 14 dots represent dosage ratio from M13 clone-derived 
control probes from the MRC Holland P200 kit (the 2 red dots 
correspond to probes targeting chromosome X and Y. Since the control 
DNA used in this experiment is a male and the proband is a female, 2/1 
dosage ratio in chromosome X and 0/1 ratio in Y confirms it.) 
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Figure 5.4 – Overlaps between various detection methods in 949 
TOF cases and 1488 non-TOF CHD cases 
Table 5.3 - Frequency of rearrangements at distal 1q21.1 in control population  
Control cohort  
cohort size 
(n) 
CNV detection 
platform 
n probes 
in critical 
region 
dup 
(n) 
del 
(n) 
      
French population cohort 841 Illumina 660W 215 0 1 
WTCCC2 control cohort  5919 Affymetrix 6.0 632 2 3 
HGDP and NINDS controls
1
 
(Itsara et al., 2009)
 
 
1854 
Illumina 550 
Illumina 650Y 
211                                                                                                                                     
247 
0 0 
HapMap individuals
2
 from 
(McCarroll et al., 2008b)
 
 
270 Affymetrix 6.0 632 0 0 
CHOP controls (Shaikh et al., 
2009) (http://cnv.chop.edu/) 
2026 Illumina 550 211 1 0 
Total  10910 
  
3 4 
1 
This control population was also evaluated in 4737 controls used in another published study 
(Mefford et al., 2008). A subset of this population also has been previously reported 
(Jakobsson et al., 2008). 
2 
Multiple CNV surveys have been conducted using the same 
population (Redon et al., 2006, Locke et al., 2006, Altshuler et al., 2010).   
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5.4.4 Frequency of 1q21.1 rearrangements in control populations 
The frequency of NAHR-mediated 1q21.1 rearrangements (spanning the known 
critical region of distal 1q21.1) was examined in 841 individuals from a French 
population cohort, 5919 WTCCC2 control individuals (obtained from personal 
communication with Dr. Matthew Hurles, Wellcome Trust Sanger Institute, 
Cambridge, UK) and 4150 control individuals from previously published works 
(Shaikh et al., 2009, Itsara et al., 2009, McCarroll et al., 2008b) that used high-
density SNP platforms comparable to those used in this study (with coverage of 
>200 probes in the critical region). Three duplications and four deletions in 
10910 controls were observed (see Table 5.3).  
5.4.5 Duplications of 1q21.1 are strongly associated with TOF  
Duplications of the distal 1q21.1 locus that span the previously reported critical 
region (Mefford et al., 2008, Brunetti-Pierri et al., 2008) were identified in nine 
unrelated TOF probands (see Table 5.4 and Figure 5.5). The duplications were 
found to be de novo in one proband, inherited from an unaffected mother in 
three probands and of unknown inheritance (due to unavailability of parental 
samples) in the remaining five probands. There were no occurrences of 1q21.1 
deletion in the TOF cohort. Thus, 1q21.1 duplications are strongly associated 
with TOF (9/949 vs. 3/10910; P = 2.3x10-8; OR = 34.8, 95% CI = 10.2-119.0), 
with population attributable risk (PAR) = 0.92%. In contrast, there was no 
evidence that deletions of 1q21.1 are associated with TOF (0/949 vs. 4/10910). 
See Table 5.5. 
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5.4.6 GJA5 duplication is associated with TOF 
In addition to NAHR-mediated events, 100-200kb rare duplications within the 
critical region of distal 1q21.1 were identified in three patients with TOF, while 
no deletion was identified.  All of these duplications encompass GJA5, a strong 
candidate gene for CHD (Gu et al., 2003, de Wit et al., 2000, Nao et al., 2003, 
Lamarche et al., 2001). See Figure 5.6. Probands LEU-30 and LEU-98 were 
found to be distantly related, with estimated genome-wide IBD sharing 
probabilities for sharing (0, 1, 2) alleles IBD to be (0.8581, 0.1369, 0.0050). 
However, their estimated IBD sharing probabilities within the ~3Mb region 
surrounding GJA5 are considerably higher (0, 0.64, 0.36), and both of them 
carry duplications with identical breakpoints. Thus, these two observations are 
likely to represent one ancestral duplication event, and the appropriate 
correction for the distant relatedness of these two individuals was later made in 
the statistical analysis (by maximum likelihood estimation method). Examination 
of 6760 controls resulted in two such duplication variants. Therefore, these 
GJA5 duplications were enriched in the TOF cohort in comparison to controls 
(3/959 vs. 2/6760; P = 0.01; OR = 10.7, 95% CI = 1.8-64.3). In the non-TOF 
CHD cohort, a GJA5 triplication was identified in one patient with pulmonary 
atresia, like TOF a cardiac outflow tract phenotype (Figure 5.6 and Table 5.4). 
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Table 5.4 - Summary of 1q21.1 CNVs in CHD patients  
chr start 
length 
CN Patient ID 
parental 
DNA 
availability 
Inheri-
tance 
Pheno-
type 
Illumina660 Affy 
6.0 
MLPA 
(kb) QS PC 
1 144106312 2187 3 ERL-11640.1 - n/a TOF Y Y n/a Y 
1 144106312 1742 3 CHA-937.1 - n/a TOF Y Y n/a Y 
1 144943150 1350 3 GOCHD-982.1 - n/a TOF Y Y n/a Y 
1 144943150 1350 3 NOTT-107.1 P+M inh-m TOF Y Y n/a Y 
1 144943150 1350 3 CHA-102.1 - n/a TOF Y Y n/a Y 
1 144967972 1325 3 CHA-137.1 P+M dn TOF Y Y Y Y 
1 144967972 1325 3 CHA-363.1 P+M inh-m TOF Y Y n/a Y 
1 144967972* 1321 3 CHA-574.1 M inh-m TOF n/a n/a n/a Y 
1 144967972 880 3 CHA-867.1 M n/a TOF/PA Y Y n/a Y 
1 145594226 254 3 LEU-30.1 P+M inh-m TOF Y Y n/a Y 
1 145594226 254 3 LEU-98.1 - n/a TOF Y Y n/a Y 
1 145658466 118 3 CHA-620.1 P+M inh-m TOF Y Y Y Y 
1 145658465 118 4 NOTT-319.1 - n/a PA Y Y n/a Y 
1 144967972 1419 1 SYD-1499.1 - n/a TGA Y Y n/a Y 
1 144967972 1325 1 FCH-397.1 - n/a ASD Y Y n/a Y 
1 144967972 1325 1 NOTT-674.1 - n/a MV/VSD Y Y n/a Y 
Chr = chromosome, CN = copy number, QS = QuantiSNP, PC = PennCNV, Affy = Affymetrix, Y = yes, 
n/a = not available, dn = de novo, inh-m = inherited from the mother, P = paternal, M = maternal, PA = 
pulmonary atresia, ASD = atrial septal defect, MV/VSD = mitral valve dysplasia with ventricular septal 
defect, TGA = transposition of the great arteries. *The proband was typed on the Illumina 660W array 
but failed SNP QC (low call rate) and thus excluded from the array analyses. However, the mother of the 
proband was also typed on the Illumina 660W array and passed QC. DNAs from both the proband and 
mother were analyzed with MLPA, which showed full 1q21.1 duplications with the same breakpoints. 
This also confirmed the array data from the mother, which passed QC. Thus, the coordinates listed here 
were inferred from the mother who transmitted the duplication to the respective proband.  
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Figure 5.5 – The 1q21.1 region and the summary of findings in TOF and non-
TOF mixed CHD cohort 
Figure 5.5 - The 1q21.1 region and the summary of findings in TOF and non-
TOF mixed CHD cohort    
(A) The region of 1q21.1 is complex (143.5 to 147.5Mb is shown) due to the presence of 
extensive segmental duplication blocks and the existing gaps in the reference human genome 
sequence (NCBI build 36.1). The largest pair of segmental duplications with >99% homology 
that mediate most of the rearrangements in this locus is indicated by large orange arrows, 
flanking the critical region of rearrangements involving distal 1q21.1. The critical region of the 
distal 1q21.1 and the upstream TAR (Thrombocytopenia-absent radius) deletion region are 
indicated by translucent gray blocks. (B)  RefSeq genes in the region are shown. (C) The 
coverage of the Illumina 660W and the location of custom-designed MLPA probes are shown.  
(D) Overview of 1q21.1 duplications (blue bars) and deletions (red bars) identified in CHD 
patients. All of the 1q21.1 rearrangements identified in this study encompass the previously 
reported critical region of distal 1q21.1. None of the deletions identified in CHD patients 
encompass the critical region for TAR syndrome. The inheritance status and cardiac phenotype 
is shown after the patient identifier. TGA = transposition of the great arteries, MV = mitral valve 
dysplasia with ventricular septal defect, ASD = atrial septal defect, NA = not available, inh = inherited. 
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Figure 5.6 - Small duplications encompassing GJA5 within the critical region 
of distal 1q21.1  
Five copy number variants were identified within the critical region of 1q21.1 in 949 TOF and 
1488 non-TOF CHD cases. Rare duplications of 100-200kb in size (shown as blue bars) 
were found in 3/949 TOF cases encompassing a single gene in common: GJA5. In 1488 
non-TOF CHD cases, a triplication variant (blue bar) encompassing GJA5 was found in one 
patient with pulmonary atresia (PA) and one deletion variant (red bar) encompassing the last 
exon of a non-coding LOC100289211 gene was found in one patient with transposition of the 
great arteries (TGA). The number of markers available on the Illumina 660W and Affymetrix 
6.0 within the minimal region (~100kb) of small duplications that encompass GJA5 are 36 
and 104, respectively. RefSeq genes in the region, the coverage for the Illumina660W 
platform and location of the MLPA probes are indicated in the hg18 UCSC Genome Browser. 
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Table 5.5 – Phenotypic specificity of distal 1q21.1 deletions and duplications 
 
    duplications      deletions 
Patient cohort  n P-value OR (95%CI) n P-value OR (95%CI) 
TOF (n=949)  9 2.3x10-8 34.8 (10.2-119.0) 0 NS - 
Non-TOF 
(n=1488) 
0 NS - 3 0.04 5.5 (1.4-22.0) 
NS = not significant                                                                               
Table 5.6 – Phenotypic summary of patients with 1q21.1 CNVs 
Patient ID sex 
year 
of 
birth 
age of 
recruitment 
CHD type 
extracardiac 
phenotype 
 
ERL-11640.1 F 1985 18 TOF with PFO mental retardation* 
L
a
rg
e
 d
u
p
lic
a
ti
o
n
 
GOCHD-982.1 M 1989 N/A TOF none 
CHA-102.1 F 2004 2 TOF none 
CHA-137.1 F 2005 1 TOF laryngomalacia 
NOTT-107.1 M 2003 <1 TOF none 
CHA-363.1 M 1996 10 TOF none 
CHA-574.1 F 2005 1 TOF none 
CHA-937.1 F 1970 36 TOF none 
CHA-867.1 M 1994 12 TOF/PA 
vesico-ureteric 
reflux, asthma, 
eczema 
LEU-30.1 F 1993 10 TOF none 
S
m
a
ll 
d
u
p
lic
a
ti
o
n
 
LEU-98.1 F 2004 <1 TOF none 
CHA-620.1 F 1997 9 TOF none 
NOTT-319.1 M 2004 <1 pulmonary atresia none 
SYD-1499.1 M 2008 <1 TGA 
submandibular cyst 
and ankyloglossia 
L
a
rg
e
 d
e
le
ti
o
n
 
FCH-397.1 F 1971 35 ASD none 
NOTT-674.1 F 2007 <1 
dysplastic mitral valve 
(parachute) and VSD 
ankyloglossia 
* After the duplication of 1q21.1 was identified, we examined the medical record of the 
respective patient and found that she had been also diagnosed with mental retardation, 
which would normally be excluded from the study.  
  
CNV 
type 
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5.4.7 Deletion of 1q21.1 is associated with non-TOF CHD 
Examination in 1488 cases with other forms of CHD (non-TOF) revealed three 
NAHR-mediated deletions and no duplication that spanned the entire critical 
region of distal 1q21.1 (see Figure 5.5).  Thus, 1q21.1 deletion was associated 
with non-TOF CHD (3/1488 vs. 4/10910; P = 0.04; OR = 5.5, 95% CI = 1.4-22.0 
with PAR = 0.17%, Table 5.5).  By contrast, there was no evidence of 
association between the reciprocal duplication and non-TOF CHD (0/1488 vs. 
3/10910; Table 5.5). The CHD phenotypes of the deleted cases differed, being 
transposition of the great arteries (n=1), atrial septal defect (n=1) and mitral 
valve dysplasia with ventricular septal defect (n=1) – see Table 5.4. 
5.5  Discussion 
In 949 TOF cases, a strong association was observed between duplication at 
distal 1q21.1 and disease risk, while no association between the reciprocal 
deletion and TOF risk was identified.  By contrast, an association between 
deletion, rather than duplication, at distal 1q21.1 and disease risk, was found in 
1488 cases of other CHD phenotypes. These findings indicate associations 
between duplication or deletion at the distal 1q21.1 region and CHD that are to 
a degree specific for particular CHD phenotypes, a novel observation.  
Furthermore, overlapping rare duplication variants of 100-200kb in size within 
the critical region of distal 1q21.1 were identified. These variants were also 
found to be enriched (P = 0.01) in the TOF cohort, and they encompass a single 
gene in common i.e. GJA5 (MIM 121013), thus indentifying GJA5 as a critical 
CHD gene in this locus.  
Chromosome 1q21.1 deletion was first proposed as a cause for CHD by 
Christiansen et al., who found deletions that span the entire critical region of 
distal 1q21.1 in one syndromic and two non-syndromic CHD cases among 505 
patients referred for clinical genetic evaluation of suspected DiGeorge or 
Williams’ syndrome.  All three of the deletion carriers had obstruction of the 
aortic arch as part of their phenotype.  However, the specificity of that 
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phenotypic association was likely to have been heavily influenced by selection 
bias, since aortic arch interruption and supravalvular aortic stenosis are classic 
cardiovascular manifestations of DiGeorge and Williams’ syndromes 
respectively.  More recently, deletion of distal 1q21.1 was shown to be present 
more frequently in patients with variable paediatric phenotypes (patients 
referred to diagnostic centres principally for mental retardation accompanied by 
other features), compared to controls (25/5218 patients; 0/4737 controls; P = 
1.1x10-7) (Mefford et al., 2008). Twelve of the 25 deletion carriers had CHD as a 
feature.  Another study of 16,557 patients referred to a clinical cytogenetics 
laboratory who were examined by array CGH for a range of abnormalities 
revealed 21 probands with distal 1q21.1 deletions and 15 with the reciprocal 
duplications. However, only one of these 36 patients had CHD without other 
strong environmental predisposing factors (Brunetti-Pierri et al., 2008).  
In sporadic, isolated TOF, Greenway et al. previously identified four duplications 
and one deletion of distal 1q21.1 in 512 cases and no occurrence in 2265 
controls (P = 0.007 and P = 0.18 for duplication and deletion, respectively; see 
Figure 5.7 ) (Greenway et al., 2009).  Therefore, the present results confirm that 
duplications of distal 1q21.1 are strongly associated with TOF. And in a cohort 
almost twice as large as that investigated by Greenway and colleagues, this 
study presented the evidence that duplication is much more strongly associated 
with TOF than is deletion, for which no evidence of association was found. No 
previous study has estimated the frequency of 1q21.1 rearrangements in 
patients with mixed CHD phenotypes ascertained on the basis of CHD, rather 
than on the basis of suspected syndromic features. The present results 
demonstrate a modest excess of distal 1q21.1 deletion in such patients, and no 
evidence of association with 1q21.1 duplication.  Interestingly, specificity of 
distal 1q21.1 copy number imbalances have been previously described in other 
associated phenotypes: duplications but not deletions of distal 1q21.1 have 
been found to be associated with macrocephaly and autism spectrum disorders, 
while deletions but not duplications were found to be associated with 
microcephaly and schizophrenia (Brunetti-Pierri et al., 2008, Crespi et al., 
2010). 
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Figure 5.7 – 1q21.1 CNVs spanning GJA5 in 2437 CHD patients 
A summary of duplications (n=13) and deletions (n=3) spanning GJA5 identified 
in this study in comparison to those reported by Greenway and colleagues 
(Greenway et al., 2009).  
NA = inheritance status is not available. TGA = transposition of the great arteries, MV = 
mitral valve anomaly, ASD = atrial septal defect, PA = pulmonary atresia. Blue bars 
represent duplications and red bars represent deletions.  
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It has been speculated that the distal 1q21.1 locus harbours a single causal 
gene critical for both cardiovascular and brain development that accounts for 
both aspects of the rearrangement phenotype, but previous studies had not 
been able to establish this (Greenway et al., 2009, Mefford et al., 2008).  In the 
present study, smaller duplications (100-200kb) within the ~1Mb critical region 
of distal 1q21.1 were identified in the TOF cohort; all of which encompass 
GJA5, the strongest candidate gene for the CHD phenotype in this locus.  
These overlapping small GJA5 duplications are rare (3/949) in comparison to 
the NAHR-mediated duplications (9/949) found in the TOF cases. Nevertheless, 
they were found to be significantly enriched in TOF compared to controls (P = 
0.01). With the exception of one patient with pulmonary atresia (a cardiac 
outflow defect like TOF) who has a GJA5 triplication, no such variant was 
identified in the non-TOF CHD cohort. This suggests that duplication of GJA5 is 
the most likely mechanism responsible for the association of NAHR-mediated 
duplication at 1q21.1 and TOF risk.  Although it is currently not possible to infer 
directly from the present data that GJA5 deletion is responsible for the 
association of NAHR-mediated deletion at 1q21.1 and the risk of other forms of 
isolated CHD, this seems likely.   
GJA5 encodes the cardiac gap junction protein connexin-40, which has key 
functions in cell adhesion and cell-cell communication.  Mice with genetically 
engineered deletion of Gja5 have a variety of complex congenital cardiac 
malformations, in particular of the cardiac outflow tract (Gu et al., 2003). There 
are as yet no data from animal models of Gja5 overexpression, although such 
data would be of evident interest.  However, mice overexpressing Gja1 (Cx43), 
another connexin isotype, have outflow tract defects (Ewart et al., 1997, 
Kirchhoff et al., 2000). Whilst the original report of the Gja5 knockout mouse 
suggested that Gja5 was not expressed in neural crest cells in the mouse, more 
recent work has disputed this finding (Gu et al., 2003, Holler et al., 2010). The 
second heart field plays a critical role in the development of the cardiac outflow 
tract, and mutations in genes expressed in the second heart field result in 
outflow tract defects both in mouse models and in humans.  Gja5 was recently 
shown to be expressed in cells derived from the second heart field during 
outflow tract development, where it is regulated by the key cardiac transcription 
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factor Hand2 (Holler et al., 2010). A number of lines of evidence also implicate 
dysregulation of GJA5 in atrial arrhythmogenesis (Gollob et al., 2006, Wirka et 
al., 2011, Liu et al., 2011b, Sinner et al., 2011). TOF patients are highly prone to 
atrial and ventricular arrhythmias in later life which represent a significant 
source of morbidity and mortality. Therefore, it would be of great interest to 
determine whether there is differential susceptibility to atrial arrhythmia in TOF 
patients with, and without duplication at 1q21.1 involving GJA5. 
The results presented in this chapter do not exclude the possibility that other 
genes in the distal 1q21.1 region may also contribute to CHD risk. Among the 
possible other candidate genes, CHD1L (MIM 613039) has been shown to be 
overexpressed in patients with TOF, double-outlet right ventricle (DORV), and 
infundibular pulmonary stenosis (IPS) compared with controls (Morano et al., 
1996). PRKAB2 (MIM 602741), which encodes the β2 subunit of AMP-activated 
protein kinase, was reported to be highly expressed in the right ventricular 
outflow tract. And mutations in PRKAG2, a γ2 subunit of the same protein, have 
been found to cause some familial forms of hypertrophic cardiomyopathy 
(Oliveira et al., 2003). However, among the 2437 CHD cases presented in this 
study, no CNV identified within the critical region implicated any gene other than 
GJA5, suggesting that any contribution of such CNVs to CHD risk, while not 
excluded  by these findings, is of small magnitude.  Finally, even though the 
association of small GJA5 duplications (P = 0.01) identified in this study is highly 
biologically plausible, replication of this result in a similarly large and ethnically 
homogeneous population of TOF patients will be of importance in due course. 
As in previous studies, marked variable penetrance was observed in 1q21.1 
CNVs.  The reasons for this observation remain uncertain.  A double-hit model 
has been previously proposed to explain this variable expressivity (Girirajan et 
al., 2010). However, the power to robustly identify such "second hits" in the 
small numbers of cases (n=16) carrying 1q21.1 CNVs in this study is low. 
Additionally, in all five TOF cases where the duplication was transmitted from an 
unaffected parent, transmission was maternal (P = 0.06).  Although this finding 
is not significant, it is possible to speculate that parent of origin effects could 
conceivably in part explain the marked variability in penetrance of cardiac 
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defects with rearrangements in 1q21 that has been observed in several 
previous studies. A larger study comparing the phenotype when the duplication 
is paternally or maternally transmitted would be required to address this. 
In summary, this study has defined the relationships between duplication of 
distal 1q21.1 and TOF, and between the reciprocal deletion and other forms of 
CHD.  Duplication confers an odds ratio for TOF of 31, and accounts for about 
1% of the population attributable risk of TOF, whereas deletion confers an odds 
ratio and PAR for non-TOF CHD of 6 and 0.2%, respectively. Additionally, 
duplication of GJA5 alone is associated with an approximately tenfold increase 
in the risk of TOF, identifying GJA5 as a critical gene for human heart 
malformation.  
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 Chapter 6: Rare de novo CNVs in TOF trios 
6 Prevalence and paternal origin of rare de novo copy 
number variants in tetralogy of Fallot trio families 
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6.1 Abstract 
De novo copy number variants have been recognized as major causative 
factors of many genomic disorders. Their contribution in complex phenotypes 
has only been appreciated recently, particularly in schizophrenia and autism 
spectrum disorders. A previous study by Greenway et al. investigated the 
occurrence of rare de novo CNVs in a cohort of 114 sporadic, isolated TOF 
patients and their respective unaffected parents. De novo CNVs that occur with 
<0.1% frequency in controls were identified in 11/114 (~10%) of the TOF trios. 
However, this finding has yet to be replicated in another independent cohort. 
Previous studies in several developmental phenotypes have also identified 
paternal origin bias in rare de novo CNV occurrences that were not mediated by 
segmental duplications (SD) (Hehir-Kwa et al., 2011, Sibbons et al., 2012). 
This chapter presents the results of a genomewide CNV analysis of 283 
sporadic, isolated TOF trio families, which was followed by an extended 
analysis in 1987 CHD patients. All probands and unaffected parents were typed 
on the Illumina 660W SNP platform. All putative de novo CNVs >30kb that 
occurred with <0.1% frequency in 1538 controls were confirmed with Affymetrix 
6.0 SNP array, CGH array or MLPA. Parental origin of de novo CNVs were 
determined and CNV breakpoints were examined for evidence of generating 
mechanisms that are mediated by SD. 
Rare de novo CNVs were observed in 13/283 (~5%) of the TOF trios. Some of 
the rare de novo CNVs spanned genes known to be involved in heart 
development (e.g. HAND2 and GJA5). Further analysis in 1987 CHD patients 
identified recurrent rare CNVs overlapping some of the de novo CNV loci 
observed in this study as well as in the previous study by Greenway et al. The 
majority of rare de novo CNVs occurred on the paternally transmitted 
chromosome where this could be unequivocally determined (10/11; P = 0.01). 
Most of the CNV breakpoints (11/13) indicated non SD-mediated generating 
mechanisms, thus suggesting the predominance of mitotic, rather than meiotic 
CNV generating events contributing to TOF pathogenesis.  
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6.2 Background 
The causative nature of large rare de novo CNVs in many genetic and 
developmental disorders is well-established (Turner et al., 2008, Carvalho et al., 
2010, Lupski et al., 2011). Many of these disorders include CHD as one of the 
main phenotypes (Goodship et al., 1998, Wessel et al., 1994, Marino et al., 
1999). However, the causative nature of de novo CNVs of submicroscopic size 
is not always clear, particularly because such de novo occurrences also have 
been observed in healthy individuals, although they are rare (Itsara et al., 2010, 
Vermeesch et al., 2011). A recent study reported a genomewide rare de novo 
CNV burden of ~10% in 114 sporadic, isolated TOF trios (TOF probands and 
their respective unaffected parents), involving 10 different loci (Greenway et al., 
2009). The frequency of the rare de novo CNVs in that study was found to be 
greater than in controls, but the difference was not found to be statistically 
significant (11/114 vs. 7/98, P = 0.18). It is possible that this is due to the 
relatively small size cohort and therefore being underpowered, especially 
considering that de novo CNVs have been shown to play a large role in the 
pathogenesis of complex psychiatric phenotypes (Sebat et al., 2007, Xu et al., 
2008, Stefansson et al., 2008). The de novo CNV findings of Greenway and 
colleagues included previously described anomalies at 22q11.2 (TBX1 [MIM 
602054]), 3p25.1 (RAF1 [MIM 164760]) and 20p12.2 (JAG1 [MIM 601920]) that 
correspond to DiGeorge (MIM 188400), Noonan (MIM 611553) and Alagille 
(MIM 118450) syndromes, respectively. De novo CNVs in several candidate loci 
for CHD at 1q21.1 (GJA5 [MIM 121013]) and 9q34.3 (NOTCH1 [MIM 190198]) 
were also observed. However, the majority of the loci identified have not been 
previously associated with CHD (7p21.3, 2p23.3, 2p15, 4q22.1 and 10q11.21). 
Additionally, those authors performed targeted MLPA analyses on 9 of the loci 
(all with the exception of 22q11.2) in another cohort of 398 TOF patients and 
identified recurrent CNVs at 3 of the loci (1q21.1, 7p21.3 and 3p25.1), some of 
which were found to be inherited from an unaffected parent, but occur very 
rarely (<0.1%) in 2265 controls.  
Several genetic predispositions and environmental risk factors for the 
occurrence of de novo CNVs in relation to disease pathogenesis have been 
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identified. Individuals that inherit certain genomic architectures (e.g. H2 
haplotype in 17q21.31 and S2 haplotype in 16p12.1) are predisposed to 
pathogenic de novo CNV events via non-allelic homologous recombination 
(NAHR) mediated by the pairs of segmental duplications with high sequence 
identity and in direct orientation that make up the H2 and S2 haplotypes. In 
contrast, individuals with H1 and S1 haplotypes have the segmental 
duplications in the opposite orientation and thus are protected from the 
recurrent de novo CNV events (Zody et al., 2008, Koolen et al., 2006, Shaw-
Smith et al., 2006, Stefansson et al., 2005, Antonacci et al., 2010, Girirajan and 
Eichler, 2010) - see Figure 1.5. Genetic variation that implicates DNA damage 
checkpoint pathways also has been proposed to influence the frequency of de 
novo CNV events during mitosis. The DNA damage checkpoint pathways 
constitute a vital response to replication stress during mitosis, and when 
perturbed may increase the occurrence of de novo CNVs via replication-based 
DNA repair mechanisms, e.g. fork-stalling and template switching (FoSTeS) 
mechanism (Arlt et al., 2012, Lieber et al., 2003, Lee et al., 2007). Aphidicolin 
(DNA polymerase inhibitor) and hydroxyurea (ribonucleotide reductase inhibitor) 
are both agents that cause replication stress, and they have been shown to be 
potent inducers of non-recurrent (i.e. non SD-mediated) de novo CNVs in 
cultured human cells (Arlt et al., 2011, Arlt et al., 2009). A subsequent analysis 
of the de novo CNV breakpoints resulting from Aphidicolin treatment also 
confirmed that most did not coincide with SDs. As such CNVs that can be 
induced by replication stress are characteristics of mitotic events, an increased 
frequency of de novo non-recurrent CNVs in the male germline compared to the 
female germline is expected, given that in males, primordial male germ cells 
undergo mitotic divisions leading to mature germ cells throughout reproductive 
life, while primordial female germ cells undergo mitotic division during foetal 
development (Crow, 2000).  
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6.3 Aims 
The aims of this chapter are:  
1) To identify and determine the prevalence of rare de novo CNVs in 283 
TOF family trios.  
2) To identify recurrent CNVs in 1987 CHD patients that overlap rare de 
novo CNV findings identified in (1) above.  
3) To determine the parental origin of the rare de novo CNVs and to 
understand the underlying mechanism of such CNVs. 
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6.4 Results 
6.4.1 Rare de novo CNV burden in TOF trios 
There were 13,375 putative de novo CNV calls that were detected using the 
PennCNV joint calling (Wang et al., 2007) in a cohort of 283 TOF probands with 
the respective unaffected parents. Subsequently, I developed a pipeline in order 
to identify rare CNVs that were truly de novo and to exclude likely artefacts (see 
Figure 6.1). CNV calls occurring in previously observed common CNV regions 
(Craddock et al., 2010, Bailey et al., 2002) and those found with >0.1% 
frequency in the 1538 controls were excluded. To reduce the occurrence of 
artefacts in the dataset while still maximizing capture, PennCNV calls >30kb 
that were confirmed with QuantiSNP (regardless of the degree of overlap 
between the two calling algorithms and without applying a threshold in 
confidence parameter, i.e. Bayes factor (Colella et al., 2007)) were subjected to 
confirmation with an independent method (Affymetrix 6.0, array CGH or MLPA). 
The flanking regions of all putative de novo calls were also examined manually 
in the respective trio individuals to detect inherited events that the algorithm 
failed to recognize (see Figure 2.1). Finally, CNV calls that appeared to be 
artificially split were joined.  
From the 28 putative de novo CNVs that passed the rigorous pipeline, ~50% 
(13/28) were successfully validated. Thus, de novo CNVs >30kb were observed 
in ~5% (13/283) of the TOF trios. Rare de novo CNVs were identified in some 
loci that have been associated with isolated or syndromic TOF or other CHD 
(1q21.1, 3q29, 4q34) as well as in regions that have not been previously 
described to be relevant to the risk of TOF (3q13.11, 5q14, 5q35.3, 6q27, 
9p22.2, 16q11.2, 16q24.2, 19p13.3 and 22q12.3) – see Table 6.1.  
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Figure 6.1 - Rare de novo CNV identification pipeline 
1
 Downloaded from UCSC Genome Browser (Karolchik et al., 2004, Bailey et al., 2002)  
2
 Obtained from WTCCC2 CNV GWAS (Craddock et al., 2010) 
  
13,375 putative de novo CNV calls
- indels (<1kb)
- calls overlapping centromeric gaps
- probands with excess de novo CNV calls
- calls with > 80% overlap with segmental duplications 1
- calls > 20% overlap with known CNP 2
- occur in >0.1% frequency in 1538 controls (697 unaffected 
family members + 841 unrelated controls)
149 putative de novo CNV calls
- calls not confirmed by QuantiSNP algorithm
71 putative de novo CNV calls
- calls < 30kb
28 putative de novo CNVs
-14 not confirmed with Affymetrix 6.0 and/or aCGH and/or MLPA
- 1 was found be inherited  (not de novo) by MLPA and CGH
13 validated de novo CNVs
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Table 6.1 – Rare de novo CNVs identified in 283 TOF  
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6.4.2 Recurrent CNVs in genomic loci implicated by de novo CNVs 
The remaining 1987 CHD probands in which no complete parental data was 
available were screened for overlapping CNVs in the de novo CNV loci 
identified in section 6.4.1. Rare CNVs were identified at 1q21.1 as described in 
chapter 5, 4q34 (HAND2 [MIM 602407]), 5q14.2 (EDIL3 [MIM 606018]), and 
5q35.3 (CNOT6 [MIM 608951]) – see Figure 6.2. In addition, rare CNVs that 
overlap previously reported rare de novo findings in 114 TOF trios (Greenway et 
al., 2009) were identified at 1q21.1, 4q22.1 (PPM1K [MIM 611065]) and 7p21.3 
(see Figure 6.3). Some of these recurrent CNVs (in 1q21.1, 4q34 and 7p21.3) 
were found to be inherited from an unaffected parent, while the inheritance 
status of the remaining CNVs could not be determined due to the unavailability 
of parental samples. The overlapping deletions at 4q34 and 7p21.3, as well as 
two of the overlapping deletions at 5q14.2 did not span known coding regions, 
but all were within the vicinity (<200kb) of RefSeq genes previously shown to be 
important for development. All of them also overlapped regions containing 
predicted human heart-specific enhancer sequences (Narlikar et al., 2010).  
Note that the 9q34.3 locus (reported by Greenway et al.) has been excluded 
from this study due to the limitation of all the currently available CNV detection 
methods to assess this region reliably (see Figure 6.4). 
6.4.3 Paternal origin bias in rare de novo CNVs in TOF trios 
The parental origins were determined by examining the B allele frequency 
(BAF) of the SNPs in the probands and the respective parents within the rare de 
novo CNV spans identified in section 6.4.1 (see Methods). In ten out of eleven 
patients that had adequate informative SNPs, the CNVs were found on the 
paternal allele (see Table 6.1 and Table 6.2). Therefore, paternal origin bias 
was observed in rare de novo CNVs identified in the TOF trios (P = 0.01).  
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Table 6.2 - De novo CNVs and the mismatches from expected inheritance 
patterns from paternal or maternal chromosomes 
Chr 
Start    
coordinate 
Length Family ID 
Copy 
number 
Mismatches for 
paternal origin 
Mismatches for 
maternal origin 
4 173538773 6551325 CHA-91 del 0 242 
3 197168088 1660486 FCH-306 del 0 47 
16 85737889 177523 CHA-617 del 0 13 
6 167037829 67836 NOTT-189b del 0 9 
19 252619 52630 CHA-767 del 0 2 
16 45056281 40613 CHA-25 del 0 0 
22 31789131 188778 CHA-64a del 5 0 
3 105183599 97653 CHA-812 del 0 6 
1 144967972 1418624 CHA-137 dup 0* 28* 
5 80936354 3045007 CHA-9 dup 0 105 
5 179681237 432453 CHA-750 dup 0 21 
5 178357798 264665 CHA-817 dup 0 27 
9 17735053 50117 NOTT-389 dup 1 5 
* This proband inherited both copies of the paternal chromosome and one copy from the maternal 
chromosome   
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Figure 6.2 - Rare CNVs overlapping rare de novo CNVs identified in TOF trios 
(legend on the next page) 
B
C
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Figure 6.2 - Rare CNVs overlapping rare de novo CNVs identified in TOF 
trios  
The remaining 1978 CHD patients were examined for recurrent CNVs that 
overlap rare de novo findings in 283 TOF trios. Overlapping CNVs were identified 
in 4q34, upstream of HAND2 (as shown in A), 5q14.2 (one rare deletion 
overlapping EDIL3 and two others overlapping a conserved region ~100kb 
upstream of EDIL3, as shown in B),  and 5q35 (a deletion overlapping CNOT6 as 
shown in C). Deletions and duplications are shown in the UCSC Genome 
Browser as red and blue bars, respectively.  
PS = pulmonary stenosis, VSD = ventricular septal defect. 
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Figure 6.3 - Rare CNVs overlapping previously reported loci 
Rare CNVs were examined in the 1987 non-trio CHD cases that overlap 
previously reported rare de novo CNVs by Greenway et al. Recurrent rare 
deletions were identified in the 7p21.3 locus (A) in two TOF probands, both of 
whom inherited the deletions from the respective unaffected fathers. Both of 
these findings had been confirmed on the Affymetrix 6.0 platform and by MLPA. 
And no overlapping CNVs were found in 841 unrelated controls and other 
unaffected family members (n=695). These rare CNVs did not overlap any known 
RefSeq genes, though there are some overlaps with transcription factor binding 
site conservation (shown). The nearest gene is NXPH1. (B) There is an 
insufficient coverage on the Illumina 660W platform (shown) overlapping the 
4q22.1 de novo variant reported by Greenway et al. Therefore, in addition to 
examining this locus in the 1987 CHD probands that had been typed on the 
Illumina 660W, this locus was screened with MLPA in 1007 CHD patients, 866 of 
which were also typed on the Illumina 660W. A duplication in a TOF proband that 
encompassed PPM1K was identified (as shown in B). No overlapping duplication 
was found in 841 unrelated controls and 697 unaffected family members. The 
parental DNAs of this proband were not available for analysis. Deletions and 
duplications are shown in the UCSC Genome Browser as red and blue bars, 
respectively. 
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Figure 6.4 – 9q34.3 region cannot be assessed reliably with the currently available CNV 
detection technologies 
(legend on the next page) 
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Figure 6.4 - 9q34.3 region cannot be assessed reliably with the 
currently available CNV detection technologies 
The 9q34.3 region harbours one of the main candidate genes for CHD i.e. 
NOTCH1 (see J). Greenway and colleagues reported a rare de novo deletion 
that implicates NOTCH1, as shown in B (Greenway et al., 2009). However, 
the high GC content throughout the region (shown in G) makes this locus 
very difficult to genotype with any of the currently available CNV detection 
platforms. This is reflected by the survey of the various datasets (Itsara et al., 
2009, Jakobsson et al., 2008, Wang et al., 2007, Perry et al., 2008, Cooper 
et al., 2008, Conrad et al., 2010, Altshuler et al., 2010) that were submitted to 
the Database of Genomic Variants (DGV). Various studies on HGDP (C and 
D) and HapMap (E) individuals that were performed using various SNP and 
CGH arrays are shown (SNP array contents are shown in A). There was not 
a single concordance between all 7 studies. Variants 53532 and 53390 
reported by Itsara et al. (C) were identified on different HGDP individuals 
than variants 30348 and 10315 that were reported by Jakobsson et al. (D) 
(Itsara et al., 2009, Jakobsson et al., 2008). MLPA experiments performed 
on this region in 1007 CHD patients (probes shown in I) also proved to be 
difficult to interpret due to the high GC content (G) and dense CpG islands 
(H) in the region. Therefore, the 9q34.3 region was excluded from all 
analyses presented in this thesis. Of interest, the gap in the reference 
sequence (F) was a result of the presence of repetitive sequences that were 
not yet possible to be assembled (personal communication with Dr. Deanna 
Church, NIH/NCBI, Bethesda, MD, USA). 
(genome.ucsc.edu) 
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6.4.4 The primary generating mechanisms for rare de novo CNVs in 
TOF trios are not mediated by segmental duplications 
CNV formations via DNA repair mechanisms that occur during mitosis have 
been associated with paternal origin bias observed in rare de novo CNV 
occurrences that were not mediated by segmental duplications (SD) in several 
developmental phenotypes (Hehir-Kwa et al., 2011, Sibbons et al., 2012). 
Therefore, all the de novo CNV findings described in section 6.4.1 were 
examined for evidence of SD in the flanking regions (see Figure 6.6 – 6.9). Only 
2/13 of the rare de novo CNVs possess the requirements for SD-mediated CNV 
formation, i.e. the breakpoints coincide with a pair of SD in direct orientation 
(see Figure 6.6). Four of the rare de novo deletions had one of the breakpoints 
coincide with SD (see Figure 6.7), while seven of the rare de novo CNVs were 
not mediated nor associated with SD (Figure 6.8 and 6.9). See summary at 
Figure 6.5. 
 
Figure 6.5 – Proportion of rare de novo CNVs in TOF 
trios according to the presence of segmental 
duplications (SD) in the CNV breakpoints  
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Figure 6.6 – Rare de novo CNVs that were mediated by segmental duplications 
(Legend can be found on the next page) 
A
B
Chr1:145891442 Chr1:144594476 
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Figure 6.6 - Rare de novo CNVs that were mediated by SD 
The pair of SD blocks with high degree of similarities (>98% identical) that 
flank the regions in 3q29 (A) and 1q21.1 (B) in the same orientation (indicated 
by the black arrows) mediated the CNV formations. Note that one of the SD 
pair in chromosome 1q21.1 (chr1:144594476) doesn’t map to the 3’ breakpoint 
of the de novo duplication (B). This “offset” of the 3’ breakpoint location 
relative to the SD is likely caused by assembly error. The 1q21.1 locus is one 
of the most challenging regions to assemble in the human genome reference 
sequence project. This is mainly due to the presence of extensive highly 
repetitive sequences in the region, which is reflected by the existing gaps 
remaining in the reference sequence of this locus. There is a considerable 
difference between the most current reference sequence (GRCh37/hg19) and 
the earlier build (NCBI Build36/hg18) that is used in this thesis. However, 
repeating the 1q21.1 CNV analyses on the most current build (not shown), did 
not improve the 3’ breakpoint location relative to the SD. It is likely that the 
future reference sequence build of this region will undergo another 
reconstruction (personal communication with Dr. Deanna Church (NIH/NCBI, 
Bethesda, MD, USA). Both of the SD-mediated de novo CNV formations (i.e. 
via homologous recombination mechanism that result in unequal crossovers) 
occurred on the paternal germline (Table 6.2). Homologous recombination 
events via SD occur predominantly during meiosis, although they may also 
occur during mitosis. (genome.ucsc.edu) 
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Figure 6.7 – Rare de novo CNVs associated with, but not mediated by SD 
Four of the de novo CNVs occurred with SD at one of the breakpoints, which suggest that 
CNV formations were not generated by SD via homologous recombination mechanisms, 
but may reflect the instability of the region due to SD. (genome.ucsc.edu) 
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Figure 6.8– De novo duplications that were not mediated or associated with SD 
4/5 rare de novo duplications identified in the TOF trios have no SD that coincide with 
any of the breakpoints (shown above). This indicates that they occur primarily during 
mitosis, via mechanisms that are initiated by double-strand breaks and exacerbated by 
any form of replication stress. (genome.ucsc.edu) 
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Figure 6.9 – Non SD-mediated/associated de novo deletions 
Three of the rare de novo deletions identified in the TOF trios have no SD coinciding 
with any of the breakpoints (shown above). Four other de novo deletions were only 
associated with SD, but did not occur via SD-mediated mechanisms (shown in Figure 
6.6). Therefore, 7/8 rare de novo deletions identified here occurred via non SD-
mediated mechanisms, which are known to be predominantly mitotic events. This is in 
agreement with the finding that the majority of the de novo CNVs reported in this 
chapter occurred on the paternal germline, which has been associated with an elevated 
rate of CNV formation during mitosis, compared to the female germline. Some of the 
known CNV-generating mechanisms that occur during mitosis are non-homologous 
end joining (NHEJ) and fork-stalling and template switching (FoSTeS); both are DNA 
repair mechanisms. (genome.ucsc.edu)  
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Different mutational mechanisms contribute disproportionately to the different 
sizes of the CNVs that are being generated (Tuzun et al., 2005, Korbel et al., 
2007, Conrad et al., 2010, Itsara et al., 2010). The rare de novo CNVs identified 
in section 6.4.1 were therefore grouped according to the presence of SD in the 
CNV breakpoints and the size distribution in each group was examined. SD-
mediated events were only found in CNVs >1Mb, while non SD-mediated 
events (“no SD” and “SD at one breakpoint”), which constitute the majority of 
the de novo CNVs, tend to be smaller (See Figure 6.10).  
The number of rare de novo CNVs identified in this study (n=13) is too small for 
further potentially meaningful analyses to be carried out. Moreover, the precise 
generating mechanisms of non SD-mediated events can only be deciphered by 
deep sequencing of the CNV breakpoints, which is beyond the scope of this 
thesis. Nevertheless, the findings presented in this chapter are consistent with 
the notion that mitotic events (e.g. DNA repair mechanisms), as opposed to 
meiotic events (e.g. unequal crossovers via homologous recombination), are the 
primary force for driving rare de novo CNV formations that are associated with 
CHD.    
  
Figure 6.10 – CNV size distribution grouped by the generating 
mechanisms according to the presence of SD 
The distribution of CNV size in log scale are shown for rare de novo CNV 
mechanisms that were SD-mediated, SD-associated (SD is present at 
one of the breakpoints) and those that were not related to SD. Each point 
represent CNV within each subgroup arranged in ascending order of size. 
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6.5 Discussion 
I observed a global rare de novo CNV burden of ~5% in 283 TOF trios. This is 
broadly concordant with that previously reported in another cohort of 114 TOF 
trios (Greenway et al., 2009), given differences in the genotyping platforms and 
analysis pipelines between the two studies.  The rare de novo CNVs identified 
in this study implicate known candidate loci (1q21.1, 3q29, 4q34) as well as 
other loci that have not been previously associated with CHD (3q13.11, 5q14, 
5q35.3, 6q27, 9p22.2, 16q11.2, 16q24.2, 19p13.3 and 22q12.3) with recurring 
CNVs in 1q21.1 (GJA5 [MIM 121013]), 4q34 (HAND2 [MIM 602407]), 5q14.2 
(EDIL3 [MIM 606018]) and 5q35.3 (CNOT6 [MIM 608951]).  
As described in Chapter 5, the distal 1q21.1 CNVs have been shown to 
contribute to the population risk of ~1% for TOF. They manifest a degree of 
phenotypic specificity in CHD as well as in other developmental phenotypes. 
Duplications of 1q21.1 are associated with TOF, autism and macrocephaly, 
while the reciprocal deletions are associated with other (non-TOF) types of 
CHD, schizophrenia and microcephaly (Soemedi et al., 2012, Brunetti-Pierri et 
al., 2008, Crespi et al., 2010). The rare de novo deletion found in one patient at 
the 4q34 locus spanned 24 RefSeq genes (see Table 6.1). One of the deleted 
genes was HAND2, a basic helix-loop-helix transcription factor known for its 
pivotal roles in cardiac development in mouse (Srivastava et al., 1997, 
Srivastava, 1999) and man (Tsai et al., 1999). The 500kb overlapping deletion 
that was found in another patient with TOF, however, did not span the coding 
region of HAND2 but encompassed a highly conserved region ~100kb upstream 
of the gene that overlaps previously predicted human heart-specific enhancer 
sequences (Narlikar et al., 2010). Although this deletion was inherited from an 
unaffected father, no overlapping CNVs were identified in the remaining 1577 
controls as well as in the Database of Genomic Variants (Iafrate et al., 2004). 
This particular deletion has also been previously discussed in more details in 
Chapter 4 (Figure 4.2 and Table 4.10).  
Additionally, recurrent CNVs were identified at the 5q35.3 locus (Figure 6.2). 
The overlapping segment spanned a single gene: CNOT6, a subunit of the 
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CCR4-NOT core transcriptional complex, which is known to be crucial for 
controlling mRNA stability during embryonic development (Temme et al., 2010, 
Goldstrohm and Wickens, 2008). RNAi silencing in Drosophila of dNOT3, 
another subunit of the same complex, and heterozygous Cnot3-knockout in 
mice both resulted in heart defects (Neely et al., 2010). Furthermore, three 
deletions were found to overlap the rare de novo duplication in the 5q14 locus. 
One of the deletions spanned the last two exons of EDIL3; it was found in a 62 
year old patient with pulmonary stenosis and secundum atrial septal defect. The 
other two deletions were situated ~100kb upstream of EDIL3, and they were 
identified in 8 year old patient with TOF and an 11 year old patient with 
ventricular septal defect. Interestingly, Glessner et al. reported the same 
deletion variants (upstream of EDIL3), which were found exclusively in 
childhood obesity cases (6/2559 cases; 0/4075 lean controls). Unfortunately, 
the CHD status of these cases was not reported (Glessner et al., 2010). This 
variant was not present in the 1578 controls, as well as in the Database of 
Genomic Variants. Both of the CHD patients that were identified with these 
deletions had no notable extracardiac phenotypes. EDIL3 (epidermal growth 
factor-like repeats and discoidin I-like domains 3) encodes a glycoprotein 
secreted by endothelial cells. It plays an important role in vessel wall 
remodelling and development during angiogenesis (Zhong et al., 2003, Fan et 
al., 2008). It is also upregulated in cardiac progenitor cells, supporting a 
potential role in early cardiac development that merits further investigation 
(Masino et al., 2004). 
With the exception of 1q21.1, no other de novo CNV loci that were previously 
reported by Greenway et al. were replicated in the TOF trios examined in this 
chapter (Greenway et al., 2009). However, in the remaining 1987 CHD patients, 
additional rare CNVs in the same regions reported by Greenway et al. (1q21.1, 
7p21.3 and 4q22.1) were identified, thus supporting the notion that they are 
involved in CHD risk. Overlapping deletions in two TOF probands were 
identified in the 7p21.3 locus; both probands inherited the deletions from the 
respective unaffected fathers. There is no RefSeq gene within the span of 
7p21.3 CNVs identified both in this study and that of Greenway et al. The 
nearest gene is NXPH1 (MIM 604639), a member of the neurexophilin family 
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that promotes adhesion between dendrites and axons. The region has been 
previously associated with autism and attention-deficit-hyperactive disorder 
(Neale et al., 2010, Salyakina et al., 2011). The overlapping duplication in the 
4q22.1 locus, on the other hand, spanned a single gene, PPM1K (PP2C 
domain-containing protein phosphatase 1K, PP2C-like mitochondrial protein 
phosphatase [MIM 611065]), which is known to be essential for cell survival, 
embryonic development, and cardiac function. Knockdown of this gene in 
zebrafish embryos resulted in abnormal cardiac development and heart failure 
from induced apoptosis (Lu et al., 2007).  
Interestingly, 91% of the rare de novo CNVs identified in the TOF trios occurred 
on the paternally transmitted chromosome (P = 0.01). A recent study of rare de 
novo CNV occurrences in 3443 patients with intellectual disability (ID) also 
reported a paternal origin bias (90/118 paternal, P = 1.14x10-8) (Hehir-Kwa et 
al., 2011). In addition, the authors reported a small but significant increase of 
median paternal age in the patients with non SD-mediated rare de novo CNVs 
(that account for ~80% of the de novo CNVs identified) in comparison to 
patients that did not carry such CNVs (34.16 +/- 4.91 vs. 32.13 +/- 41.17; P = 
0.02). However, since the authors did not perform the analysis using controls 
from trio families unaffected with ID, it remains possible that rare de novo point 
mutations causative for ID, (which are known to occur in increased frequency in 
advanced paternal age) were present in the patients who were used as 
“controls” in the paternal age comparison (Crow, 2000). Thus, their observed 
paternal age effect might be underestimated.  A similar finding of an excess of 
paternal origin in non SD-mediated de novo CNV events (P = 0.02) was 
observed in 173 patients with multi-system abnormalities (Sibbons et al., 2012). 
The authors did not observe a significant difference in the paternal age, but this 
is most likely due to the study being underpowered. Interestingly, another study 
of de novo CNV occurrences in asthmatic trios found no parent of origin effect 
(Itsara et al., 2010). In that study, SD-mediated events accounted for the 
majority (63%) of de novo CNV events, in contrast to the findings in 
developmental phenotypes, in which case only the minority of the de novo CNV 
events were mediated by SD (Hehir-Kwa et al., 2011, Sibbons et al., 2012, 
Itsara et al., 2010). Mechanisms via homologous recombination mediated by 
Chapter 6: Rare de novo CNVs in TOF trios 
156 
 
segmental duplications (SD) are the primary generating force for CNVs in the 
human genome (Kidd et al., 2008, Korbel et al., 2007). They predominantly 
occur during meiosis. But in agreement with the previous studies in 
developmental phenotypes, the majority of the rare de novo CNV findings in the 
TOF trios were not mediated by SD and most originated on the paternal 
chromosomes (Table 6.2, Figure 6.5-6.9). Such findings are highly congruent 
with the hypothesis that the frequency of copy number mutations via DNA repair 
mechanisms is likely to be higher in the male germline, resulting from a greater 
number of mitotic divisions during spermatogenesis (particularly in older males) 
compared to oogenesis (Crow, 2000).  Some of the known mitotic events that 
may result in CNV formation include fork-stalling and template switching 
(FoSTeS) and non-homologous end joining (NHEJ). Advanced paternal age has 
been previously observed as an independent risk factor for CHD (Olshan et al., 
1994). Unfortunately, the paternal age of most of the patients with rare de novo 
CNVs identified in this study was not available. 
It should be noted that due to the limitation of the technology used in this study, 
many smaller CNVs may not have been detected. However, the results of the 
study presented in Chapter 4 of this thesis suggest that such CNVs are likely to 
contribute minimally to the risk for CHD. Furthermore, it is unlikely that the main 
conclusion of this study will change when a technology that can reliably detect 
smaller CNVs (i.e. whole-genome sequencing) is used. SD-mediated events are 
known to predominantly generate large CNVs, in contrast to non SD-mediated 
events (i.e. mitotic events), which are the primary generating force for smaller 
CNVs (Tuzun et al., 2005, Korbel et al., 2007, Conrad et al., 2010), in 
accordance with the observations made in this chapter. Also, there was a higher 
frequency of de novo deletions compared to de novo duplications observed in 
this study. This may either reflect a difference in pathogenic significance 
between deletions and duplications, or it may also reflect the limitation of the 
technology (which can more readily detect deletions than duplications), 
particularly in this study where smaller CNVs (<100kb) were included in the 
analyses. The discrepancy in the power of detection between deletions and 
duplications is likely to be greater as the size of the CNVs gets smaller. Finally, 
this study was restricted to autosomal CNVs. Thus, the contribution of 
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pathogenic rare de novo CNVs that may occur in the sex chromosomes, which 
harbour many known candidate genes for CHD, is not taken into consideration. 
This is due to the fact that the primary algorithm used in this study (PennCNV) 
was only designed to analyze autosomal chromosomes (Wang et al., 2007).  
In conclusion, this chapter establishes a rare de novo CNV burden of ~5% in 
283 TOF trio families with a significant paternal origin bias that can be attributed 
to the preponderance of mitotic CNV-generating events. The rare de novo 
CNVs identified in this study spanned known candidate loci for CHD as well as 
recurrent loci that involve genes known for their significance in development, but 
have not been previously associated with CHD. Thus, the findings presented in 
this chapter represent a significant contribution to the understanding of the 
pathogenesis of TOF, as well as other CHD.  
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7.1 Abstract 
Rare genic CNVs represent a significant risk as a whole to various complex 
traits, including CHD. But with the exception of recurrent rare CNVs in 
chromosome 1q21.1 and 15q11.2, their significance in the remaining loci is 
unknown, due to the lack of statistical power to evaluate variants that occur with 
exceedingly rare frequency. Over the years, studies in human syndromic CHD 
and rare familial CHD, as well as work in animal models for CHD have led to 
hundreds of genes being proposed to cause sporadic CHD in humans, although 
in the majority of them, the evidence remains inconclusive. This chapter 
proposes an exploratory study to identify individual rare genic CNVs that show 
genomic dosage alteration in the genes that are most likely to pose risk to CHD, 
and thus aiding the interpretation of CNVs that contribute significantly to CHD 
as a whole, but whose significance in individual loci is unknown. In order to do 
this, a list of 400 autosomal candidate genes was compiled from multiple 
sources and their transcription boundaries were obtained. CNVs in 2256 CHD 
cases that occur with <0.1% frequency in 1538 controls and overlap the 400 
candidate genes were queried. In total, 34 rare CNVs overlapping 33 candidate 
genes that are likely to pose high risk for CHD were identified. Recurrent CNVs 
were observed in several candidate gene loci, including GATA4, PTGER3 and 
SALL4. This study complements the findings from the previous chapters of this 
thesis by presenting additional CNV loci that are likely to contribute risk to 
human sporadic CHD, and thus can be incorporated in future prioritization 
algorithms for interpreting exome sequencing or other high-throughput genomic 
data. 
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7.2 Results 
7.2.1 Candidate genes 
A total of 400 candidate genes (Table 7.1) that are located in autosomal 
chromosomes were compiled from the list of genes that had been previously 
gathered from the contributing investigators in the CHeartED project 
(http://www.chearted.eu/) as well as from the list of candidate genes that are 
contained in CHD Wiki (Barriot et al., 2010). They are largely composed of 1) 
genes that are known to cause the Mendelian form of CHD, both syndromic and 
non-syndromic, 2) genes that when perturbed (either by gains of function or 
dosage effects) have been shown to cause CHD in animal models and 3) genes 
that are predicted to be involved in CHD pathogenesis on the basis of their 
known interactions with causal genes for CHD, both in humans and animal 
models. The respective hg18 (NCBI Build 36.1) RefSeq coordinates were 
obtained from the UCSC Genome Browser (http://genome.ucsc.edu). Galaxy 
script (Goecks et al., 2010) was used to join the genomic coordinates of the 
candidate genes with CNVs identified in 2256 CHD patients (as described in 
Chapter 4). All CNVs that overlap candidate genes were examined manually in 
order to identify artificial splits that may have occurred.  
Table 7.1 – List of 400 autosomal candidate genes with description, OMIM ID and 
Illumina 660W coverage 
Gene symbol Gene description MIM 
n 
probes 
AATK apoptosis-associated tyrosine kinase 605276 10 
ACTC1 actin, alpha, cardiac muscle 1 102540 12 
ACTG1 actin, gamma 1 102560 11 
ACTN2 actinin, alpha 2 102573 66 
ACVR2B activin A receptor, type IIB 602730 6 
ACVRL1 activin A receptor type II-like 1 601284 12 
ADAM17 ADAM metallopeptidase domain 17 603639 10 
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 603640 31 
ADCYAP1 adenylate cyclase activating polypeptide 1 (pituitary) 102980 9 
ADNP2 ADNP homeobox 2 n/a 8 
ADRB1 adrenergic, beta-1-, receptor 109630 12 
ALDH1A2 aldehyde dehydrogenase 1 family, member A2 603687 115 
ANK2 ankyrin 2, neuronal 106410 163 
ANKRD1 ankyrin repeat domain 1 (cardiac muscle) 609599 6 
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ANKRD2 ankyrin repeat domain 2 (stretch responsive muscle) 610734 7 
AP1B1 adaptor-related protein complex 1, beta 1 subunit 600157 30 
ARID4A AT rich interactive domain 4A (RBP1-like) 180201 19 
BARX1 BARX homeobox 1 603260 3 
BARX2 BARX homeobox 2 604823 38 
BCCIP BRCA2 and CDKN1A interacting protein 611883 1 
BIRC7 baculoviral IAP repeat-containing 7 605737 6 
BMP10 bone morphogenetic protein 10 608748 5 
BMP2 bone morphogenetic protein 2 112261 11 
BMP4 bone morphogenetic protein 4 112262 7 
BMPR1A bone morphogenetic protein receptor, type IA; similar to ALK-3 601299 37 
BMPR1B bone morphogenetic protein receptor, type IB 603248 112 
BOP1 block of proliferation 1 610596 4 
BRAF v-raf murine sarcoma viral oncogene homolog B1 164757 17 
CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit 601012 42 
CASQ2 calsequestrin 2 (cardiac muscle) 114251 30 
CAV2 caveolin 2 601048 6 
CAV3 caveolin 3 601253 25 
CDC16 cell division cycle 16 homolog (S. cerevisiae) 603461 22 
CECR1 cat eye syndrome chromosome region, candidate 1 607575 17 
CECR2 cat eye syndrome chromosome region, candidate 2 607576 39 
CELF2 CUG triplet repeat, RNA binding protein 2 602538 144 
CFC1 cripto, FRL-1, cryptic family 1 605194 17 
CHD7 chromodomain helicase DNA binding protein 7 608892 30 
CHFR checkpoint with forkhead and ring finger domains 605209 21 
CHL1 
cell adhesion molecule with homology to L1CAM (close homolog of 
L1) 
607416 137 
CITED2 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-
terminal domain, 2 
602937 3 
CLTC clathrin, heavy chain (Hc) 118955 10 
CNBP CCHC-type zinc finger, nucleic acid binding protein 116955 3 
COL2A1 collagen, type II, alpha 1 120140 26 
CREBBP CREB binding protein 600140 49 
CRELD1 cysteine-rich with EGF-like domains 1 607170 3 
CRYAB crystallin, alpha B 123590 0 
CSDE1 cold shock domain containing E1, RNA-binding 191510 9 
CSNK1D casein kinase 1, delta 600864 20 
CSRP1 cysteine and glycine-rich protein 1 123876 14 
CSRP3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 600824 15 
CTF1 cardiotrophin 1 600435 1 
CXADR 
coxsackie virus and adenovirus receptor pseudogene 2; coxsackie 
virus and adenovirus receptor 
602621 20 
DES desmin 125660 3 
DGCR14 DiGeorge syndrome critical region gene 14 601755 7 
DGCR2 DiGeorge syndrome critical region gene 2 600594 33 
DLGAP5 discs, large (Drosophila) homolog-associated protein 5 n/a 7 
DNER delta/notch-like EGF repeat containing 607299 99 
DPF3 D4, zinc and double PHD fingers, family 3 601672 75 
DRAP1 DR1-associated protein 1 (negative cofactor 2 alpha) 602289 2 
DRG2 developmentally regulated GTP binding protein 2 602986 9 
DSC2 desmocollin 2 125645 18 
DSCAM Down syndrome cell adhesion molecule 602523 299 
DSG2 desmoglein 2 125671 24 
DSP desmoplakin 125647 21 
DVL1 
dishevelled, dsh homolog 1 (Drosophila); dishevelled, dsh homolog 
1 (Drosophila)-like 1 
601365 18 
DVL2 dishevelled, dsh homolog 2 (Drosophila) 602151 4 
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DVL3 dishevelled, dsh homolog 3 (Drosophila) 601368 9 
DYRK1B dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1B 604556 9 
EDN2 endothelin 2 131241 13 
EFEMP2 EGF-containing fibulin-like extracellular matrix protein 2 604633 19 
EGFR 
epidermal growth factor receptor (erythroblastic leukemia viral (v-
erb-b) oncogene homolog, avian) 
131550 104 
EGLN1 egl nine homolog 1 (C. elegans) 606425 7 
EGR3 early growth response 3 602419 5 
EHMT1 euchromatic histone-lysine N-methyltransferase 1 607001 26 
ELN elastin 130160 10 
ENG endoglin 131195 13 
EP300 E1A binding protein p300 602700 7 
ERBB2 
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (avian) 
164870 3 
ERBB3 v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) 190151 4 
ERBB4 v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) 600543 386 
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 164720 61 
EVC Ellis van Creveld syndrome 604831 65 
EVC2 Ellis van Creveld syndrome 2 607261 50 
EWSR1 
similar to Ewing sarcoma breakpoint region 1; Ewing sarcoma 
breakpoint region 1 
133450 26 
EXO1 exonuclease 1 606063 14 
EXT1 exostoses (multiple) 1 608177 110 
FBLN5 fibulin 5 604580 42 
FBN1 fibrillin 1 134797 33 
FBN2 fibrillin 2 612570 70 
FGF10 fibroblast growth factor 10 602115 17 
FGF12 fibroblast growth factor 12 601513 184 
FGF19 fibroblast growth factor 19 603891 4 
FGF2 fibroblast growth factor 2 (basic) 134920 18 
FGF6 fibroblast growth factor 6 134921 10 
FGF8 fibroblast growth factor 8 (androgen-induced) 600483 1 
FGF9 fibroblast growth factor 9 (glia-activating factor) 600921 15 
FGFR1 fibroblast growth factor receptor 1 136350 10 
FGFR2 fibroblast growth factor receptor 2 176943 39 
FHL3 four and a half LIM domains 3 602790 4 
FKBP6 FK506 binding protein 6, 36kDa 604839 2 
FKRP fukutin related protein 606596 3 
FKTN fukutin 607440 11 
FLNC filamin C, gamma (actin binding protein 280) 102565 7 
FOXA2 forkhead box A2 600288 1 
FOXC1 forkhead box C1 601090 3 
FOXC2 forkhead box C2 (MFH-1, mesenchyme forkhead 1) 602402 4 
FOXH1 forkhead box H1 603621 11 
FOXK1 forkhead box K1 n/a 16 
FOXK2 forkhead box K2 147685 21 
FOXL2 forkhead box L2 605597 3 
FOXM1 forkhead box M1 602341 5 
FOXO3 forkhead box O3; forkhead box O3B pseudogene 602681 48 
FOXP1 forkhead box P1 605515 173 
FSTL3 follistatin-like 3 (secreted glycoprotein) 605343 5 
GAB1 GRB2-associated binding protein 1 604439 21 
GALNS galactosamine (N-acetyl)-6-sulfate sulfatase 612222 28 
GATA4 GATA binding protein 4 600576 38 
GATA5 GATA binding protein 5 611496 5 
GATA6 GATA binding protein 6 601656 8 
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GDF1 growth differentiation factor 1; LAG1 homolog, ceramide synthase 1 602880 10 
GJA1 gap junction protein, alpha 1, 43kDa 121014 9 
GJA9 gap junction protein, alpha 9, 59kDa 611923 8 
GLI2 GLI family zinc finger 2 165230 33 
GTF2I 
general transcription factor II, i; general transcription factor II, i, 
pseudogene 
601679 7 
GTF2IRD1 GTF2I repeat domain containing 1 604318 14 
GTPBP4 GTP binding protein 4 n/a 14 
HAND1 heart and neural crest derivatives expressed 1 602406 9 
HAND2 heart and neural crest derivatives expressed 2 602407 11 
HBEGF heparin-binding EGF-like growth factor 126150 7 
HDAC2 histone deacetylase 2 605164 8 
HDAC4 histone deacetylase 4 605314 139 
HDAC5 histone deacetylase 5 605315 7 
HDAC7 histone deacetylase 7 606542 16 
HDAC9 histone deacetylase 9 606543 184 
HES1 hairy and enhancer of split 1, (Drosophila) 139605 3 
HES4 hairy and enhancer of split 4 (Drosophila) 608060 0 
HEY1 hairy/enhancer-of-split related with YRPW motif 1 602953 7 
HEY2 
hypothetical LOC100129733; hairy/enhancer-of-split related with 
YRPW motif 2 
604674 2 
HHEX hematopoietically expressed homeobox 604420 16 
HIRA HIR histone cell cycle regulation defective homolog A (S. cerevisiae) 600237 31 
HMGB2 high-mobility group box 2 163906 1 
HOPX HOP homeobox 607275 10 
HOXA1 homeobox A1 142955 5 
HOXA3 homeobox A3 142954 4 
HOXB2 homeobox B2 142967 6 
HRAS v-Ha-ras Harvey rat sarcoma viral oncogene homolog 190020 0 
HSPB7 heat shock 27kDa protein family, member 7 (cardiovascular) 610692 7 
HTR2B 5-hydroxytryptamine (serotonin) receptor 2B 601122 4 
ID2 
inhibitor of DNA binding 2, dominant negative helix-loop-helix 
protein 
600386 1 
IDUA iduronidase, alpha-L- 252800 22 
IGF1 insulin-like growth factor 1 (somatomedin C) 147440 21 
IGF1R insulin-like growth factor 1 receptor 147370 122 
IGF2 
insulin-like growth factor 2 (somatomedin A); insulin; INS-IGF2 
readthrough transcript 
147470 7 
IGFBP3 insulin-like growth factor binding protein 3 146732 7 
IGFBP4 insulin-like growth factor binding protein 4 146733 4 
IL15 interleukin 15 600554 10 
INSR insulin receptor 147670 58 
IRF2 interferon regulatory factor 2 147576 57 
IRX3 iroquois homeobox 3 612985 7 
IRX4 iroquois homeobox 4 606199 4 
IRX5 iroquois homeobox 5 606195 3 
ISL1 ISL LIM homeobox 1 600366 2 
ITGA11 integrin, alpha 11 604789 79 
ITGA4 
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 
receptor) 
192975 24 
ITGA7 integrin, alpha 7 600536 8 
ITGB1BP3 integrin beta 1 binding protein 3 608705 23 
JAG1 jagged 1 (Alagille syndrome) 601920 13 
JAG2 jagged 2 602570 23 
JAK2 Janus kinase 2 147796 20 
JPH1 junctophilin 1 605266 22 
JUN jun oncogene 165160 19 
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JUP junction plakoglobin 173325 7 
KCNA5 
potassium voltage-gated channel, shaker-related subfamily, 
member 5 
176267 17 
KCNE1 potassium voltage-gated channel, Isk-related family, member 1 176261 34 
KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 600681 5 
KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1 607542 142 
KRAS v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog 190070 27 
KREMEN1 kringle containing transmembrane protein 1 609898 32 
LAMA2 laminin, alpha 2 156225 132 
LAMA5 laminin, alpha 5 601033 15 
LBH limb bud and heart development homolog (mouse) 611763 15 
LBR lamin B receptor 600024 12 
LBX1 ladybird homeobox 1 604255 3 
LDB3 LIM domain binding 3 605906 20 
LEFTY1 left-right determination factor 1 603037 4 
LEFTY2 left-right determination factor 2 601877 6 
LIMK1 LIM domain kinase 1 601329 9 
LMBR1 limb region 1 homolog (mouse) 605522 35 
LMNA lamin A/C 150330 5 
LRRC20 leucine rich repeat containing 20 n/a 40 
MAFG 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog G 
(avian) 
602020 0 
MAFK 
v-maf musculoaponeurotic fibrosarcoma oncogene homolog K 
(avian) 
600197 22 
MAML1 mastermind-like 1 (Drosophila) 605424 5 
MAP2K1 mitogen-activated protein kinase kinase 1 176872 11 
MAP2K2 
mitogen-activated protein kinase kinase 2 pseudogene; mitogen-
activated protein kinase kinase 2 
601263 9 
MAP2K3 mitogen-activated protein kinase kinase 3 602315 3 
MAP2K6 mitogen-activated protein kinase kinase 6 601254 35 
MAPK12 mitogen-activated protein kinase 12 602399 4 
MAPK14 mitogen-activated protein kinase 14 600289 19 
MBNL1 muscleblind-like (Drosophila) 606516 29 
MED13L mediator complex subunit 13-like 608771 66 
MEF2A myocyte enhancer factor 2A 600660 25 
MEF2B 
LOC729991-MEF2B readthrough transcript; myocyte enhancer 
factor 2B 
600661 11 
MEF2C myocyte enhancer factor 2C 600662 32 
MEF2D myocyte enhancer factor 2D 600663 8 
MEIS1 Meis homeobox 1 601739 40 
MESP1 mesoderm posterior 1 homolog (mouse) 608689 1 
MET met proto-oncogene (hepatocyte growth factor receptor) 164860 26 
MGP matrix Gla protein 154870 3 
MIB1 mindbomb homolog 1 (Drosophila) 608677 14 
MKL2 MKL/myocardin-like 2 609463 19 
MRAS muscle RAS oncogene homolog 608435 13 
MSX1 msh homeobox 1 142983 4 
MTPN myotrophin; leucine zipper protein 6 606484 11 
MUSK muscle, skeletal, receptor tyrosine kinase 601296 68 
MYBPC3 myosin binding protein C, cardiac 600958 7 
MYH11 myosin, heavy chain 11, smooth muscle 160745 78 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 160710 19 
MYH7 myosin, heavy chain 7, cardiac muscle, beta 160760 12 
MYL1 myosin, light chain 1, alkali; skeletal, fast 160780 6 
MYL2 myosin, light chain 2, regulatory, cardiac, slow 160781 7 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow 160790 6 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 160770 10 
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MYL5 myosin, light chain 5, regulatory 160782 0 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle 609931 4 
MYL6B myosin, light chain 6B, alkali, smooth muscle and non-muscle 609930 3 
MYL7 myosin, light chain 7, regulatory 613993 6 
MYL9 myosin, light chain 9, regulatory 609905 3 
MYLK2 myosin light chain kinase 2 606566 7 
MYLK3 myosin light chain kinase 3 612147 2 
MYOCD myocardin 606127 50 
MYOD1 myogenic differentiation 1 159970 2 
MYOG myogenin (myogenic factor 4) 159980 16 
MYOM1 myomesin 1, 185kDa 603508 51 
MYOM2 myomesin (M-protein) 2, 165kDa 603509 96 
MYOZ2 myozenin 2 605602 15 
NCAM1 neural cell adhesion molecule 1 116930 94 
NCAM2 neural cell adhesion molecule 2 602040 144 
NCBP2 nuclear cap binding protein subunit 2, 20kDa 605133 8 
NCOA6 nuclear receptor coactivator 6 605299 9 
NCOR2 nuclear receptor co-repressor 2 600848 81 
NDN necdin homolog (mouse) 602117 1 
NF1 neurofibromin 1 613113 70 
NFATC1 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 1 
600489 85 
NFATC3 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 3 
602698 9 
NFATC4 
nuclear factor of activated T-cells, cytoplasmic, calcineurin-
dependent 4 
602699 8 
NINJ2 ninjurin 2 607297 49 
NKX2-3 NK2 transcription factor related, locus 3 (Drosophila) 606727 2 
NKX2-5 NK2 transcription factor related, locus 5 (Drosophila) 600584 5 
NKX2-6 NK2 transcription factor related, locus 6 (Drosophila) 611770 9 
NODAL nodal homolog (mouse) 601265 5 
NOS3 nitric oxide synthase 3 (endothelial cell) 163729 5 
NOTCH1 Notch homolog 1, translocation-associated (Drosophila) 190198 10 
NOTCH2 Notch homolog 2 (Drosophila) 600275 30 
NPHP3 
nephronophthisis 3 (adolescent); acyl-Coenzyme A dehydrogenase 
family, member 11 
608002 12 
NPPA natriuretic peptide precursor A 108780 7 
NPTX1 neuronal pentraxin I 602367 8 
NR2C2 nuclear receptor subfamily 2, group C, member 2 601426 18 
NR2F2 nuclear receptor subfamily 2, group F, member 2 107773 21 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 164790 6 
NRG1 neuregulin 1 142445 81 
NSD1 nuclear receptor binding SET domain protein 1 606681 11 
NTF3 neurotrophin 3 162660 40 
NTRK3 neurotrophic tyrosine kinase, receptor, type 3 191316 78 
OCA2 oculocutaneous albinism II 611409 88 
OTX2 orthodenticle homeobox 2 600037 4 
PAX3 paired box 3 606597 40 
PBRM1 polybromo 1 606083 15 
PCSK5 proprotein convertase subtilisin/kexin type 5 600488 206 
PCSK6 proprotein convertase subtilisin/kexin type 6 167405 133 
PDGFA platelet-derived growth factor alpha polypeptide 173430 0 
PDGFRA platelet-derived growth factor receptor, alpha polypeptide 173490 13 
PDLIM3 PDZ and LIM domain 3 605889 27 
PDPK1 3-phosphoinositide dependent protein kinase-1 605213 32 
PEG3AS paternally expressed 3; PEG3 antisense RNA (non-protein coding); n/a 5 
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zinc finger, imprinted 2 
PGAM2 phosphoglycerate mutase 2 (muscle) 612931 3 
PHC1 
polyhomeotic homolog 1B (Drosophila); polyhomeotic homolog 1 
(Drosophila) 
602978 15 
PIAS1 protein inhibitor of activated STAT, 1 603566 13 
PIGQ phosphatidylinositol glycan anchor biosynthesis, class Q 605754 10 
PITX2 paired-like homeodomain 2 601542 6 
PKP2 plakophilin 2 602861 35 
PLAGL1 pleiomorphic adenoma gene-like 1 603044 36 
PLN phospholamban 172405 7 
PLXNA2 plexin A2 601054 94 
POU6F1 POU class 6 homeobox 1 n/a 9 
PPP1R12A protein phosphatase 1, regulatory (inhibitor) subunit 12A 602021 27 
PPP1R12B protein phosphatase 1, regulatory (inhibitor) subunit 12B 603768 52 
PPP3CA protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform 114105 76 
PPP3CB protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform 114106 4 
PPP3R1 
protein phosphatase 3 (formerly 2B), regulatory subunit B, alpha 
isoform 
601302 4 
PRDM6 PR domain containing 6 n/a 44 
PRKAG2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 602743 127 
PRKAR1A 
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue 
specific extinguisher 1) 
188830 5 
PRKCA protein kinase C, alpha 176960 139 
PRKCZ protein kinase C, zeta 176982 34 
PRKDC 
similar to protein kinase, DNA-activated, catalytic polypeptide; 
protein kinase, DNA-activated, catalytic polypeptide 
600899 16 
PRKG1 protein kinase, cGMP-dependent, type I 176894 434 
PRMT2 protein arginine methyltransferase 2 601961 8 
PROX1 prospero homeobox 1 601546 9 
PSEN1 presenilin 1 104311 10 
PTGER2 prostaglandin E receptor 2 (subtype EP2), 53kDa 176804 23 
PTGER3 prostaglandin E receptor 3 (subtype EP3) 176806 175 
PTPN11 
protein tyrosine phosphatase, non-receptor type 11; similar to 
protein tyrosine phosphatase, non-receptor type 11 
176876 5 
PTPRJ protein tyrosine phosphatase, receptor type, J 600925 27 
RAB3GAP2 RAB3 GTPase activating protein subunit 2 (non-catalytic) 609275 17 
RAI1 retinoic acid induced 1 607642 13 
RAN RAN, member RAS oncogene family 601179 14 
ROCK1 
similar to Rho-associated, coiled-coil containing protein kinase 1; 
Rho-associated, coiled-coil containing protein kinase 1 
601702 11 
ROCK2 Rho-associated, coiled-coil containing protein kinase 2 604002 27 
ROR2 receptor tyrosine kinase-like orphan receptor 2 602337 74 
RPA1 replication protein A1, 70kDa 179835 23 
RXRA retinoid X receptor, alpha 180245 35 
RYR2 ryanodine receptor 2 (cardiac) 180902 221 
SALL1 sal-like 1 (Drosophila) 602218 3 
SALL4 sal-like 4 (Drosophila) 607343 7 
SATB1 SATB homeobox 1 602075 23 
SC5DL 
sterol-C5-desaturase (ERG3 delta-5-desaturase homolog, S. 
cerevisiae)-like 
602286 5 
SCN5A sodium channel, voltage-gated, type V, alpha subunit 600163 46 
SCXA scleraxis homolog A (mouse); scleraxis homolog B (mouse) 609067 1 
SCXB scleraxis homolog A (mouse); scleraxis homolog B (mouse) n/a 1 
SEMA3C 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3C 
602645 42 
SEPT2 septin 2 601506 8 
SESN1 sestrin 1 606103 12 
SGCB sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 600900 3 
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SGCD sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 601411 92 
SGCG sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 608896 76 
SH3YL1 SH3 domain containing, Ysc84-like 1 (S. cerevisiae) n/a 26 
SHH sonic hedgehog homolog (Drosophila) 600725 6 
SHOC2 soc-2 suppressor of clear homolog (C. elegans) 602775 13 
SHOX2 short stature homeobox 2 602504 5 
SIRT1 
sirtuin (silent mating type information regulation 2 homolog) 1 (S. 
cerevisiae) 
604479 4 
SIRT2 
sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
604480 7 
SKI v-ski sarcoma viral oncogene homolog (avian) 164780 46 
SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 606145 11 
SLC2A4 solute carrier family 2 (facilitated glucose transporter), member 4 138190 5 
SLC6A6 
solute carrier family 6 (neurotransmitter transporter, taurine), 
member 6 
186854 46 
SLC8A1 solute carrier family 8 (sodium/calcium exchanger), member 1 182305 240 
SMAD6 SMAD family member 6 602931 31 
SMAD7 SMAD family member 7 602932 18 
SMTN smoothelin 602127 10 
SMYD1 SET and MYND domain containing 1 606846 23 
SOS1 son of sevenless homolog 1 (Drosophila) 182530 17 
SOX15 SRY (sex determining region Y)-box 15 601297 3 
SOX2 SRY (sex determining region Y)-box 2 184429 0 
SOX4 SRY (sex determining region Y)-box 4 184430 2 
SOX6 SRY (sex determining region Y)-box 6 607257 71 
SOX9 SRY (sex determining region Y)-box 9 608160 6 
SPOCK3 
sparc/osteonectin, cwcv and kazal-like domains proteoglycan 
(testican) 3 
607989 109 
SRF 
serum response factor (c-fos serum response element-binding 
transcription factor) 
600589 4 
SSPN sarcospan (Kras oncogene-associated gene) 601599 25 
STRA6 stimulated by retinoic acid gene 6 homolog (mouse) 610745 8 
TAB1 
mitogen-activated protein kinase kinase kinase 7 interacting protein 
1 
602615 6 
TAB2 
mitogen-activated protein kinase kinase kinase 7 interacting protein 
2 
605101 15 
TBL2 transducin (beta)-like 2 605842 4 
TBX1 T-box 1 602054 16 
TBX18 T-box 18 604613 8 
TBX2 T-box 2 600747 5 
TBX20 T-box 20 606061 6 
TBX3 T-box 3 601621 3 
TBX5 T-box 5 601620 23 
TBX6 T-box 6 602427 4 
TCAP titin-cap (telethonin) 604488 8 
TCF21 transcription factor 21 603306 7 
TDGF1 
teratocarcinoma-derived growth factor 3, pseudogene; 
teratocarcinoma-derived growth factor 1 
187395 2 
TEAD1 
TEA domain family member 1 (SV40 transcriptional enhancer 
factor) 
189967 65 
TFAP2B 
transcription factor AP-2 beta (activating enhancer binding protein 2 
beta) 
601601 7 
TGFB2 transforming growth factor, beta 2 190220 26 
TGFBR3 transforming growth factor, beta receptor III 600742 94 
THOC5 THO complex 5 612733 12 
TLL1 tolloid-like 1 606742 50 
TMEM43 transmembrane protein 43 612048 18 
TMOD4 tropomodulin 4 (muscle) 605834 2 
TMPO thymopoietin 188380 7 
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TNNC1 troponin C type 1 (slow) 191040 1 
TNNI1 troponin I type 1 (skeletal, slow) 191042 12 
TNNI2 troponin I type 2 (skeletal, fast) 191043 2 
TNNI3 troponin I type 3 (cardiac) 191044 0 
TNNT2 troponin T type 2 (cardiac) 191045 16 
TP73 tumor protein p73 601990 21 
TPM1 tropomyosin 1 (alpha) 191010 12 
TWIST1 twist homolog 1 (Drosophila) 601622 3 
TXNRD2 thioredoxin reductase 2 606448 32 
TYMP thymidine phosphorylase 131222 7 
UBE3A ubiquitin protein ligase E3A 601623 8 
UFD1L ubiquitin fusion degradation 1 like (yeast) 601754 9 
VANGL2 vang-like 2 (van gogh, Drosophila) 600533 9 
VCL vinculin 193065 13 
VEGFA vascular endothelial growth factor A 192240 8 
VEGFC vascular endothelial growth factor C 601528 18 
WNT3A wingless-type MMTV integration site family, member 3A 606359 15 
WNT4 wingless-type MMTV integration site family, member 4 603490 7 
WNT5A wingless-type MMTV integration site family, member 5A 164975 9 
WNT7B wingless-type MMTV integration site family, member 7B 601967 0 
YY1AP1 YY1 associated protein 1; gon-4-like (C. elegans) 607860 22 
ZEB2 zinc finger E-box binding homeobox 2 605802 31 
ZFPM1 zinc finger protein, multitype 1 601950 39 
ZFPM2 zinc finger protein, multitype 2 603693 125 
ZYX zyxin 602002 6 
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7.2.2 Rare CNVs overlapping 400 candidate genes 
This study identified 39 rare CNVs (<0.1% frequency in 1538 controls) that 
overlap 34 candidate genes (see Table 7.2). Five recurrent CNVs spanning 
GATA4 [MIM 600576] at chromosome 8p23.1 were identified: deletions were 
found in two patients with TOF, a patient with atrioventricular septal defect and 
a patient with ventricular septal defect, while a duplication was identified in a 
patient with bicuspid aortic valve with aortic regurgitation (see Figure 7.1). At the 
16p13.11 locus, five recurrent CNVs spanning MYH11 [MIM 160745] were 
observed (four duplications and one deletion) - see Figure 7.2. A deletion and a 
duplication overlapping PTGER3 [MIM 176806] at chromosome 1p31.1 were 
found in patients with TOF and truncus arteriosus, respectively, and recurrent 
duplications encompassing SALL4 [MIM 607343] at 20q13.2 were also 
observed in patients with TOF and ventricular septal defect (see Figure 7.3 and 
Table 7.2). Other genes implicated in rare CNVs found in CHD patients were 
BMPR1A (MIM 601299), BMPR1B (MIM 603248), CECR1 (MIM 607575), 
DSCAM (MIM 602523), EGLN1 (MIM 606425), ERBB4 (MIM 600543), FKTN 
(MIM 607440), FOXC1 (MIM 601090), HAND2 (MIM 602407), HMGB2 (MIM 
163906), VEGFC (MIM 601528), HDAC4 (MIM 605314), HES4 (MIM 608060), 
DVL1 (MIM 601365), ITGA7 (MIM 600536), LAMA2 (MIM 156225), LDB3 (MIM 
605906), MED13L (MIM 608771), MSX1 (MIM 142983), MTPN (MIM 606484), 
MYL4 (MIM 160770), MYL5 (MIM 160782), MYOM1 (MIM 603508), MYOM2 
(MIM 603509), NCBP2 (MIM 605133), PCSK6 (MIM 167405), SGCG (MIM 
608896), SLC8A1 (MIM 182305), SMYD1 (MIM 606846) and ZFPM1 (MIM 
601950); see Table 7.2. 
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Table 7.2 – Genetic and phenotypic information of CHD patients with CNVs overlapping 400 candidate genes 
Family ID start 
length 
(kb) 
CN Cyto band 
candidate 
gene(s) 
RefSeq genes 
n 
genes 
Sex Age
§
 
CHD 
type 
extracardiac 
phenotype 
OX-2110.1 95496334 418 dup 4q22.3 BMPR1B PDLIM5, BMPR1B 2 F NA ASD none 
NOTT-379.1 15774989 329 del 22q11.1 CECR1 
GAB4, CECR7, IL17RA, CECR6, CECR5, 
CECR5-AS1, CECR1 
7 F 14 TOF none 
SYD-1784.1 39163153 2228 dup 21q22.2 DSCAM 
PSMG1, BRWD1, BRWD1-IT2, HMGN1, 
WRB, LCA5L, SH3BGR, C21orf88, 
B3GALT5, IGSF5, PCP4, DSCAM, 
MIR4760, DSCAM-AS1 
14 M <1 AVSD none 
OX-1870.1 229014206 1894 dup 1q42.2 EGLN1 
C1orf198, TTC13, ARV1, FAM89A, 
MIR1182, TRIM67, LOC149373, C1orf131, 
GNPAT, EXOC8, C1orf124, EGLN1, 
SNRPD2P2, TSNAX-DISC1, TSNAX, 
LOC100287814, DISC1, DISC2, SIPA1L2 
19 F NA Other none 
SYD-2024.1 212625003 172 del 2q34 ERBB4 ERBB4 1 F <1 AS none 
CHA-4.1* 107283314 175 dup 9q31.2 FKTN FSD1L, FKTN 2 M 9 TOF none 
FCH-367.1 110391 2611 del 
6p25.2-
p25.3 
FOXC1 
DUSP22, IRF4, EXOC2, HUS1B, 
LOC285768, FOXQ1, FOXF2, FOXC1, 
GMDS, LOC100508120, C6orf195, 
MYLK4, WRNIP1 
13 F 9 AS 
 
none 
OX-2726.1* 10131787 1804 dup 8p23.1 GATA4 
MSRA, PRSS55, RP1L1, MIR4286, 
C8orf74, SOX7, PINX1, MIR1322, XKR6, 
MIR598, MTMR9, SLC35G5, TDH, 
C8orf12, FAM167A, BLK, LINC00208, 
GATA4, NEIL2, FDFT1, CTSB, DEFB136, 
DEFB135, DEFB134 
24 M NA BAV none 
ERL-
13343.1* 
10405572 1295 del 8p23.1 GATA4 
PRSS55, RP1L1, MIR4286, C8orf74, 
SOX7, PINX1, MIR1322, XKR6, MIR598, 
MTMR9, SLC35G5, TDH, C8orf12, 
FAM167A, BLK, LINC00208, GATA4, 
NEIL2, FDFT1 
36 F NA TOF none 
OX-2843.1* 11313952 472 del 8p23.1 GATA4 
C8orf12, FAM167A, BLK, LINC00208, 
GATA4, NEIL2, FDFT1, CTSB 
8 F NA VSD none 
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GOCHD-
2266.1* 
11642267 96 del 8p23.1 GATA4 GATA4, NEIL2, FDFT1, CTSB 4 F NA TOF none 
SYD-1552.1 320328 11966 del 
8p23.1-
p23.3 
MYOM2, 
GATA4 
FBXO25, C8orf42, ERICH1, LOC286083, 
DLGAP2, CLN8, MIR596, ARHGEF10, 
KBTBD11, MYOM2, CSMD1, 
LOC100287015, MCPH1, ANGPT2, 
AGPAT5, MIR4659A, MIR4659B, XKR5, 
LOC100652791, DEFB1, DEFA6, DEFA4, 
DEFA10P, DEFA1, DEFA1B, DEFT1P2, 
DEFT1P, DEFA3, DEFA5, LOC349196, 
FAM66B, DEFB109P1B, USP17L1P, 
USP17L4, ZNF705G, DEFB4B, 
DEFB103B, DEFB103A, SPAG11B, 
DEFB104B, DEFB104A, DEFB106A, 
DEFB106B, DEFB105B, DEFB105A, 
DEFB107A, DEFB107B, FAM90A7P, 
FAM90A10P, SPAG11A, DEFB4A, 
LOC100132396, FAM66E, USP17L8, 
USP17L3, MIR548I3, FLJ10661, SGK223, 
CLDN23, MFHAS1, ERI1, MIR4660, 
PPP1R3B, LOC157273, TNKS, MIR597, 
LOC157627, MIR124-1, MSRA, PRSS55, 
RP1L1, MIR4286, C8orf74, SOX7, PINX1, 
MIR1322, XKR6, MIR598, MTMR9, 
SLC35G5, TDH, C8orf12, FAM167A, BLK, 
LINC00208, GATA4, NEIL2, FDFT1, 
CTSB, DEFB136, DEFB135, DEFB134, 
DEFB130, LOC100133267, ZNF705D, 
FAM66D, LOC392196, USP17L7, 
USP17L2, FAM90A2P, FAM86B1, 
FAM66A, LOC649352 
103 M <1 AVSD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
none 
CHA-91.1* 173538773 6551 del 
4q34.1-
q34.3 
HAND2, 
HMGB2, 
VEGFC 
GALNTL6, GALNT7, HMGB2, SAP30, 
SCRG1, HAND2, NBLA00301, FBXO8, 
CEP44, MIR4276, HPGD, GLRA3, 
ADAM29, GPM6A, MIR1267, WDR17, 
SPATA4, ASB5, SPCS3, VEGFC, NEIL3, 
AGA, LOC285501 
23 M 10 TOF 
Bilateral 
cryptorchidism 
CHA-349.1* 239497749 491 dup 2q37.3 HDAC4 
FLJ43879, HDAC4, MIR4440, MIR4441, 
MGC16025, MIR4269, MIR2467 
7 M 40 TOF 
Imperforate anus, 
duodenal atresia 
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SYD-1522.1 859306 445 dup 1p36.33 HES4, DVL1 
SAMD11, NOC2L, KLHL17, PLEKHN1, 
C1orf170, HES4, ISG15, AGRN, RNF223, 
C1orf159, LOC254099, MIR200B, 
MIR200A, MIR429, TTLL10, TNFRSF18, 
TNFRSF4, SDF4, B3GALT6, FAM132A, 
UBE2J2, SCNN1D, ACAP3, PUSL1, 
CPSF3L, GLTPD1, TAS1R3, DVL1, 
MXRA8, AURKAIP1 
30 F <1 PS 
Fetal abnormality,  
Twin-to-twin 
transfusion 
syndrome,   
CHA-812.1* 53595383 855 dup 12q13.2 ITGA7 
KIAA0748, NEUROD4, OR9K2, OR10A7, 
OR6C74, OR6C6, OR6C1, OR6C3, 
OR6C75, OR6C65, OR6C76, OR6C2, 
OR6C70, OR6C68, OR6C4, OR10P1, 
METTL7B, ITGA7, BLOC1S1-RDH5, 
BLOC1S1, RDH5, CD63, GDF11, SARNP 
24 M 8 TOF Asthma 
CHA-581.1 128942356 539 del 6q22.33 LAMA2 LAMA2 1 M 19 TOF none 
OX-439.1 81631178 7098 del 
10q22.3-
q23.2 
LDB3, 
BMPR1A 
LOC100288974, MBL1P, SFTPD, 
LOC219347, C10orf57, PLAC9, ANXA11, 
LOC439990, MAT1A, DYDC1, DYDC2, 
FAM213A, TSPAN14, SH2D4B, NRG3, 
GHITM, C10orf99, CDHR1, LRIT2, LRIT1, 
RGR, LOC170425, FAM190B, 
LOC100507470, GRID1, MIR346, WAPAL, 
OPN4, LDB3, BMPR1A, MMRN2, SNCG, 
C10orf116, AGAP11 
34 F NA Other 
                                                                           
 
 
 
none 
FCH-453.8 114737218 270 dup 12q24.21 MED13L MED13L 1 M 6 VSD none 
NOTT-774.1 4845715 361 del 
4p16.1-
p16.2 
MSX1 MSX1, CYTL1, STK32B 3 M 75 ASD Hypertension 
FCH-43.1 133815486 1909 del 7q33 MTPN 
AKR1B10, AKR1B15, BPGM, CALD1, 
AGBL3, TMEM140, C7orf49, WDR91, 
STRA8, CNOT4, NUP205, C7orf73, 
SLC13A4, FAM180A, MTPN, LUZP6 
16 F 3 ASD none 
FCH-326.1 15192528 1005 del 16p13.11 MYH11 
MPV17L, C16orf45, KIAA0430, NDE1, 
MIR484, MYH11, FOPNL, ABCC1, ABCC6 
9 F 30 ASD none 
SYD-1982.1 15192528 1005 dup 16p13.11 MYH11 
MPV17L, C16orf45, KIAA0430, NDE1, 
MIR484, MYH11, FOPNL, ABCC1, ABCC6 
9 F <1 VSD 
Neonatal disorder, 
premature birth  
NOTT-528.1 15192528 1005 dup 16p13.11 MYH11 
MPV17L, C16orf45, KIAA0430, NDE1, 
MIR484, MYH11, FOPNL, ABCC1, ABCC6 
9 M <1 
TAPV
D 
none 
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ERL-
12882.1* 
15387380 418 dup 16p13.11 MYH11 
MPV17L, C16orf45, KIAA0430, NDE1, 
MIR484, MYH11 
6 F NA TOF none 
LEU-93.1 15387380 546 dup 16p13.11 MYH11 
MPV17L, C16orf45, KIAA0430, NDE1, 
MIR484, MYH11, FOPNL 
7 F <1 CoA none 
FCH-553.1* 42599821 178 del 17q21.32 MYL4 CDC27, MYL4, ITGB3, C17orf57 4 M <1 TOF none 
GOCHD-
1978.1 
615962 128 dup 4p16.3 MYL5 PDE6B, ATP5I, MYL5, MFSD7, PCGF3 5 M NA TGA none 
CHA-50.1* 3147104 163 del 18p11.31 MYOM1 MYOM1, MYL12A, MYL12B 3 M 18 TOF none 
FCH-306.1* 197172067 1627 del 3q29 NCBP2 
SDHAP1, TFRC, LOC401109, ZDHHC19, 
OSTalpha, PCYT1A, TCTEX1D2, 
TM4SF19-TCTEX1D2, TM4SF19, UBXN7, 
RNF168, C3orf43, WDR53, FBXO45, 
LRRC33, CEP19, PIGX, PAK2, SENP5, 
NCBP2, LOC152217, PIGZ, MFI2, MFI2-
AS1, DLG1, MIR4797, LOC100507086, 
BDH1 
28 M <1 TOF none 
LEU-78.1 99846751 137 dup 15q26.3 PCSK6 PCSK6 1 M <1 PS none 
CHA-110.1 71194152 119 dup 1p31.1 PTGER3 PTGER3, ZRANB2-AS1, ZRANB2, MIR186 4 M 13 TOF 
Unilateral 
cryptorchidism 
LEU-45.1 65454131 12970 del 
1p31.1-
p31.3 
PTGER3 
AK4, DNAJC6, LEPROT, LEPR, PDE4B, 
SGIP1, MIR3117, TCTEX1D1, INSL5, 
WDR78, MIER1, SLC35D1, C1orf141, 
IL23R, IL12RB2, SERBP1, GADD45A, 
GNG12, LOC100289178, DIRAS3, WLS, 
MIR1262, RPE65, DEPDC1, LRRC7, 
PIN1P1, LRRC40, SRSF11, ANKRD13C, 
HHLA3, CTH, PTGER3, ZRANB2-AS1, 
ZRANB2, MIR186, ZRANB2-AS2, NEGR1, 
NEGR1-IT1, LRRIQ3, FPGT-TNNI3K, 
FPGT, TNNI3K, C1orf173, CRYZ, TYW3, 
LHX8, SLC44A5, ACADM, RABGGTB, 
SNORD45C, SNORD45A, SNORD45B, 
MSH4, ASB17, ST6GALNAC3, 
ST6GALNAC5, PIGK, AK5, ZZZ3, USP33, 
FAM73A, NEXN, FUBP1, DNAJB4, GIPC2 
65 F <1 CAT 
asymmetric thymus, 
mild facial 
dysmorphism 
CHA-793.1* 49540120 355 dup 20q13.2 SALL4 NFATC2, ATP9A, SALL4 3 M 8 TOF none 
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NOTT-383.1 49552249 934 dup 20q13.2 SALL4 NFATC2, ATP9A, SALL4, ZFP64 4 M 7 VSD asthma 
GOCHD-
2460.1 
22466143 1347 del 13q12.12 SGCG 
SGCG, SACS, LINC00327, TNFRSF19, 
MIPEP, C1QTNF9B-AS1, C1QTNF9B, 
SPATA13, MIR2276, C1QTNF9 
10 F NA TGA none 
GOCHD-
1277.1 
40075710 172 del 2p22.1 SLC8A1 LOC100128590, SLC8A1 2 F <1 TOF none 
GOCHD-
2090.1 
88103373 498 dup 2p11.2 SMYD1 
KRCC1, SMYD1, MIR4780, FABP1, 
THNSL2, FOXI3 
6 F <1 TOF none 
SYD-1387.1 87127381 263 del 
16q24.2-
q24.3 
ZFPM1 
ZFPM1, ZC3H18, IL17C, CYBA, MVD, 
MGC23284, SNAI3, RNF166, CTU2, 
PIEZO1, MIR4722 
11 F <1 ASD none 
 
§ Patient’s age at the time of recruitment. * Confirmed with Affymetrix 6.0, CGH or MLPA. CN = copy number, del = deletion, dup = duplication. ASD = atrial septal defect, AVSD = 
atrioventricular septal defect, AS = aortic stenosis, BAV = bicuspid arterial vave, VSD = ventricular septal defect, MV = mitral valve anomaly, TGA = transposition of the great artery, 
PS = pulmonary stenosis, TAPVD = total anomalous pulmonary venouos drainage, CoA = coarctation of the aorta, CAT = truncus arteriosus. 
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Figure 7.1 - CNVs spanning GATA4 in 2256 CHD patients 
(A) Four deletions encompassing GATA4 were identified in one patient with 
atrioventricular septal defect (AVSD), one patient with ventricular septal defect (VSD) 
and two patients with TOF (shown as red bars). The smallest deletion encompasses 
the last 5 exons of GATA4 as well as the whole coding regions of NEIL2 and FDFT1 
(shown in B). In addition, a duplication was identified in a patient with bicuspid aortic 
valve with aortic regurgitation (blue bar). The parental samples of these probands are 
not available for analysis. Only two deletions were recurrent (mediated by the SD 
blocks). The remaining CNVs were non-recurrent and generated by mechanisms that 
are not mediated by SD.  
Blue bars represent duplications and red bars represent deletions. 
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Figure 7.2 –CNVs spanning MYH11 in 2256 CHD patients 
Four duplications encompassing MYH11 at 16p13.11 were identified in patients with 
TOF, coarctation of the aorta (CoA), ventricular septal defect (VSD) and total 
anomalous pulmonary venous drainage (TAPVD). One deletion encompassing 
MYH11 was found in a patient with atrial septal defect (ASD). All CNVs identified at 
this locus have recurrent breakpoints (mediated by the flanking segmental 
duplications, as shown).  
Blue bars represent duplications and red bars represent deletions.  
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7.3 Discussion 
This thesis has previously established that rare genic CNVs as a whole play a 
significant role in CHD pathogenesis. An exploratory investigation of such CNVs 
that overlap the genomic spans of 400 autosomal candidate genes of 2256 
CHD patients resulted in 39 rare CNVs that are likely to contribute to disease 
risk on the basis of their rarity and involvement of 34 genes that have been 
previously shown or predicted to cause CHD either in humans or animal models 
or both. Recurrent CNVs were observed in GATA4 (MIM 600576), MYH11 
(MIM160745), PTGER3 (MIM 176806) and SALL4 (MIM 607343).  
Deletion of a 5Mb region at 8p23 that encompasses GATA4 has previously 
been associated with multiple malformations that include CHD (Marino et al., 
1999, Pehlivan et al., 1999, Giglio et al., 2000, Devriendt et al., 1999). GATA4 is 
a transcription factor essential for cardiac development (Molkentin et al., 1997, 
Kuo et al., 1997). Multiple studies have identified GATA4 missense mutations in 
isolated CHD, including highly penetrant mutations that cause CHD in 
Mendelian fashion (Garg et al., 2003, Moskowitz et al., 2011, Tomita-Mitchell et 
al., 2007, Butler et al., 2010). In this study, four deletions and one duplication 
encompassing GATA4 were observed in 2256 CHD cases. This finding didn’t 
reach statistical significance when compared to controls (5/2256 vs. 0/1538; P = 
0.08). However, Cooper et al. recently reported three deletions and one 
duplication that spanned GATA4 in 575 CHD patients, while no deletions or 
duplications encompassing GATA4 were found in their 8329 controls (5/575 vs. 
0/8329; P = 1.7 x 10-5 by Fisher’s two-tailed exact test) (Cooper et al., 2011). 
There are also no reports of CNVs overlapping GATA4 in any of the control 
populations that have been catalogued in the Database of Genomic Variants 
(Iafrate et al., 2004). Thus, considering these data in the context of the 
previously demonstrated causative nature of GATA4 missense mutations in 
CHD, the CHD phenotypes observed in the five patients described in this 
chapter are highly likely to result from dosage sensitivity of GATA4.  
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Figure 7.3 – Rare CNVs spanning candidate genes SALL4 and PTGER3 
Duplications spanning SALL4 at chromosome 20p13.2 were found in a patient with 
TOF and a patient with ventricular septal defect (VSD), as shown in (A). At the 
1p31.1 locus, a 13Mb deletion in a patient with truncus arteriosus was found 
spanning 65 RefSeq genes, including PTGER3, one of the candidate genes for CHD 
– see (B); only the ~1Mb span around PTGER3 is shown. An overlapping 
duplication that span a single gene i.e. PTGER3 was additionally found in a patient 
with TOF.  
Blue bars represent duplications and red bars represent deletions.  
A
B
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Five CNVs (four duplications and one deletion) were also identified spanning 
MYH11, a strong candidate gene for CHD. MYH11 mutations have been shown 
to result in syndromic familial and isolated sporadic form of thoracic aortic 
aneurysm and aortic dissection with patent ductus arteriosus (Zhu et al., 2006, 
Zhu et al., 2007, Glancy et al., 2001, Pannu et al., 2007). The gene, which 
encodes a smooth muscle heavy chain, is located at chromosome 16p13.11, 
within a genomic span that is a recognized hotspot for homologous 
recombination that has been associated with intellectual disability, autism, 
schizophrenia and idiopathic generalized epilepsies (Hannes et al., 2009, de 
Kovel et al., 2010, Mefford et al., 2010, Sahoo et al., 2011). All of the CNVs 
observed in CHD patients that encompassed MYH11 shared the same 
breakpoints as most of the CNVs reported in those studies, due the role of SD-
mediated homologous recombination in their formation. However, none of the 
patients identified in this study had any of the associated phenotypes that were 
reported in the previous studies, although two of the duplicated patients were 
recruited when they were newborns, thus most of these phenotypes may not be 
evident at the time they were recruited to the study. However, recently Cooper 
et al. observed 12 duplications and 3 deletions in 8329 controls (that correspond 
to a frequency of 0.1% and 0.04%, respectively). They did not observe any 
16p13.11 CNV among the 575 patients with CHD as a component of the 
phenotype. It is possible that this is due to the difference in patient 
ascertainment, as mentioned in the previous chapters of this thesis. However, 
the observed frequency of duplications and deletions in 2256 CHD patients in 
the present study is 0.2% and 0.04%, respectively, thus closely resembling the 
observed control frequency in the study by Cooper and colleagues (Cooper et 
al., 2011). Therefore, considered together, all the data offer no support in 
suggesting the involvement of 16p13.11 CNVs in CHD risk (P = 0.54 and P = 
0.59 for 16p13.11 duplications and deletions, respectively).   
Additionally, a duplication and a deletion spanning PTGER3, which encodes a 
prostaglandin E receptor, were observed in patients with TOF and truncus 
arteriosus, respectively. The gene’s candidacy was mainly based on the 
overexpression data of Ptger3 in mice, which was shown to result in marked 
myocardial hypertrophy, thought to be mediated by the calcineurin signaling 
Chapter 7: Rare CNVs spanning candidate genes 
180 
 
pathway (Meyer-Kirchrath et al., 2009). Duplications spanning another 
candidate gene, SALL4, which encodes a putative zinc finger transcription 
factor, were also observed in patients with TOF and ventricular septal defect 
(VSD). Mutations in SALL4, including intragenic small duplications and deletions 
as well as deletions that spanned the whole gene, were previously shown to 
cause syndromic TOF and VSD (Borozdin et al., 2004, Kohlhase et al., 2002, 
Kohlhase et al., 2003). There has been only one unconfirmed deletion report at 
the Database of Genomic Variants (Iafrate et al., 2004), which is likely to be a 
false discovery. And no CNV spanning SALL4 was observed in the 1538 
controls at the present study, as well as in 8329 controls reported by Cooper et 
al. Therefore, these duplications encompassing SALL4 are likely to contribute to 
the causal genetic risk for CHD in these patients. In contrast to CNVs spanning 
GATA4 at chromosome 8p23.1 and MYH11 at chromosome 16p13.11, all of the 
breakpoints of the rare CNVs overlapping PTGER3 and SALL4 were non-
recurrent, due to their generating mechanisms that were not mediated by SD.  
Of note, the analysis presented in this chapter captured the two largest CNVs in 
the dataset. They were of macroscopic size (~12Mb) and located at regions in 
chromosome 8p23 and 1p31 that span 103 and 65 genes, respectively. In both 
of these cases, the patients were recruited as newborns. It is very likely, 
therefore, that these are in fact syndromic cases with multisystem involvements 
that were not recognized at the time of the patients’ recruitments. As discussed 
in chapter 3, this “contamination” is expected, due to the fact that this study 
recruited CHD patients from all age group (newborns, paediatrics and adults) in 
order not to be bias in recruiting only certain spectrum of sporadic CHD cases 
that favour survival. But as previously discussed at section 4.4.2, this 
contamination is likely to be minimal.    
In conclusion, this chapter highlight some rare CNV loci, including some single-
occurrence CNV loci, that are likely to pose CHD risk but could not be identified 
by any of the other means used in the previous chapters of this thesis, due to 
the lack of statistical power to assess exceedingly rare events. The hypothesis 
for their contribution to CHD risk was based on their overlap with known 
candidate genes for CHD, as well as by the rareness of the events, which has 
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been previously shown to pose significant risk for CHD. After excluding MYH11 
CNVs (for which the combined evidence are pointing against their candidacy as 
risk CNV loci associated to CHD), this chapter thus presents 34 rare CNVs 
(mostly singletons) for consideration as high-risk loci for human CHD that 
maybe adopted in a prioritization algorithm for interpreting exome sequencing 
studies or for future development of diagnosis algorithms for clinical 
applications. Additionally, these findings may also be subjected for future 
replication studies when larger cohorts become available. Of interest, only two 
(NFATC1 and WNT7B) out of thirteen Wnt signalling genes identified in Chapter 
4 were among the candidate genes included in the analysis performed for this 
chapter. This was due to the fact that the candidate genes list was compiled 
prior to the attainment of the result from the GREAT analysis (McLean et al., 
2010).  Future candidate genes studies for CHD should therefore include the 
remaining Wnt signalling genes (see Chapter 4, page 86) that were found to be 
implicated in rare deletions that were shown to pose disease risk to CHD 
patients. 
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8 General discussion and future directions  
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CHD is the second leading cause of neonatal mortality and morbidity in the 
Western world, as well as the most commonly found congenital anomaly. Since 
the completion of the Human Genome Project in 2003, extraordinary advances 
have been made in the understanding of human genetic variation and its 
contribution to disease traits, including CHD. But currently, the genetic aetiology 
of highly heritable complex CHD traits that constitute ~80% of the CHD cases 
remains largely unknown. In the past decade, the exponential growth of the 
microarray technology has facilitated the newly found appreciation of the 
landscape of structural variation in the human genome, particularly in the class 
of submicroscopic variants that can alter gene dosage, i.e. CNVs, which 
account for ~20% of the genome. This thesis thus aims to test the hypothesis 
that CNVs are likely to contribute significantly to the genetic susceptibility of 
sporadic CHD.  
This thesis work examined sporadic CHD patients, trio TOF families and 
ancestry-matched controls that were typed on the Illumina 660W-Q SNP 
platform. Genome-wide CNV analyses were conducted on 2256 CHD patients, 
841 unrelated controls and 697 unaffected family members of CHD probands, 
using highly stringent measures that were followed by an extensive validation 
study and the identification of unreliable regions for exclusion. Rare de novo 
CNVs were also identified in 283 TOF trio families, using a lower stringency in 
order to maximize capture, but all putative de novo CNV calls were subjected to 
confirmation by Affymetrix 6.0, CGH or MLPA. Functional annotation analyses 
were subsequently performed on all CNVs and candidate genes analysis was 
conducted to facilitate further interpretation of the CNVs. 
 The findings of this thesis work can be summarized as below: 
1) The global CNV study shows that rare genic deletions are significantly 
enriched in sporadic CHD patients. These rare deletions have higher 
gene content compared to those of healthy controls. The genes spanned 
by rare deletions in CHD are also associated with higher 
haploinsufficiency scores and the Wnt signalling pathway, which has 
been previously shown to have critical roles in cardiac development. In 
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contrast, there is no evidence for duplication enrichment in CHD. 
However, the number of genes that span the rare duplications in CHD is 
also significantly higher than controls.  
2) This work also establishes a genome-wide rare de novo CNV burden of 
~5% in 283 TOF family trios. These rare de novo CNV occurrences 
implicate candidate (e.g. GJA5 and HAND2) as well as novel loci (e.g. 
EDIL3 and CNOT6) for CHD. Significant paternal origin bias is observed 
in these rare de novo CNV occurrences, in line with the finding that the 
majority (~85%) of the rare de novo CNVs identified in TOF trios are 
generated by non SD-mediated CNV formation events, known to be 
largely composed of DNA repair mechanisms that occur during mitosis, 
and thus subject for an upward bias in the rate of CNV formation in male 
germ lines.  
3) Locus-specific enrichments in CHD vs. controls are found in two loci: 
1q21.1 and 15q11.2. Phenotype-specific effect is observed in the 
recurrent rearrangements of chromosome 1q21.1: duplications are 
associated with TOF, while deletions are associated with non-TOF CHD. 
Duplications of the GJA5 gene within the critical region of 1q21.1 also 
pose risk for TOF, thus identifying GJA5 as the critical gene for CHD in 
this locus. This thesis also reports an association of 15q11.2 deletions 
that encompass TUBGCP5, CYF1P1, NIPA2 and NIPA1 with CHD risk. 
However, the critical gene for the CHD phenotype within the deletion 
locus is currently unknown. 
4) Previously proposed candidate genes are implicated in rare CNVs that 
confer risk to CHD. Rare CNVs are found to span GATA4 (n=5), 
PTGER3 (n=2) and SALL4 (n=2). Other candidate genes for CHD 
spanned by single occurrence CNVs include BMPR1A, BMPR1B, 
CECR1, DSCAM, EGLN1, ERBB4, FKTN, FOXC1, HDAC4, HES4, 
DVL1, ITGA7, LAMA2, LDB3, MED13L, MSX1, MTPN, MYL4, MYL5, 
MYOM1, MYOM2, PCSK6, SGCG, SLC8A1, SMYD1 and ZFPM1. 
Additionally, recurrent rare CNVs at a genomic hotspot in chromosome 
Chapter 8: General Discussion 
185 
 
16p13.11, which encompasses one of the candidate genes, MYH11, are 
observed. However, a published study reported a nearly identical 
frequency of 16p13.11 CNVs in 8329 healthy controls (Cooper et al., 
2011). Thus, taking all the data into account, evidence suggests that 
16p13.11 CNVs spanning MYH11 are unlikely to pose risk to CHD.   
This thesis describes a comprehensive CNV study in the largest cohort of 
patients recruited on the basis of CHD to date. CNV discovery in both cases 
and controls were performed on DNA samples that have been genotyped on the 
same SNP platform at the same genotyping centre.  Stringent pipelines were 
adopted to ensure that all samples that originated from multiple centres are 
comparable in sensitivity and reliability of CNV detection. However, by 
effectively reducing the false-positive discoveries, this study also increases the 
rate of false-negative discoveries. Many smaller CNVs with lower confidence 
scores are not accounted for. And because the study mainly focuses on CNVs 
>100kb, most of the genic CNVs identified encompass multiple genes, and thus 
causing a greater challenge in indentifying critical genes that pose disease risk. 
Furthermore, due to the limitation of the detection algorithm used in this study, 
only autosomal CNVs were analyzed, while many candidate genes for CHD are 
known to map to the X chromosome. And as with the majority of CNV detection 
methods, the technology used in this study is less reliable in detecting 
duplications, common CNV loci and certain regions in the genome with 
sequences that are high in GC content. The extent of the data from such loci 
that are missed by CNV detection methods used in this study is not known, and 
thus it is not clear whether those CNVs not accounted for are in fact constitutes 
risks for CHD.  
Moreover, the methodologies used in this work generally cannot differentiate 
between germline and somatic mutations. And depending on the percentage of 
cells that are affected, somatic CNVs are also likely to escape detection. Since 
the cohort under study here is composed mainly of paediatric cases (see Figure 
3.4), the occurrence of somatic events in this data series is likely to be minimal. 
However, a small number of CNVs observed in this study is expected to result 
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from somatic, rather than germline mutations, and it is possible that some 
pathogenic CNVs resulting from the somatic events have missed detection. A 
report of chromosomal mosaicism in a pair of monozygous twins discordant for 
CHD was recently described (Breckpot et al., 2012). Somatic CNV mutations 
are common, and known to accumulate throughout life (Flores et al., 2007, 
Fischer et al., 2012), as also evident from the discordance of CNV profiles 
observed in both concordant and discordant monozygous twin pairs for a 
neurodegenerative phenotype (Bruder et al., 2008). The majority of somatic 
mutations are believed to have no major phenotypic consequence, but certain 
mutations that occur in specific tissues or specific developmental stage, 
especially those occurring in pathogenic regions of the genome can have 
serious phenotypic consequences (Notini et al., 2008).  
In addition, the patient recruitment design that is inclusive for all age groups, 
while ensuring the inclusion of the complete spectrum of CHD phenotypes, also 
predisposes the cohort to “contamination” with syndromic CHD cases. Some of 
the cases with CHD that are caused by well-established chromosomal disorders 
and classical syndromic phenotypes (e.g. DGS and WBS) can be readily 
screened and such cases are excluded from the analyses. However, other 
“less-established” causative genetic factors for general syndromic features 
cannot be systematically excluded. It is difficult to determine whether all CNVs 
>5Mb (that are classified as macroscopic CNVs) cause syndromic CHD. Such 
CNVs in non-syndromic CHD cases have been reported in a study when upon 
finding such CNVs, patients were re-evaluated for possible syndromic features 
(Greenway et al., 2009). In this study, CNVs >5Mb were identified in 5/2256 
CHD cases, as well as in 1 of the 1538 reportedly healthy controls. The two 
largest CNVs found in CHD cases are likely to exhibit syndromic phenotypes 
(based on the size (12Mb) and the fact that they were recruited as newborns). 
This work establishes the contribution of global rare CNVs collectively to the risk 
of sporadic CHD. However, the bulk of the findings constitute single occurrence 
CNVs, whose associations to CHD at each individual locus cannot be 
statistically evaluated. With the exception of the regions in chromosome 1q21.1 
and 15q11.2, it is likely that the individual contribution of the remaining risk loci 
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will not be able to be ascertained until large-scale meta-analyses of tens of 
thousands of participants can be conducted. As this work has shown, recurrent 
CNVs that spanned individual genes provide a very useful tool to identify strong 
novel candidate genes for CHD (EDIL3 and CNOT6). However, since CNVs that 
can be reliably detected are relatively large, the majority of the observed 
smallest regions of overlap (see Figure 1.4) in these CNVs span multiple genes. 
Functional studies to characterize the role of the genes that are spanned by 
these CNVs will help in identifying further causative genes for CHD; among the 
targets for such studies, genes with strong characteristics to be dosage-
sensitive (high haploinsufficiency scores) are of particular interest.  
Although this work has made substantial contributions to the understanding of 
the genetic aetiology of sporadic CHD, the extent of which that can be 
translated into clinical practice is currently limited. The identification of CHD risk 
that is attributed to GJA5 dosage alteration has led to the hypothesis that TOF 
patients with such CNVs maybe at greater risk to develop atrial fibrillation (as 
discussed in chapter 5). Proving this hypothesis may open a new window of 
opportunity to identify TOF patients with elevated risk to develop this condition 
that may lead to a more advanced care in the patient population with 
duplications in the 1q21.1 locus (which account for ~1% of all TOF cases). This 
work also identifies a paternal origin bias in the rare de novo CNV events 
observed in sporadic CHD patients. Such bias had been observed in other 
developmental phenotypes, but not in non-pathogenic and non-developmental 
disease traits (Itsara et al., 2010, Hehir-Kwa et al., 2011, Sibbons et al., 2012). 
This finding has some important implications, particularly because the paternal 
origin bias is further associated with rare de novo CNV formations that are non 
SD-mediated (not mediated by NAHR), thus highly indicative of the involvement 
of DNA repair mechanisms that occur during mitotic divisions in the generation 
of these rare de novo CNV events that pose risk to complex developmental 
phenotypes. Most known genomic disorders are associated with NAHR events 
in the known rearrangement hotspots, which comprise the majority of what is 
known about the genetic aetiology in developmental phenotypes (see Figure 
1.2). Yet the role of NAHR hotspots in the risk for sporadic CHD is minimal; 
1q21.1 and 15q11.2 together account for mere 0.8% of the population 
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attributable risk for CHD.  This raises the possibility that a significant part of the 
aetiology of sporadic CHD may be related to the paternal age or paternal 
genotypes that affect the rate of NHEJ or FoSTeS mechanisms in the rare de 
novo CNV formation during spermatogenesis. Environmental factors, such as 
exposure to agents that cause replicative stress, have also been shown to 
increase the risk for pathogenic rare de novo CNV events. Thus, further 
investigations are needed to examine the possible paternal genetic risks in the 
variants of the genes that encode proteins responsible for such DNA repair 
mechanisms that can lead to pathogenic CNV formations, as well as in the 
paternal risk associated with treatments of certain agents (e.g. aphidicolin and 
hydroxyurea) that have been shown to cause replicative stress and increase in 
CNV formations. 
As the paediatric CHD management has significantly improved in recent years 
(particularly due to the major advancements of surgical treatments in some of 
the most severe forms of CHD), the prevalence of adult CHD patients that reach 
childbearing age has also dramatically increased (Marelli et al., 2007). 
Therefore, currently there is an urgent need for rapid translations of what has 
been learned from the genomic studies that has flourished in the past decade 
(including from this work in sporadic CHD) to genetic counselling practice. One 
can also foresee as the $1000 genome is expected to hit the genetic market in 
imminent future, there will be concrete demands for the developments of 
genetic diagnosis algorithm or prioritization/prediction algorithm that will largely 
depend on an up-to-date sophisticated knowledge base. The findings from this 
work, e.g. in chromosome 1q21.1 and 15q11.2, as well as the rarer CNVs in 
previously unreported (e.g. EDIL3 and CNOT6) and candidate loci (e.g. GATA4 
and SALL4) that are highly indicative to pose risk to sporadic CHD, can be 
incorporated into such knowledge base that should be adaptable as more data 
from future genomics and functional studies become available. Such algorithms 
will also depend on another knowledge base for genetic variant occurrences in 
healthy controls. Unfortunately, the largest of such database for CNVs, i.e. the 
Database of Genomic Variants (DGV), which is largely used to aid CNV 
interpretation in diagnostic settings, currently contains many artefacts, due to 
the fact that the database simply serves as a compilation of collections of 
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published data, most of which have not been validated (and some of which 
failed to validate; see Figure 6.4). This makes the utilization of the DGV in an 
automated (non-curated) manner impossible, while adequate interpretation of 
the DGV data can only be performed with certain levels of expertise and 
knowledge in the different limitations of various CNV detection methods. 
Therefore, there is also an urgent need for the development of a superior 
database for CNV data in healthy control populations.  
Finally, with the arrival of the era of next-generation sequencing, genomic 
studies can now investigate the whole spectrum of human genetic variation 
encompassing all levels of sequence and structural variation. And coupled with 
the concurrent emergence of the next-generation high-throughput functional 
profiling studies, they will likely to provide an ever more superior and 
comprehensive picture of the genotype-phenotype correlations in human 
complex traits, including sporadic CHD. Such improvements will be critical in 
paving the way for an era of “genomic medicine” that will undoubtedly 
revolutionize patients care in the years to come.  
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Appendix: maximum likelihood estimation for GJA5 duplications 
A.4 Calculation of exact test for small duplications in GJA5, allowing for 
the relationship between two TOF individuals (from Soemedi et al., 
2012) 
A maximum-likelihood based exact test for the observation that small 
duplications involving the GJA5 gene are commoner in cases of TOF than in 
controls was constructed by Prof. Heather J. Cordell as follows: Given 949 TOF 
cases, of which 3 possess the duplication, and 6760 controls, of which 2 
possess the duplication, then assuming all individuals are independent, the 
likelihood of the data under the alternative hypothesis can be written as: 
 
   
 
            
    
 
             
where   and   are parameters representing the probability of possessing the 
duplication in cases and controls respectively. The likelihood may be maximised 
to generate maximum likelihood estimates   =3/949 and  =2/6760 respectively. 
The likelihood of the data under the null hypothesis may be obtained from the 
same expression by assuming that    . The null likelihood can similarly be 
maximised, and a comparison of twice the difference between the maximised 
log likelihoods (under the alternative and null hypothesis respectively) to a chi-
squared on 1 degree of freedom generates a test of the null hypothesis. 
This test may be adapted to allow for the fact that two of the TOF individuals are 
distantly related. The relationship between the individuals may be modelled via 
their estimated genome-wide IBD sharing, the proportion of the genome over 
which they share 0, 1 or 2 alleles identical by descent (IBD) i.e. inherited from a 
common ancestor. Unrelated outbred individuals would be expected to share 0, 
1 or 2 alleles IBD with probabilities (1, 0, 0) respectively. Using genotype data 
from 41692 autosomal SNPs (selected from the original SNPs typed on the 
Illumina 660W-Quad platform to have high minor allele frequencies and to show 
low levels of inter-SNP LD) we used the “- - Z-genome” command in the 
computer program PLINK(Purcell et al., 2007) to estimate the (0, 1 ,2) IBD 
sharing probabilities between the two distantly-related TOF individuals as 
Appendix: maximum likelihood estimation for GJA5 duplications 
232 
 
(0.9501, 0.0350, 0.0059). The overall likelihood of the data may therefore be 
written as  
 
    
 
                                         
where   ,   ,   , are the likelihood contributions for the cases, assuming that the 
two distantly-related TOF individuals share 0, 1 or 2 alleles IBD. If the two 
distantly-related TOF individuals share 0 alleles IBD, they are equivalent to 
unrelated individuals, and the overall case likelihood contribution is    
    
 
            as before. If the two distantly-related TOF individuals share 2 
alleles IBD, they are equivalent to monozygotic twins, and they must either both 
possess the duplication (which occurs with probability  ), or neither possess the 
duplication (which occurs with probability    ). If both have the duplication 
then one other case out of the remaining 947 cases must also have the 
duplication, while if neither has the duplication then three out of the remaining 
947 cases must have the duplication. Thus the likelihood contribution is: 
     
   
 
                  
   
 
           
  
   
 
             
   
 
            
If the two distantly-related TOF individuals share 1 allele IBD, then they must 
have some probability of both sharing the duplication, some probability of one 
having the duplication and the other not, and some probability of neither having 
the duplication. Denote by (a, b, c) the alleles in the two individuals, where b is 
the allele shared IBD. Denote by    the probability that a particular allele in an 
individual contains the duplication, so that              (assuming that 
duplications occur independently on the maternal/paternal alleles of an 
individual). We therefore have             . The likelihood    is composed 
of 8 terms corresponding to the situation where none of (a, b, c) contain the 
duplication, a is duplicated only, b is duplicated only, c is duplicated only, a and 
b are duplicated only, a and c are duplicated only, b and c are duplicated only 
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and all three of a, b, c are duplicated, each term occurring with probability 
             where   refers to the number of duplicated alleles. For the 
situation where none of (a, b, c) contain the duplication, the remaining factor in 
the likelihood is     
 
            (corresponding to the fact that three of the 
remaining 947 cases must contain the duplication). For the situations where 
only a or only c is duplicated, the remaining factor in the likelihood is     
 
      
      (corresponding to the fact that two of the remaining 947 cases must 
contain the duplication). For all other situations the remaining factor in the 
likelihood is     
 
            (corresponding to the fact that one of the 
remaining 947 cases must contain the duplication). Thus the likelihood 
contribution is:          
                   
     
 
                        
 
            
                     +                       
 
            
The overall likelihood may be maximized under the null hypothesis (p=q) and 
alternative hypothesis (p, q estimated) as before, and a comparison of twice the 
difference between the maximised log likelihoods to a chi-squared on 1 degree 
of freedom generates a test of the null hypothesis. An estimate of the variance 
of the parameter estimates   and   is provided by the inverse of the negative of 
the Hessian matrix, which can also be used to construct confidence intervals for 
the log odds ratio                                   . 
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A.5 MLPA probes 
Cytoband length Hg18 target LHS RHS 
14q13.2-1 132 
chr14:35095677-
35095766 
CTGCGTCTCAATTAGGAGACAGGCAGGACACCTGGTACTTCTTTA TCTAAGTCCCATGGGCTGCCAGATGACTCAAAATCCATAACAGGT 
14q13.2-2 136 
chr14:35155766-
35155859 
CAGTTTCAGTATAGCAGTAGAGGTAGGAGCTAGGTAGTTCTGAGGTA AGCAAGACAGAAAAAGTGGTATGATTCCTGTTCCCAAGGACTTGACC 
14q13.2-3 140 
chr14:35202433-
35202530 
CTCCTCTCTCTCAACACTTCTAATTCTAGGGACCAATTCAGGTCACATA CAAAGACCATCTGGCAATTACTGTGACAAGCACAACTTCTCAGGACTGT 
14q13.2-4 132 
chr14:35239128-
35239217  
CATCAGAAAGGGGAGTGAGAACAATATCAGGCAAGAAGGGTTTGG AAGTATGGATCAGAACAGGAGCACTTTTAGCACTGCGTATATAGG 
14q13.2-5 140 
chr14:35111333-
35111430 
CTGTTTTAGCTCCTTCTGAACCAGGCTTAGGCAATCCATGTAGCTACCA GGGTCTATGTAACATTTACCCTCAGTTTCACAACTTGATGCCTACTCCA 
16p13.3 116 
chr16:392472-
392545 
GAAATCATTTTTCCGGAAGACCCAGAAGGCCCAGGAA TGCCAGGTTTTGCCCAGCAGCTCTTCATTTTCCTGCA 
16q11.2-1 116 
chr16:45062501-
45062574 
GTTCCAGAATCTGTGGCAGTAGTGATGCCTAGGAGTA CCTGACTGATGGTGAAGGGGGAAAACAAGGGGCCTAA 
16q11.2-2 120 
chr16:45068379-
45068456 
GAATCATTCAGAACAACAATTCCCTGGGGAGAAGGAGAT AGCCGAGATCAAAGAGAACTCAGTCATCTCCAAAGGTGA 
17q22-2 128 
chr17:54246172-
54246257  
GAAGTAGACATATGTACTGGAGGCAACCTAGCTTGGTGTGATG AGCAACAGATTGGAACACAGAGCAGCACTAGGTGTACAGTGTC 
17q22-1 108 
chr17:54127398-
54127463 
TGTACAGCACTGGAACTTCTTGAGCAGGAGCAT ACCCAGGGCTTCATAATCACCTTCTGTTCAGCA 
17q22-4 124 
chr17:54075064-
54075145 
GGTCCTATCTCTGGTCTGGGCCCTTCTATATCTGTCTTCCA TTCTCTAGTCCTCCAATCTTTCTGGAAACCTCTCACCATCC 
17q22-3 112 
chr17:54020094-
54020163  
TTCTTGACAGAACCAAAAGCCCACCAGCCCATCCA GAGGACCTGTTCCCTACTCCCTAAGCCATTCCTAG 
18q11.1-1 116 
chr18:16799804-
16799877 
GCCACACAAGAATGAGGCCAGGGATCACATAGCATAC AGAGAGGAGCTGAATTCATTTCCCACTTTGAGTCCCA 
18q11.1-2 120 
chr18:16840474-
16840551 
GACTTGCTCATCTCTGTGTGACTCTTCCTCAATCTTACA GCTGTGTCCGATTCTGTCCTAAGTAAGTCATTGGCTTCT 
1p36.21-1 136 
chr1:15825783-
15825876 
CCACAGATCATTGGCTTCTTATGGCTTGAAAGATGGGGACGTTGTGA TTTTACGACAGAAGGAGAATGCAGACCCTCGACCTCCAGTGCAGTTC 
1p36.21-2 140 
chr1:15860526-
15860623 
CAGGGCATACAGAATTCAGTAACAGACAGGCCTGAAACCAGAGAAAATG TCTGTCCTGATGCTTCGAGGCCATTACTTGAATATGAACCACCTACCAG 
1q21-1 108 
chr1:145637880-
145637945 
TGCGACGTGTATGTGGTAGCAGTGGACCCAAAC ACCACAGAAAACTTGGGGCAGCCACACAATGGT 
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1q21-2 112 
chr1:145642678-
145642747 
TCTCTTGCTGAGCTTGGAAATCTGGGTGAGGATCA AACAGTCCTTGCTTATGGTTCATATGGGGCTCTGC 
20p12-1 116 
chr20:12099917-
12099990 
GCTGTGTGTGAGATCTGGAGAAAGGGCTGATGCTTGT TGCGTCTCATGATGGAAGACCAGAAGTGCTTAATTAC 
20p12-2 120 
chr20:12108883-
12108960 
GTGCTGGCTGAGTCTTGTCCTGAAAGTCTGTGCTCTTTC AAGCTTCTTGTGTACGTTCCACTCCCCTGGGTTCACGTT 
2p15-1 100 
chr2:61450957-
61451014 
TACCTGTGCTGCAGCCCAAATACAGTCAA TATGTTGAGTACTCAGTCGCCCTTCTGCT 
2p15-2 104 
chr2:61617659-
61617720 
TCACATGCCACTCTGCAAAACCGGAGAGCTT TCGAGTTTCCTTGCTGGAGGAACAGGGAGTC 
2p15-3 108 
chr2:61269274-
61269339 
TGATGCAGCTGTCTACAGTGTGCTCCTCATCAC TGCTAACACGCCGCCTTTTAATGGGAGTTGCTC 
2p15-4 124 
chr2:61492363-
61492444 
GCCTACTCACCATTTAACCATCATACAGTAGTGGCCAACAT CTGAGATGCCCTGACCACAGAGGCCTTCAAATTCACTTTTT 
2p15-5 128 
chr2:61486588-
61486673 
GGTTCTTCTGCTTGATTACTCTCATCTTGCCACGTGGAATCTA TGTTAATGGTAGTACAATGTTTACAAAGCTGGTCCCGGAGCAC 
2p15-6 132 
chr2:61522023-
61522111 
CGAAAGGCAGTAAATTTTGGAGCTTTATGGAGTCCCTGCCCTTCCT GAAAAGGTGGCTGCAGAGAGACTAGAGCTGGTTGGGGGAAGAac 
2p15-7 136 
chr2:61511078-
61511163 
cttaCTTAGGTGACAAAGCACATCAGCAGTTACGACAATGCAGAGTT GGTGGTGGGGCTGATTACAAACAGGAATGAGGAATAACTGGGTaaag 
2p23-1 100 
chr2:26167353-
26167410 
TTGGCCTGAGGCGCTAAAAAGCTGATGGA AAGCAGAGTAGAAAAGGGTGGGGCTTGTC 
2p23-2 104 
chr2:26149787-
26149848  
TTGCCATTGTACTGGGCTTCCCACCATTGTG TTGCCTATGAGCTCAAGCCACAGCCACTGAC 
3p25-1 100 
chr3:12628469-
12628526 
TCTGAACACTGCACAGCACTCTGGTTGCA GGCCCCTCACCTTGAGTGCTTTCATAAGG 
3p25-2 104 
chr3:12659590-
12659651 
TGGTAAGGCAAGACACAACTCCCACCCATAA CACTGCATCTCTGTCCTCAGGCAACAAATCA 
3p25-c 140 
chr3:12593145-
12593242 
CCGTGTGATATCAGAGTTTGTAATTCCAAGTGTGTATTGGGTGGAAGAT CAGAATAAAAAGAACGAGTTGATTGAAGCTTTCAAACAGGGGATGGGGT 
3q29 116 
chr3:197924295-
197924368  
GGACTCCGTGGCAAACTGCTAGTTGTTCGTGCAAGTA GTAGTTGGCAAACTGCTTGTACTACTGAGACGGGCAA 
3q29 120 
chr3:198789918-
198789995  
GAAGGCAGAGTTCAGAGTCATATCCCAAAGGGTGCCAAA GAGAGACATCCCATCAAGACACTGCAATGGCGAGGACAA 
3q29-1 100 
chr3:197341890-
197341947 
TCTGGCTGCTGAACTCTTTCCACCACATC CCTGCTGCTTTGGGCCATCATTTACGTCA 
3q29-2 104 
chr3:197091248-
197091309 
TTTAAGACCTCTGCTCGCCCTGGGTGTAAAG CCAGCTGCTCGTTAAGATGACCATGCGTCCT 
4q35.1-1 108 
chr4:184258306-
184258371 
TAGTGGGTGTGACTGACTTTGCCCCTCAGAGTT TAAAAACGCGCGTTTGGGGGTTTCGCTGTCTGT 
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4q35.1-2 112 
chr4:184277547-
184277616  
TTCCTGCATCCTCGCCTCTTCTTCAGGTCACTATT GAGAATGAACCCTGAAGCACTTGTCCTTTACACAG 
5q13.2-1 116 
chr5:68426302-
68426375 
GTGTCACCATCAGCTCTCTTCAGGCGACGAAACCAAA GTACATACGTGAACTTGGATGTTCAGGGGAACTTGGA 
5q13.2-2 120 
chr5:68459270-
68459347 
GCCTTCCTACTCAGAGCTGCCATACTAGCATCATTCCTA GGTGAGATTTTTTTTCCCCCACACATCTGTAGCCTCCAG 
5q21.3-1 132 
chr5:106297023-
106297112  
CTCCACCTCCTTCTACTTTTCTATTCACATTCTGTGCGGGAGTCT CTTGGTCTATTCATCCTTCTCCTTAAGCATCCCCTGGGTTCCTGT 
5q21.3-2 136 
chr5:106324808-
106324901 
CTTGCTTGAAATCCTGGTCCTGAGTATGCAGGGATCTCACATTCTCT CACGGAAGGTAATGAGCATGGTGCCTGGATATGGAACTGTGACAATT 
6p24.3-1 100 
chr6:7388918-
7388975 
TCTCCTTTGTCTGCATCTGTCTGGTGGTT TTAGTTGAGGATCTTGGGACAAACAGGCT 
6p24.3-2 104 
chr6:7413426-
7413487  
TACTCCTGGGAGAGTTAGGGAGGAAAAGCTT TGCTAAAAGCTGCTGGAAGTAGTGGGTGTCT 
6q15-1 108 
chr6:90622634-
90622699  
TACGGGTTTAAAATGGCTCTTGGGGGACACTGT TGATGCCTTCACAGCTTTTGCCAAAATGACCTA 
6q15-2 112 
chr6:90634246-
90634315 
TCAAGTTGTTCTTCTTCCTGGACAAGCCGATCTGT TGCTCCAGGCTTTCAGTACCACCCTAATCTACCTA 
6q27-1 100 
chr6:167084143-
167084200 
TAGAACATGCCAGGCACGCAGCACAGATG GGTGTCATTGGTCTGGGACATTGCCACGG 
6q27-2 104 
chr6:167062444-
167062505 
TCACTAGCCAGACAGACCAAAGGAGGAAGTG ACTGCTGCAAAAAGTGACCACAGGCTGACAC 
7p21-1  108 
chr7:8948159-
8948224 
TGAAAGTAGAAGTAGCCATTCCCGTTGCCAGAA GGGAGCTGGTAGGCAAAGACAGAAAGTGAAGTA 
7p21-2 112 
chr7:8985344-
8985413 
GCATATGCAGATGCAGGTCAGCAGTGAAGGAATAA AGACTCTTTTCACCTAGAGGATAGCCCTGAACAAC 
7q11.23-1 132 
chr7:73099475-
73099564 
CAAGGAGAGCATGGGAAAGTCATCTGCAGGTATTGAACTCACACA CACACGCTCATGCACAGAGACCCATAGTCCCGATCTGAAGCTATT 
7q11.23-2 144 
chr7:73105277-
73105378 
CTCTCTGATGAGTAGGATCCATGCAGAGGAAATGTCAACCCACCTGCAAT
C 
CTGCATTCAGGACCAACTGTCACTTCCATACTCTACTAACCACCCTTCTAG 
8p23.1-1 100 
chr8:11649427-
11649484  
TGCCTGGCCTAGCACCCACTTTTTGTTTT CAGGGTCCTTGTGTGGATGATAAAGGCTT 
8p23.1-2 104 
chr8:11653353-
11653414 
TGGTCTTGGCCGACAGTCACGGGGACATAAT CACTGCGTAATCTTCCCTCTTCCCTCCTCAA 
8p23.1-3 116 
chr8:11652291-
11652364  
GGAAACAAAGAGAGGGGAGTCCAGGGCTGGCATACAG CATGGGTGGCAGGGGCGGAAAACAACACAGAAGTACA 
8q24.3-1 124 
chr8:144331882-
144331963 
GAGATGGTGATGGGGGCTCAAATGCAACAGTTTAGCAATCC CTGGTCCCGACAAAGCATTAGCAAGGCGAGGGGAGAAATTA 
8q24.3-2 128 
chr8:144326247-
144326332  
CATTCCTGAGTCCCGCATTCTCTTGGGTAAATATTGGGGTACA GAGTTGCCGTGTCCAGAGTTGCTGTGTCCAAAGGTCAAGTAAA 
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8q24.3-3 132 
chr8:145651110-
145651199 
CATGTGGAGAACCGACAGTGAGGACAAAGCCCTCTTTCATGGAAT CCACATCCACATGAACACCACCCGTTACCTGCATTCAATCCTCAA 
9p22.2-1 120 
chr9:17691085-
17691162 
GTGGGCCCACAGAAGAAGAGAGGGTAGAGAGTGAAAATG GAGTCACAAACCCAGCAGAGAATCCTCCCTCTGGTTTCT 
9p22.2-2 124 
chr9:17740208-
17740289 
GCTCAGTGTTCCCAAGCAGACAGAAGAATTGCCTTTCCATA GTTTGTTTTCTGCTCGTCAGGCATTTGGGGTAGAGAGACCT 
9p22.2-3 128 
chr9:17772630-
17772715 
GAGTGGTGTGATCAGATTGTATCAGCAGCCTCTAGTGCCATTC CAAAGCACAGTGGGCGGTCATGGTACTTCTGAACAGGAAAGCT 
CHD1L-1 112 
chr1:145207288-
145207357 
TGCCTTCTCTGTGACTACACTCCCACCCCATTCTA TCCCACTCCACCCCTTCCACAATCATTCTTTCGTT 
CHD1L-2 136 
chr1:145231879-
145231972 
CATGTTGGGTTGGTCATCTAATGGTGGTTCTTTCCAGTTGGCCTTGA TTGTGGCTCAGCATCGTGATCGTTCCAATGTCCTGTCTGGCATTAAG 
FOXH1-1 100 
chr8:145671365-
145671422  
TGGAGGAAAGGTTGTGGCGAATGGAGTCT TTCCAGCCCTCGTAGTCTTCCCTGAAGAA 
FOXH1-
2CpG 
104 
chr8:145671824-
145671885 
TCATGGCCAAGTAGGTGTAGGGGGGCTTGTC ATGTCGCAGGTACCTCTTCTTCCTCCTCTTA 
GATA4-1 108 
chr8:11649875-
11649940 
TGCCTTCTCGCAGCAGGTGTGTGTCTTTCAATG CTGTAGCAGACTACGCAGAAATGGAAAACCCTA 
GATA4-2 112 
chr8:11615150-
11615219 
TAAAATCGAGTGTCTTCCGGCATGCCCCGTGATAG TCATTCAGGCTGACTTTGTCTTTCCCGGTACCACA 
HOXA10 128 
chr7:27176441-
27176526 
CTGGGGCTCCCGAAAGAAATCCTGTTTGGCTTCCTCTGTCTAT GTAGCTCCCCTCTCAACTGAAATCACTGGTCCAAGACAGCCAC 
HOXA5 124 
chr7:27147364-
27147445 
GCTTATAAGAGCCACTTCCAGAGTTCGTGCAAAGGGTCCTA TAAAGGCACGCAGGGACACACCGCTTGGAGTCACAGTTTTC 
NIPA1 116 
chr15:20597162-
20597235 
GGCTTTGTGGTGCTGGGTTAGGGTTAGAATCCTTAAT TGGCCCTACCTTTGATCAATGAGCAGAACAGGAAGCA 
NIPA2 120 
chr15:20579309-
20579386 
GGTCCCACTCTGCTCCCTCTCTCTGTAACTGAAGGTCTA TCACAGCCGGGAGAGCCTGCAACAGAGATATTTTTTCTT 
PPM1K-1 100 
chr4:89406481-
89406538 
TGCCACAGAAGTAGAGGTGGGCGATTATT TGGCTTGGTGGAAAAGGGAAGTTGGGGCA 
PPM1K-2 104 
chr4:89407617-
89407678 
TGCAGGTGAGGAAGAACAGCAGGACCATTTC ACCAGGAGAATTCCATAGCTGGGGTGAAACA 
4q22-1 108 
chr4:89440123-
89440188 
TGTGTGGCAGAGAACAGTGGGGCAAGTAAGAAA CCTCACATCCACTGAAGCCTTAATTGTTGGTCC 
4q22-2 112 
chr4:89437766-
89437835 
GGCTAAGCCCAAAATCAAGAGGCAGGGAAGTTTAC TCTCCATATGACAAGTGTGTGGATGCATGGAGGGT 
HERC6 116 
chr4:89582811-
89582884 
GGCAGGAGAATAGGGTACAGAGATAGGGATCTAAGGA TGACTTGGACACACTCCCTGGCACTGAAGAGTCTGAA 
HERC5 120 
chr4:89607282-
89607359 
GGTTCTGGAAAAGATGGACAACTGGGAAATGGTGGAACA CGTGACCAGCTGATGCCGCTTCCAGTGAAAGTATCATCA 
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GSPM1 124 
chr9:138343908-
138343989 
GTCTCCTCTGCCCCGTCTACTGCCTTCCCACACTGACATTC CTTCCTGGAGAGAGGAGTTTCAGCTTTTAAAATGGGGAACT 
SNAPC4 128 
chr9:138403710-
138403795 
GAGCTGTGAGTTTTGCTTCCAAGGCTTTCTTCCCCACCAAGTC CTTCCCAGCTCGCTACATCACAGGTCTATCTGAGACTCGTTCA 
NOTCH1-
1 
132 
chr9:138553091-
138553180 
CTGAGTGTGGAGCTGTCATCGCTGCATTATTGAGGAAGGCAAGCT AGACGCCCAATCGATTCTGCAAAGCCACATCCTTTCACTATTTAT 
NOTCH1-
2 
136 
chr9:138516866-
138516959 
CTCACCCACTCTCCTCCATCCCGCCCTCCAAAATAAGGTCATTTTCT ACGCGATTAATCAGAATTGCAAACTATCGCTAAATTCTCTCCTGCAC 
5’NOTCH
1 
140 
chr9:138567828-
138567925 
CAAAGCTGGGGGTCCTGAGTGTGGTTGGGGTAACGTCTGGTCCTCCTTA GAACAGTGGGGCTTGGAATTCATTCAAGGGAAGAAGAGTGAAGGAACGC 
Notch1-53 108 
chr9:138533760-
138533825 
TCCACACAGGCACCCCCGTTCTTGCAGTTGTTT CCTGGACAATCGTCGATATTTTCCTCACAGTTC 
Notch1-50 112 
chr9:138509628-
138509695 
tgTGATTGGTACCATGGGTGCACTCTTGGCATACA CACTCCGAGAACACATTTTCACAAGCATGCTTGCA 
9qc-1 116 
chr9:139990147-
139990220 
GAGCTAATCCCCCTCTTCTCCGGCTTCTCCTAGATTT TGCAGAGTTTGTTTTCCTGGGTCTCTTCCTCACAGAG 
9qc-2 120 
chr9:139591527-
139591604 
GAAGTCAGAAAACTCCCATCACTTCCCCGGCTGGAACAT GACAAAGGAAATAAGCCCCAGGTAAAGCACTCCCCAGGT 
Notch1-55 132 
chr9:138553091-
138553180 
CTGAGTGTGGAGCTGTCATCGCTGCATTATTGAGGAAGGCAAGCT AGACGCCCAATCGATTCTGCAAAGCCACATCCTTTCACTATTTAT 
Notch1-51 136 
chr9:138516866-
138516959 
CTCACCCACTCTCCTCCATCCCGCCCTCCAAAATAAGGTCATTTTCT ACGCGATTAATCAGAATTGCAAACTATCGCTAAATTCTCTCCTGCAC 
16q24-dn1 100 
chr16:83860448-
83860505 
TGGGAGGCGAGCGTAATTGACTTGTAACA TACAGACCGTGGCAGGCTGTCATCTGCGT 
16q24-dn2 104 
chr16:83860937-
83860990 
tcaaGTAGGTGGGATGCCTGTGCCCTACACA CACGCCATGTTGATGACCAAGCAGCACaaag 
16q24-5’-2 108 
chr16:83858172-
83858237 
TCTCCCGCTCAGCTAATTATGTGGAAAATTGGA AGAAATTGCACGAGCCTTGGTGGGAAATGAGGT 
16q24-5’-3 112 
chr16:83859403-
83859472 
TGTACTCCCCCCGCAGTCCTCCTCCTGATAATGAT AATGGTCACAGTACAAACACTGCCAGGTCCCCACT 
16q24-1 116 
chr16:83861406-
83861479 
GTGATGATCCCAGTGACCTGCTGCTCTCCCTGTCTGA TGGATAGAGAGAGTCTCCTTCTTGGTGTCCTTCTTCT 
16q24-2 120 
chr16:83861706-
83861783 
GTATTTGTTGGATTGATGTTGCCCTGGGCTGGCTGCTTT GTTAATGCTCTGTCCTGCGTGCGGCCTTGAAGGAAACAC 
6q24.1-1 124 
chr6:139646001-
139646082 
GTACTGCGTTTATTGTAGGAGAAAGTGCAGCCTCAAAAGGA AAAAGAAGTCCTGGGAGCTTAGGTTGTAGAGACATTTCCCA 
6q24.1-2 128 
chr6:139645762-
139645847 
GTGAATGAGCTTTGTTTTTCTCCCAGCCCACATAATGTTGTCA AAGAAGTGATAAATGAGAGATACCTCTGAGCCTGGAGGATGCG 
6q24-c 132 
chr6:139642399-
139642488 
CCATTGGTGTTGTGGGACTAGGGTGCTATGTGAAGTAATCATGGA GGAGGGGAGTAGACAGAGACTTGCTCATCATCTACAAAAGGCTAT 
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16q24-5’ 136 
chr16:83856548-
83856641 
CCTGTGGACCTCACTGCTGACATCGTTGCCCCAGTTCAGGCCAATTC CTGGCCTTTTCTAGAATATGTCCGGACTATATCTCATAACTGGGCAG 
16q24-3’ 140 
chr16:83862429-
83862526 
CGCTCCTGCCTGTTTGACATCTCTGCTCACATGAATGGCTCATCTTCCT CTCAGTCAGCTCCTTGGGGTTTCTGTGGGATGCAGATATATATTCAGAA 
16p-1 100 
chr16:16634989-
16635046 
TGTAACTGGCACTTGAACGTCTCCATCCA AGTGCCCCTTTGTGGCAGATGAAGAGTTC 
16p-2 104 
chr16:16634167-
16634228 
TGCTCAATAAGTGTTGGCTCCTGATTTCCTT CACTCCCAGGAGCTGGTAACTCTCTATTTGT 
16p-3 108 
chr16:16634406-
16634471 
TCCCCATCTCCCTATTCTAGCCAGTATCACAGA ATATGCAACATCTTGACAAACCAAAGGCACTGG 
MYH11 112 
chr16:15732205-
15732274 
TTCGGTACTGCTATTTACCAGCTCCCACTCCCATA CACCGCAAAGAGTTCCAACAACGGGAGAGTGATTT 
NDE1 116 
chr16:15692682-
15692755 
GTAAGGGGAGTGGGAATTGCAGGATTTTCTCGGTTCA CAAAGTGTTTCTGGGTAAGAATCTGGGGTGGGTCCTG 
NDE1-
MYH11 
120 
chr16:15722743-
15722820 
GAAACATGGACGAGAAAAACCACCCAGAGCCACTTACGT TCTTGCCCACGTCATCCTTGGAGCTGACCAGGTCTTCCA 
ABCC6 124 
chr16:16190634-
16190715 
GGACAGCAGAGTTTTTGATCTTGGTAGCCCTGTTGTTCTAG ACGTGGTGGAACTTGTGATTCTAGAGTCCCTTGGAAGATGA 
7p-1 128 
chr7:8909214-
8909299 
CATTCATCGCCCCTGCTTGATGCATACCTGGATATGATTAATG TAGACATGCTCTCAGGACTAGGATGACTATTCACAGAAGTTGG 
7p-2 132 
chr7:8887859-
8887948 
CATGAGGAGTAATGCATAGGATCTAGGATTGCAAAGAGGGAAGAA AGTTGCATGGGGTGAAATCAGTTACTAACTTGAGATGTGAGACAG 
7p-3 136 
chr7:9005015-
9005108 
CTCCTCCTCAGCTGCATCACATATAAGCACAACGGGTTCTTGTTCTC ATCTTAGGGATCTGCGTACGCAACCCTAATTTACCCAGACAGAAAGC 
7p-4 140 
chr7:8991629-
8991726 
CATCTCCCAGTGCAAGAAGGCTGATAGCAGAGGAGGCAAGCAATGAGAA TCTCATACTACCGATGTGTTTACACAGAGCAGCAACTGATCAGGGAGAG 
Cx40_Pro
m.1* 
136 
chr1:145713090-
145713183 
GAGTCTGGGGGAGAAGTTGGAGAATGGGAGGGTTTGAGGGAAGAGAT ACCCCCACAGTTTCTGAATTTGGTCACCTGTGGCATGTGATCTAACA 
Cx40_Pro
m.2* 
104 
chr1:145712339-
145712400 
TGGTGCACCAGCGGCCCGGGGGAGAGGCAAT GTGGAGGACTGCTGTGAGGACAAGGACAACA 
Cx40_Ex1.
a* 
108 
chr1:145712015-
145712080 
TGACAGGCTCAAGAGCAAAAAGCGTGGGCAGTT GGAGAAGAAGCAGCCAGAGTGTGAAGAAGCCCA 
Cx40_Ex1.
b* 
120 
chr1:145699257-
145699334 
GGTGATACAGAAGAAAAGACAGTCTCCATTTTCAAACAG TCCCTCCTGGGAGAACACAGACAGGCAGAGGATTACAAC 
Cx40_Int1
.b* 
112 
chr1:145699489-
145699558 
TCTGGAGCATTCCCTCTACTTTAGATTCTCCCCAT ACCTCACCTACCAGAACTAACTGCAGAGGAGATTA 
Cx40_Ex2.
1* 
124 
chr1:145697867-
145697948 
GAAATTTCCTGGAGGAAGTACACAAGCACTCGACCGTGGTA GGCAAGGTCTGGCTCACTGTCCTCTTCATATTCCGTATGCT 
Cx40_Ex2.
2* 
128 
chr1:145696505-
145696590 
GAAGGGATAGCCAGAGGGATAGAATGACTCTCTCTCTACATAC CAGCAGCATACCAAATGCGTTCTCTAAGTTCCTACCTCCTTGA 
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Cx40_Ex2.
3* 
132 
chr1:145695162-
145695251 
GACACTTGGATGCTATTGTTGGGTGGAAAGATAAATGAGAGTGGA GAGGTGGAGGAAAGTGACTAGGATGCCATTTAGGAAGGAATGTCT 
ACP6_1* 140 
chr1:145592937-
145593034 
GGAATCTCAGAGGATTTGAAAAAGGTGAAGGACAGGATGGGCATTGACA GTAGTGATAAAGTGGACTTCTTCATCCTCCTGGACAACGTGGCTGCCGA 
ACP6_2* 112 
chr1:145608605-
145608674 
TGTCCGGTCGACCGCAGCCTGCTGAAGTTGAAAAT GGTGCAGGTCGTGTTTCGACACGGGGCTCGGAGTC 
GJA8_1* 132 
chr1:145846649-
145846738 
GTTGCATTGCGGCCGCTCAGCTCTTGCCTTCTCCCTCATTTCTTC AGGTGGGTGAGAAATGGGCGACTGGAGTTTCCTGGGGAACATCTT 
GJA8_2* 108 
chr1:145841543-
145841608 
TTGCCATTTTGCTGCTGAGCGCCAAGAGAGAAA GAGCACATATTTCTCCGTGGGACACTCCTTGTA 
NBPF11_1
* 
124 
chr1:146074665-
146074746 
GTAAATAAATTATTTGTTTCTTCTTGGTAGCCCTTGAAGAT AAGGATGGTCAAACAAAATAATATCATACCTGGAGAAACTC 
PRKAB2_1
* 
104 
chr1:145097696-
145097757 
TCTTGCCTCTAAGGATTCAGGAGAAGCATCT CCCTTGCATTTCTGGACTGAACCAGTCTTAC 
PRKAB2_2
* 
120 
chr1:145110962-
145111039 
GAGCACCGGAGCCCAGGGAGGCGGCCTCCGAGTGTCATT TGGGGACGTCCCTTCTGCCGGGTAGTCTCAGAGGCCAAG 
PRKAB2_3
* 
120 
chr1:145110723-
145110800 
GAACGCGCACTGGGCGGACTCCGCGCCGCCGGCCTTGTA GCCATTTTAGGAGGAATCGCTGGTCGCCAGCGAGGGGTG 
CX40* 100 
chr1:145713130-
145713187 
TGAGGAGTCTGGGGGAGAAGTTGGAGAAT GGGAGGGTTTGAGGGAAGAGATACCCCCA 
*designed by Dr. Ana Topf and incorporated in some assays
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